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ABSTRACT 
Diabetes mellitus is a prevailing chronic disease in Canada and around the world.  The 
population with diabetes is rapidly increasing.  The growth of diabetes prevalence places a heavy 
burden on the health care system and causes a significant loss to society.  The prevention and 
treatment of diabetes is a complex problem that involves many parties such as government, 
health care system, communities and patients.  It is very difficult to design cost-effective 
interventions that will suit all parties to slow the prevalence of diabetes. 
The diabetes-related burden, such as diabetes prevalence and incidence, in the Saskatoon 
Health Region were investigated by using the System Dynamics approach.   A System Dynamics 
model was built based on the current diabetes situation of the Saskatoon Health Region.  The 
model is able to simulate the entire disease progress as a dynamic system and to catch the 
interactions and feedbacks between factors.  According to the simulation result, the diabetes 
prevalence and the number of incident cases will continue to increase in the next four decades.      
The model is able to help the decision-makers to observe the future impacts of current 
interventions and find bottlenecks, as well as key uncertainties.  The model has the capability to 
answer many “what-if” and “why” questions.  The decision-makers can use the model as a useful 
tool to evaluate different interventions by performing different experimental scenarios.     
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CHAPTER 1 
INTRODUCTION 
Diabetes Mellitus, colloquially referred as “diabetes”, is a chronic syndrome that results 
from insufficient secretion or inefficient use of insulin.  The disease significantly reduces 
patients’ overall wellness and quality of life, and leads to a broad set of serious complications.  
Society also is impacted negatively from loss of productivity and heavy burden on public health 
care system. 
My research proposes to develop a System Dynamic model that simulates Type 2 
diabetes burdens such as the incidence and the prevalence of Type 2 diabetes in the Saskatoon 
Health Region.  The model will be used to better understand the population-wide progression of 
Type 2 diabetes as a complex system, predict future prevalence and other burdens of Type 2 
diabetes and evaluate possible interventions.  My research focuses on understanding the 
population-level impact of diabetes rather than discussing the syndrome at a clinical level.    
1.1 Problem and Motivation 
The prevalence of Diabetes Mellitus has rapidly increased due to population increase, 
population aging, urbanization, and increasing prevalence of obesity.  An estimated 171 million 
people suffered from diabetes worldwide in the year 2000; the estimated number grew to more 
than 180 million in the year 2006.  The diabetic population is projected to increase to 366 
million by 2030 [1, 2].  In Canada, the prevalence of diabetes is high and rapidly increasing.  
National Diabetes Surveillance System (NDSS) data estimated that 1.128 million people – about 
4.8% of the total 20+ age population – were diagnosed with diabetes during 1998-99.  If one 
factors in the estimate of the undiagnosed diabetics population, there were a total of 1.7 million 
Canadian with diabetes during 1998-99 [3, 4].  A recent report from the NDSS shows that the 
prevalence of diagnosed diabetes increased to approximately 1.783 million in the year 2004-05 
[5].  The prevalence including undiagnosed diabetics increased to more than 2 million and is 
expected to rise to 3 million by the end of the decade [4, 6]. 
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The prevalence of diabetes places a heavy burden on diabetic patients, the health care 
system, and society.  Diabetic patients not only physically suffer from diabetic complications, 
but also economically suffer from medical and day-to-day care expense.  Diabetes also is a 
costly disease socially since it consumes a large portion of health care resources.  It directly 
adds additional physician service costs, hospital service costs, long-term care costs, medication 
costs, laboratory costs and other therapy and management costs to the health care system and 
society.  If indirect costs are counted in, the number will be twofold to threefold more than the 
direct costs.   Diabetes led health spending costs by imposing $884 million of direct health care 
costs in 2000 in Canada; and indirect costs from lost productivity and premature death imposed 
another $1.7 billion in costs to the Canadian economy [7].          
Saskatoon is not an exception to Canadian’s high diabetes prevalence.  Diabetes is the 
chronic disease with the third highest mortality burden in the Saskatoon Health Region (SHR) 
demographically.  Obesity is a well-known risk factor of developing Type 2 diabetes.  A high 
prevalence of obesity in the Saskatoon Health Region makes a considerable contribution to the 
high diabetes prevalence.  The cold winters in Saskatchewan restrict outdoor physical activities 
and limited recreation facilities restrict indoor physical activities.  Many urban residents also 
find it difficult and costly to access healthier food.  Many people in the Saskatoon Health 
Region are overweight or obese.  A total of 30.63% of the residents in the Saskatoon Health 
Region were overweight and 16.88% were obese in 2005 [8].  Partly as the consequence of the 
high prevalence of obesity, diabetes is also prevalent in the Saskatoon Health Region. 
In additional to the prevalence of obesity, the increase in diabetes burden also results 
from population structure.  The populations of the younger groups in the health region are 
continuously decreasing or remain stable; at the same time, the populations of the older groups 
keep increase as shows in Figure 1-1.  Chronic diseases like diabetes, which commonly onset at 
older age, are prevalent in the elderly populations. 
 
3 
 
 
Figure 1-1. Estimated Population Percent Change for Saskatoon Health Region in Year 
2005    
Aboriginal people are the higher risk ethnic group for having diabetes in North America 
[68-69].  About 8.7% of the population of the Saskatoon Health Region are aboriginal, and over 
50% of those are Status Indians based on Statistics Canada 2001 data.   This relatively large 
percentage of aboriginal population when compared to other areas in Canada also contributes to 
the elevated diabetes prevalence seen in the SHR. 
With the limited budget available for preventing and treating diabetes and its 
complications, cost-effective intervention policies are needed in order to slow the increase of 
prevalence of diabetes and lower the burdens imposed by diabetes, and save as many lives as 
possible. 
1.2 Solution and Goal        
It is not easy to develop the best diabetes intervention plan within a complex environment 
full with limitations and contradictions.  How do we save the most diabetic patients’ lives in 
next year, over the next decade, over the next two decades?  How do we minimize the burden 
imposed by diabetes to diabetic patients, health care system and society?  There are many 
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questions that need to be answered.  In this thesis, we are trying to provide potential solutions 
by using the System Dynamics approach. 
The System Dynamics approach, first formulated by Jay W. Forrester in early 1960s, is a 
computer-aided methodology for understanding, analyzing and managing complex feedback 
systems [9-11].  Diabetes is a complex social problem rather than a simple medical problem.  
Any snapshot view will not capture the dynamic relationships within the system and possibly 
miss potential outcomes.  A System Dynamics model is able to create a systems-level view that 
captures dynamics (changes over time) across the whole system rather than for a piece of the 
system considered in isolation.  It also monitors every interaction between system components 
and interaction between the system and exogenous factors.       
The goal of this research is to develop a System Dynamics model that characterizes the 
health and demographic structure of diabetes in the Saskatoon Health Region.  This model will 
be used as a learning tool to improve our understanding of the drivers underlying observed and 
future changes in the diabetes prevalence and incidence, answering questions such as “What are 
the main contributing factors for the high prevalence of diabetes in SHR?  Are they the 
prevalence of obesity, the population age structure, the population ethnic structure or something 
else?”.  The model also could be used as an evaluation tool to examine the tradeoffs between 
different interventions and to try to identify the best combination of interventions that will 
address the SHR’s strategic plans. 
 
Our research involves 5 stages of work: 
 
1. Construct a system dynamics model that accords with the local society and health care 
system but that draws on elements of two previous models: a model from the United 
States Centers for Disease Control and Prevention (CDC) and one from New Zealand.   
 
Previously, researchers at the U. S. Centers for Disease Control and Prevention and the 
New Zealand Ministry of Health developed System Dynamics models for diabetes in the 
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U. S. and New Zealand, respectively.  We adapted the structures from these models, and 
modified the structure based on features of the local situation.  The CDC model and the 
New Zealand model will be described in the chapter 3, and the adaption process will be 
described in the chapter 4. 
 
2. Parameterize the model with local data or other data sources.   
 
After the model is constructed, most of parameters in the model are substituted with local 
values.  If some parameters do not have local data available, we use data from other 
sources instead.  There sources includes data for Saskatchewan, data for Canada and 
data for other countries.  In most cases, we do not anticipate that these data will exhibit 
a large difference from actual local values.  The parameterization will be explained in 
the chapter 4 with model structure.   
 
3. Calibrate the model with historical data and estimate unknown parameters.   
 
In this step, we calibrated and verified model structure and parameters with historical 
data.  Using changes to values of model parameters and structure, we tried to find a best 
match between model output and the historical data.  After the calibration, the model is 
able to adequately reproduce the historical trace of the diabetes burden within the SHR.   
 
In the calibration process, we also estimated values for unknown parameters in the model.  
Data on some parameters is difficult to collect data because of their definition, such as 
undiagnosed diabetic population.  We use the simulation software to simultaneously and 
randomly change the values across unknown parameters within a reasonable range.  If a 
value in a given range leads the model outputs to best match the historical data, then this 
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value is considered the best estimate for the unknown parameter.  The calibration 
process will be described in the chapter 5.           
 
4. Use the calibrated the model to depict the underlying diabetes burden in the SHR in the 
near future.  
 
After the model is calibrated, it can simulate the diabetes burdens in the SHR with a 
reasonable accuracy based on the available information.  We use the model to project 
several important indicators of diabetes burdens.  These indicators show the trend of 
diabetes burdens in the SHR in the near future.  The simulation results will be exhibited 
in the chapter 6.   
 
5. Test sensitivity of selected model variables and test potential interventions 
 
In this step, we tested the sensitivity levels of the system responses to changes in several 
selected model variables.  We alter the values of several key variables in the model and 
observe the changes in the model results.  Changes in some variables may lead to a large 
change in the model outputs; changes in other variables may lead to a small change.   
 
Based on observations  from the sensitivity analysis, we propose several potential 
interventions.  Interventions alter key variables which can to lead changes in the 
diabetes burdens.  The simulation results show that the interventions have the potential 
to lower the diabetes burden from their original forecast.  The sensitivity analysis and its 
results will be described in chapter 7.  
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CHAPTER 2 
BACKGROUND AND RELATED RESEARCH 
2.1 Diabetes Mellitus 
Diabetes is a prevalent chronic metabolic disease that affects people regardless of age, 
gender or race.  The basic pathogenesis of diabetes is that the pancreas cannot produce enough 
insulin, or the insulin cannot be used effectively by body cells.  Insulin is the hormone produced 
by the pancreas to trigger body cells to convert glucose to energy for the human body.  When 
the pancreas cannot produce insulin or cells do not respond to insulin, the blood glucose level 
raises.  Constant high levels of glucose in the bloodstream damage blood vessels, kidney, 
nerves, heart and result in many chronic complications; such as retinopathy, neuropathy and 
nephropathy.  
2.1.1 Classification  
Diabetes is groups of metabolic disorders that are characterized by hyperglycemia 
resulting from defects on insulin secretion, insulin action or both [12, 13].  There are guidelines 
that provide an appropriate classification system to identify various forms and stages of diabetes.  
The classification, published by World Health Organization (WHO) in 1980, is the first 
classification that has been widely accepted and used by professionals and the general public. 
This classification was based on the classification system that the National Diabetes Data Groups 
developed and published in 1979 [13-16].   
Diabetes is divided into five major types based on clinical and etiological features in the 
WHO 1980 classification and its 1985 revision [13-17]. The first two primary types are 
insulin-dependent diabetes mellitus (IDDM or Type 1 diabetes), and non-insulin-dependent 
diabetes mellitus (NIDDM or Type 2 diabetes).  Beside the first two major types, there are 
several other types of diabetes that have different etiological character, such as diabetes induced 
through pancreatic disease, disease of hormonal etiology, drug- or chemical-induced conditions, 
insulin receptor abnormalities and certain genetic syndromes.  They are grouped in the “other 
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types of diabetes” class.  Gestational diabetes mellitus (GDM) was in this classification as a 
temporary high blood glucose level condition during pregnancy.  Malnutrition-related diabetes 
mellitus (MRDM) was not defined in the original 1980’s classification, but it was recognized as 
the fifth major type in the WHO classification’s 1985 revision.     
Impaired glucose tolerance (IGT) was also defined in the 1980’s version of classification 
as an intermediate stage for people who have hyperglycemia but blood glucose levels are not 
sufficiently elevated to meet diabetes requirement.   
With the growth of knowledge and understanding about diabetes, the 1980’s 
classification is no longer able to fill the requirement of classifying diabetes precisely.  An 
international diabetes experts committee among the World Health Organization and the 
American Diabetes Association released a revised classification based on etiology in 1997.  In 
the new classification, diabetes has been divided into four major classes: Type 1 diabetes, Type 2 
diabetes, other specific types and gestational diabetes.  The terms “insulin-dependent diabetes 
mellitus” and “non-insulin-dependent diabetes mellitus” are eliminated since these terms 
classified patient based on treatment rather than etiology [13].  The term “Type 1 diabetes” 
replaced the old term “insulin-dependent diabetes mellitus” and the acronym “IDDM” to classify 
diabetes that results from β-cell destruction.  The term “Type 2 diabetes” replaced the term 
“non-insulin-dependent diabetes mellitus” and the acronym “NIDDM” to classify diabetes that 
results from insulin resistance. The “other specific types” class includes many other types 
diabetes which are caused by different factors.  The class “gestational diabetes mellitus” retains 
the same as the previous classification.   
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Table 2-1. Criteria for the Diagnosis of Diabetes Mellitus 
1. Symptoms of diabetes plus casual plasma glucose concentration ≥ 200 
mg/dl (11.1 mmol/l).  “Casual” is defined as any time of day without regard 
to time since last meal.  The classic symptoms of diabetes include polyuria, 
polydipsia, and unexplained weight loss. 
or 
2. Fasting Plasma Glucose (FPG) ≥ 126 mg/dl (7.0 mmol/l). “Fasting” is 
defined as no caloric intake for at least 8 hour. 
or 
3. 2-hour PG ≥ 200mg/dl (11.1 mmol/l) during an Oral Glucose Tolerance 
Test (OGTT). The test should be performed as described by the WHO, using a 
glucose load containing the equivalent of 75 g anhydrous glucose dissolved in 
water. 
 
Table 2-1 lists the criteria for the diagnosis of diabetes.  In its 1997 classification, the 
international diabetes experts committee also defined two intermediate stages, impaired glucose 
tolerance (IGT) and impaired fasting glucose (IFG).  The intermediate stages are commonly 
referred as prediabetes since they have higher level of glucose than normoglycemia but lower 
than the glucose levels used in the criteria for diabetes diagnosis.     
2.1.2 Pathophysiology 
Type 1 diabetes (previously known as insulin-dependent diabetes mellitus) is 
characterized by destruction of pancreatic β-cells and not enough or no insulin being produced 
by the pancreas.  Type 1 diabetes is known not to be caused by unhealthy diets or lifestyle but 
by combinations of genetic and environmental factors.  After a person eats, islet cells in the 
pancreas secrete insulin to signal insulin-sensitive tissues.  An immunological deficiency causes 
pancreatic β-cells in islets to be totally destroyed or sufficiently damaged by the immune system, 
thereby extinguishing the production of insulin.   
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The onset of Type 1 diabetes usually occurs in childhood or adolescence. The incidence 
rate of Type 1 diabetes varies with age, but it peaks at about 11-13 years of age [18]. At the same 
time, epidemiological data shows about 30-50% cases develop Type 1 diabetes symptoms after 
age 20 [19-21].  About 10% of the total Canadian diabetic population are Type 1 [3, 4, 22], and 
the fraction is decreasing due to the rising prevalence of Type 2 diabetes.   
The remaining 90% of diabetes cases are associated with Type 2 diabetes, which used to be 
termed non-insulin-dependent diabetes mellitus (NIDDM).  Type 2 diabetes is characterized by 
abnormalities in both insulin secretion and insulin action.  Insulin resistance is a well known 
major driver of hyperglycemia of Type 2 diabetes.  Defects in insulin receptors in cells and 
postreceptors in organs cause insulin-sensitive tissues in a diabetic patient’s body that do not 
respond to normal level of insulin and refuse to absorb glucose.  Insulin resistance lowers 
glucose disposal in skeletal muscle and speeds up endogenous glucose production in the liver.  
Both actions result in hyperglycemia of Type 2 diabetes.  
A defect in insulin secretion is another driver of hyperglycemia in Type 2 diabetes.  
Studies carried out in humans of varying ethnicity (Caucasians, Native American Indians, 
Mexican-Americans) and Rhesus monkeys indicate that Type 2 diabetes patients have a 
progressive decline in insulin secretion when plasma glucose level exceeds 120 to 140 mg%; and 
the level of circulating insulin diminishes (insulinopenic) when the plasma glucose level exceeds 
180 to 200 mg% [23]. 
Type 2 diabetes is highly associated with obesity and physical inactivity.  Obesity 
greatly increases the risk of developing Type 2 diabetes.  Being overweight and gaining weight 
are strong predictor of diabetes [24-26].  Studies show obese middle age and elderly males 
(from age 40 to 75) whose body mass index (BMI) ≥ 35 kg/m2 have a multivariate relative risk 
of 42.1 in 5 years compared to male whose BMI < 23 kg/m2 [27].  Another study documented 
that age adjusted cumulative incidence of diabetes is 26.2% for people BMI > 37 compared to 
9.6% for people with BMI < 29 [24].  It is expected that the current prevalence of obesity will 
lead to a high prevalence of diabetes in the future.  Studies have suggested that for every 1 kg 
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increase in population-measured body weight, the prevalence of diabetes increases by 5% to 10 % 
[3, 25, 26]. 
Gestational diabetes mellitus (GDM) is a temporary glucose intolerance that happens 
during pregnancy.  Gestational diabetes usually does not have obvious symptoms, hence it only 
can be detected by screening. GDM increases the risk of prenatal deaths for mothers slightly, and 
the risk of prenatal death for baby by about 3 times compared to the general population [28].  
Babies whose mothers have GDM during pregnancy sometimes are heavier and larger than 
normal babies.  These babies are called macrosomic and have a disproportionately high fat 
content; and caesarean section is most likely needed for delivery.    
Even though most gestational diabetic patients will revert to normoglycemia after 
delivery, GDM is a strong risk factor for both mother and baby to develop Type 2 diabetes in 
their later life stage.  Women who have gestational diabetes will have 20% to 50% chance of 
developing Type 2 diabetes in next 5 to 10 years [22].  Babies who have a diabetic mother suffer 
from a higher diabetes incidence rate with a prevalence of 1.5% at 25 years [28], and this prevalence 
is far higher in certain Aboriginal groups [68].   
Type 1 diabetes is related to genetic and environment factors. It is therefore hard to 
develop a feasible intervention to slow down prevalence in a relatively short term.  Moreover, 
Type 1 diabetes only represents about 10% of the total diabetic population, and a much smaller 
fraction of diabetics among the rapidly-growing Aboriginal subpopulation.  In my research, I 
only focus on Type 2 diabetes.           
2.1.3 Symptoms and Diagnosis 
Type 2 diabetes is not easy to symptomatically diagnose since the onset is a slow process 
after patients are exposed to elevated levels of blood glucose for a long time period.  Not all 
people with diabetes are diagnosed immediately, because at the early stage, diabetes usually has 
no obvious symptom and the disease may not be diagnosed.  Prediabetes, the intermediate 
stages between normoglycemia and diabetes, usually does not have any obvious signs or 
symptom.  Plus, the symptoms of early stage Type 2 diabetes seem harmless such as frequent 
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urination, extreme hunger and thirst, rapid weight loss and blurry vision. The mildness of such 
symptoms places additional barriers to the diagnosis of Type 2 diabetes in the early stage.  
According to the National Diabetes Surveillance System (NDSS) 1998/99 data, an estimated 
1.128 million Canadians were diagnosed with diabetes [3].  However, this number does not 
include all diabetes cases in Canada. It has been estimated about one third of diabetes instances 
are not diagnosed [29, 30]. In 2006, the Centers for Disease Control and Prevention (CDC) 
estimated that 6.2 million people in the United States have undiagnosed diabetes among a total of 
20.8 million diabetics [22]. 
People with undiagnosed diabetes may not be seen as suffering from diabetes-imposed 
burdens, but those people are usually obese and have other symptoms such as high blood 
pressure. The progression of diabetes for unmanaged diabetic patients can be much quicker than 
for well managed patients, and causes an even heavier burden later. 
The World Health Organization published its revised recommendation on diabetes 
diagnosis criterion in the WHO diabetes classification, as shown in Table 2-1 [12, 13].  This 
criterion also defines an intermediate level of glucose, which does not meet the diabetes level but 
is higher than normal level.  People who have FPG levels ≥ 110 mg/dl (7.0 mmol/l) but < 126 
mg/dl (7.0 mmol/l) or 2 hour OGTT value ≥ 140 mg/dl (7.8 mmol/l) but < 200 mg/dl (11.1 
mmol/l) are considered “prediabetic”.  Based on the WHO recommendation, a patient is 
diagnosed with diabetes if a positive result is given from any of three methods shown in Table 
2-1, and this positive result must be confirmed on a subsequent day by any one of these three 
methods. 
2.1.4 Complications 
Diabetic complications are the foremost causes of mortality in diabetic patients.  
Preventing and slowing the progression of diabetic complications are the keys saving diabetic 
patients’ lives.  If diabetes is not diagnosed at the early stage and blood glucose levels remain 
unmanaged, the development of chronic complications can be accelerated.  These long-term 
complications, such as cardiovascular diseases, high blood pressure, nephropathies (kidney 
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diseases), neuropathies (nervous system disorders) and retinopathies (eye diseases), impose a 
huge amount of illness to diabetic patients and can greatly compromise their quality of life.   
Diabetes was the main cause for nearly 45% kidney failure cases in the United States in 
2005 [31]. Diabetes related kidney failure usually takes 13 to 16 years to develop and can be 
extremely expensive once it occurs.  However, with good care and management, kidney disease 
can be prevented or slowed.  Retinopathy is another serious complication that results from 
diabetes.  High levels of blood glucose damage the blood vessels in the retina and cause vision 
loss or even blindness. About 40% to 45% diabetics in the United State are affected by 
retinopathy [32].  Beside nephropathy and retinopathy, other chronic diabetic complications 
also lead to serious organ failure, and even death.  Diabetic complications will commonly 
shorten the average life span and significantly reduce quality of life among diabetic patients.       
2.1.5 Local Prevalence 
Saskatoon Health Region is the largest health region in Saskatchewan.  It services 
285,000 people (approximately 28.5% of the provincial population) in 2 cities; 69 towns, villages 
and hamlets; 47 whole or partial rural municipalities; and 6 First Nations reserves [8]. 
A considerable fraction of the population in Saskatoon Health Region (SHR) is 
overweight or obese.  59.7% of the age 18+ male population and 41.3% of the age 18+ female 
population in the SHR were reported overweight or obese in 2001[33].  This large high risk 
population could have a significant effect on future diabetes prevalence.     
Not only obesity but also an aging population structure in the SHR has a major 
contribution on developing Type 2 diabetes.  Figure 2-1 illustrates the population age structure 
in SHR; a large percentage of the population in the SHR is elderly: 12.6% of the city population 
and 15.5% of the rural population in the Health Region are over the age of 65 [8].  When 
considered for the SHR as a whole, the population of older age groups continuously increases 
and the population of younger age groups keep stable or slightly decrease.  As for obesity, age 
also makes substantial contributions to the risk of Type 2 diabetes.  People who are older than 
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age 45 have higher risk of developing Type 2 diabetes than younger people.  Combining both 
obesity and age, it is not surprising that diabetes is prevalent in the SHR. 
As the largest health region in the province, SHR covers about a quarter of diabetes 
patients in Saskatchewan.  Compared to other health region in the province, prevalence rate of 
diabetes in SHR is relatively lower.  The incidence rates vary from year to year with statistical 
noise, but the Aboriginal population has a significantly higher incidence rate than the 
non-Aboriginal population.  The incidence rates for Aboriginal and non-Aboriginal population 
in Saskatchewan, which are very close to the rates for the populations in the SHR, are shown in 
Table 2-2 [69].  Even though the incidence rate decreases, new cases still develop every year 
and results in an increases in the prevalence rate as shown in Table 2-3 [34]. 
 
Table 2-2. Diabetes Incidence Rates (per 1000 person) for Aboriginal and Non-Aboriginal 
Population in Saskatchewan 
 
Year Non-Aboriginal 
Male 
Non-Aboriginal 
Female 
Aboriginal 
Male 
Aboriginal 
Female 
1999 5.86 4.46 17.08 19.10 
2000 5.99 4.92 16.38 19.57 
2001 6.62 4.99 16.28 19.96 
2002 7.26 5.42 17.73 18.06 
2003 6.77 5.29 17.80 17.95 
 
Table 2-3. Age-Sex Adjusted Prevalence Rate in SHR and Saskatchewan 
 
Year 00-01 01-02 02-03 03-04 
Saskatoon Health Region 4.3 4.7 5.1 5.4 
Provincial 4.8 5.2 5.6 6.0 
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Figure 2-1. Saskatoon Health Region Population Pyramid (taken from [8]) 
 
A total of 286,314 people in the SHR and 15,805 people self-identified as having 
Registered Indian Status (RIS) according SHR data [61].  Unlike the overall population 
structure, the age structure for the Aboriginal population is young.  About 48% of the 
Aboriginal population is under age 20 [35].  On the other hand, the prevalence of diabetes is 
higher in the Aboriginal population than others.  Many surveys result, including the Aboriginal 
People Survey (APS), the First Nations and Inuit Regional Health Survey (FNIRHS) and First 
Nations Regional Longitudinal Health Survey (RHS), indicated that diabetes prevalence among 
the Aboriginal population are 3 to 5 times higher than for the general Canadian population [36, 
37].   
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2.2 Health Related Quality of Life (HRQoL) 
Diabetes not only physically damages the human body, but also mentally and 
economically destroys people’s life. People with diabetes often feel that they are challenged by 
the disease and day-to-day disease management [40].  Health related quality of life is an 
important component and indicator in the measurement of quality of life [38, 39].  Health related 
quality of life is a multi-dimensional factor that takes into account people’s physical and mental 
health, and health related social and economic well-being [40].  An improvement of health 
related quality of life means improvements in physical as well as mental health well-being.  
Hence, the improvement of health related quality of life can be used to evaluate the effectiveness 
of health programs or policies. 
Health related quality of life is significantly reduced by diabetes.  Results from the 
Canadian Community Health Survey (CCHS) shown in Figure 2-2 suggests that the health 
related quality of life for diabetic population is lower than the health related quality of life for the 
general population across all age groups and genders.  An effective diabetes intervention should 
not only slow the prevention, and lower diabetes related burden in terms of extending the length 
of life, but also improves health related quality of life for diabetics. 
 
Figure 2-2. Comparison of Health Related Quality of Life (HUI3) between General Population and Diabetic 
Population in Canada (Calculated from CCHS data) 
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2.3 System Dynamics Approach 
The System Dynamics approach – originally called industrial dynamics – is a 
computer-aided methodology for analyzing and managing complex feedback system [9, 10]. 
Since it was formulated by Jay W. Forrester in the early 60s, System Dynamics methodology 
focuses on complex social, physical, and biological issues [41].  A well built System Dynamics 
model is able to systemically represent a complex problem in terms of a set of interacting 
feedback systems.  By observing interactions within and between these feedback systems, users 
of the System Dynamics model tool can identify key factors in the complex problem and gain a 
better understanding of the problem.  A System Dynamics model can be used as simulator to 
answer “what-if” questions.  Decision makers will be able to examine expensive interventions 
without the needs to actual undertake the interventions.  A System Dynamics model can 
simulate interventions, project possible outcomes and assist decision makers in creating the most 
effective intervention.  A System Dynamics model also can be used as a learning tool to deliver 
detailed information about the complex problems to researchers and to the general public. 
The health of the population, the health care and public health systems is a complex 
feedback system that involves many factors in diverse areas. The factors in the system are linked 
and affect each other nonlinearly in either positive or negative ways. For instance, additional 
primary health care resources for diabetes could save lives from the complications of diabetes; 
but this requires additional financial resources and human resources that may cause a burden on 
other areas, and will also elevate the prevalence of diabetes.  Moreover, diabetes is a chronic 
disease, and any political intervention to it will take long time to show results. For example, 
school-based physical activity or nutrition programs will not have an immediately effect on 
saving patients’ lives, but it will show its contributions on slowing the prevalence of diabetes 
over the course of decades. Consequently, diabetes must be viewed as a complex social problem 
rather than as a simple medical problem. A snapshot view will not capture the dynamic 
relationships within the system and is likely to miss possible outcomes. The System Dynamics 
approach offers a useful analysis tool for understanding and studying diabetes. 
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2.3.1 Dynamic Behavior of Complex System 
A complex system is composed of many components.  The components in the system 
are often tightly coupled and interact with each other to form dynamic behaviors of the system.  
The complexity of the system results not only from its complex structures and components, but 
also from the many aspects of the system such as the interactions between components in the 
system, time delays between taking a decision and its effects, and the history of the system.   
The interactions between components commonly form what are called feedbacks in 
System Dynamics studies.  Such feedback underlies much of the complex behaviors in the 
system, including system stability, rapid changes and instability, oscillation, and other frequent 
phenomena.  There are only two types of feedback loops: positive and negative feedback loop 
are shown in Figure 2-3 as a causal loop diagram.  The left loop that labeled “R” is a positive 
feedback loop or self-reinforcing loop.  A change in a certain direction within a positive 
feedback loop will lead to a cascading set of changes that will ripple around and amplify the 
original changes.  This new change can trigger a similar amplification.  An example of the 
instability and rapid changes from a positive feedback loop can be observed commonly from the 
volume rapid increase when a microphone is placed close to a speaker.  The positive feedback 
loop in Figure 2-3 will finally result both new born babies and total population growing 
exponentially if we ignore the other loop.      
The right loop in Figure 2-3 that labeled “B” is a negative feedback loop or 
self-balancing loop.  A change in a certain direction within a negative feedback back will lead 
to a cascading set of changes as “resistance force” that will push back the original changes.  The 
negative feedback loop tends to “self-regulate” deviation and stability.  A real life example can 
be observed from a driving car: faster the car drives the larger resistance force the car faces.  
When the resistance force equals the drive force from the engine, the car stay in a homeostasis 
status and the speed of the car does not change.  The negative feedback loop in Figure 2-3 will 
result in a balance point for both total population and death, which is 0 in both cases, if we 
ignore the positive feedback loop on the other side.    
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Figure 2-3. Feedback Loops 
 
The existence of only two types of feedback loop does not mean less complexity in a 
system.  In fact, a system could easily have thousands of feedback loops that are nested and 
interact to create the dynamic behavior of the system. 
Time delays between taking a decision and its effects also lead to additional dynamic 
complexity of systems and create instability in systems [11].  A hot housing market generates 
considerable new construction sites.  The price of a house acts as a feedback that tells 
developers of the high demand in the housing market.  Developers will continuously increase 
market supply by starting new construction sites in response to the rise in house prices.  
Developers often will not stop constructions until house prices fall, when it is too late.  These 
new constructions could not stop immediately and will overshoot actual demand; and the 
oversupply can lead to oscillations in the house prices. 
A system is frequently history-dependent since many actions in the system are 
irreversible or long delays occur between an action and its reverse action [11].  The current state 
of the system is determined by previous states, and the current state will determine future states 
of the system.  For instance, in the design of city layout, the current layout of the City of 
Saskatoon is based on the layout decades ago, and it is virtually impossible to change the entire 
layout in the near future.              
2.3.2 System Dynamics Model Structure  
Creating an accurate System Dynamics model involves several important steps: 
identifying the real world problem, identifying relationships between entities, identifying stocks 
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and flows, writing formulae for particular variables and parameterizing the model with initial 
values.     
In the last section, we showed that the causal loop diagrams using feedback loops to 
illustrate relationships between entities in a complex system, but it shows little quantitative 
details of the system.  We use stock and flow diagrams to illustrate greater quantitative detail, 
and use equations that lie behind stock and flow diagrams to simulate the system.  Stock and 
flow on one hand, and feedback on the other hand, are the two central concepts of dynamic 
system theory [11]. 
As suggested by its name, a stock and flow diagram uses stocks and flows to characterize 
a system.  Stocks are accumulations of system entities.  Stocks collectively characterize the 
state of a system, and provide the basis for actions, inertia and memory in a system.  Stocks also 
create delays, decouple rates of flows, and break equilibrium in a system.  Stocks are variables 
in a system; flows are rates of changes of these variables.  In stock and flow diagrams, stocks 
are drawn as boxes with a name inside, and flows are presented as pipes with a “valve” symbol.  
Figure 2-4 is the stock and flow diagram adapted from Figure 2-3.  Flows determine the 
changes of stocks; on the other hand, stocks’ value influence flows as well.  The “death” 
outflow decreases the size of the population.  As the population size decreases, the death flow 
(measured in terms of deaths per unit time – e.g. per year) will drop as well, as there are fewer 
people at risk of death.  Both stocks and flows work together to create dynamics in systems.      
 
 
Figure 2-4. Stock and Flow Diagram 
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Stock and flow diagrams visually present a real life problem in a systems level to people; 
equations allow for mathematical simulation of the system and produce results behind the scenes.  
A flow in the model is mathematically presented by formulae.  A flow is also a component of 
the derivatives of the related stock.  Each flow is mathematically presented by a parameter in an 
integral equation, which is for calculation of the size of the stock.  Integral Equation 2.1 
simulates the inflow (new born babies), outflow (death) and accumulation of the stock (total 
population) in above stock and flow diagram.   
 
𝑡𝑜𝑡𝑎𝑙 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛(𝑇) =  � [𝑛𝑒𝑤 𝑏𝑜𝑟𝑛 𝑏𝑎𝑏𝑖𝑒𝑠 − 𝑑𝑒𝑎𝑡ℎ]𝑑𝑡𝑇
0
 . 
 (2.1) 
In a large scale model, step by step, hundreds or even thousands of equations work 
together to simulate a system and calculate results.  In the model developed by me, there are 
680 stocks and more than 1 thousand flows.    
After creating simulation model structure in a stock and flow diagrams and writing 
equations, we need to collect and apply initial values and constants of the model.  Without 
accurate initial values and constants, the model may not be able to simulate the real world 
problem and could even produce misleading results. 
2.3.3 System Dynamics Modeling Software 
Theoretically speaking, it is possible to build a system dynamics model without a system 
dynamics modeling software.  Using Microsoft Excel to write equation also can yield the same 
results as using a modeling software; then why do we need modeling software? 
Modeling software allows developers graphically create a system dynamics model.  
Using such software, developers can visually construct the model with stocks and connect stocks 
with flows.  Modeling software also allows simulations to run in “slow motion”, and observe 
changes in the system step by step.  Hence, developers can easily locate and track unexpected 
changes, and identify the causes cross entire simulation period.   
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In many situations, an entity in a model has many different concepts or has multiple 
classes.   For example, population in a model can be classified into different subgroups 
according to age, gender or ethnicity based on modeling requirements.  However, no matter 
how many classes an entity has, they all have the same structure and equations in the model since 
they are under a same umbrella of the entity.  Many System Dynamics modeling software 
provide subscript functionality to use one variable or equation to represent multiple concepts and 
reduce duplications.  Figure 2-5(a) shows the population structure in Figure 2-4 if we classify 
the total population of western Canada into several different subgroups based on geography: 
population in British Columbia, Alberta, Saskatchewan and Manitoba.  Although population for 
all provinces has the exactly same structure, modelers still need to draw the same structure and 
enter equations four times if there is no subscript.  
 
 
       (a) structure without subscript         (b) structure with subscript 
Figure 2-5. Population Groups without Subscript Structure vs. with Subscript Structure 
 
With subscript support, modelers can reuse the same structure and equations for all 
classes.  Figure 2-5(b) shows all population groups can use the same stock and flow diagram, 
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and Equation 2.2 calculates populations stocks across all provinces using subscripts.  Subscripts 
are heavily applied in my model since many entities are classified into different subclasses.  I 
will describe the subscripts used in my model in chapter 4.       
     
𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑤𝑒𝑠𝑡𝑒𝑟𝑛 𝑝𝑟𝑜𝑣𝑖𝑛𝑐𝑒[𝐵𝐶,𝐴𝐵, 𝑆𝐾,𝑀𝐵](𝑇) = ∫ [𝑛𝑒𝑤 𝑏𝑜𝑟𝑛 𝑏𝑎𝑏𝑖𝑒𝑠 𝑖𝑛 𝑤𝑒𝑠𝑡𝑒𝑟 𝑝𝑟𝑜𝑣𝑖𝑛𝑐𝑒[𝐵𝐶,𝐴𝐵, 𝑆𝐾,𝑀𝐵] −𝑇0
𝑑𝑒𝑎𝑡ℎ 𝑖𝑛 𝑤𝑒𝑠𝑡𝑒𝑟 𝑝𝑟𝑜𝑣𝑖𝑛𝑐𝑒[𝐵𝐶,𝐴𝐵, 𝑆𝐾,𝑀𝐵] ]𝑑𝑡 +
𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑤𝑒𝑠𝑡𝑒𝑟𝑛 𝑝𝑟𝑜𝑣𝑖𝑛𝑐𝑒[𝐵𝐶,𝐴𝐵, 𝑆𝐾,𝑀𝐵](𝑡 = 0). 
(2.2) 
 
In my research, I selected Vensim as the modeling software.  It has a sketch mode that 
modelers can use to create conceptual causal loop diagrams or stock and flow model structure 
graphically.  Vensim also provides a flexible text based editor that allows experienced 
developers to create and modify a model in more efficient ways by using mathematical equations 
directly.  The software can be obtained from the official website http://vensim.com/.     
2.4 Summary 
In this chapter, I briefly explained some background information about our research.  
Diabetes is highly associated with many chronic conditions, including nephropathy and 
retinopathy, which could destroy people’s life entirely.  Nevertheless, with high prevalence of 
obesity, Type 2 diabetes is prevalent in the SHR population.  We are seeking for a tool to gain a 
better understanding of the local situation, and a potential solution to slow the rise in prevalence.  
System Dynamics approaches became desirable selection for achieving our goal.   
I also explained some foundational concepts about the System Dynamics approach and 
basic components of a System Dynamics simulation model in this chapter.  In the next chapter, 
I will review some existing research that uses the System Dynamics approach in the public 
health area.  In chapter 4, I will explain our diabetes model in details. 
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CHAPTER 3 
RELATED RESEARCH AND MAJOR DATA SOURCES 
Modeling approaches used in public health broadly started from statistical approaches, 
moved to stochastic and Markov approaches, then into “systems thinking” modeling including 
System Dynamics modeling and Agent-Based modeling methods. The use of System Dynamics 
approaches to analyze issues in the public health area is well established. The System Dynamics 
approach was previously applied to many public health areas such as heart disease, diabetes, 
HIV/AIDS, cancer, tobacco, etc.  In this chapter, I describe some pioneering research in this 
area, since they provided a solid foundation for my study.  I also describe some related studies 
including medical research, which were used as major data sources for my study.     
3.1 System Dynamics Applications in the Public Health Area 
The System Dynamics approach serves as a powerful tool to analyze chronic diseases 
since chronic diseases form part of a complex feedback and time varying (dynamic) systems.  
Chronic disease prevention is a dynamically complex problem in which interventions can have 
very different types of effects and will show impacts after different degrees of delay.  The 
health care system is challenged to meet multiple goals, such as saving patients life in the 
emergency room and preventing disease in the first place, but these goals may conflict with each 
other due to limited resources.  Many public health interventions fall short of their goal since 
they are made in a piecemeal fashion and with a lack of system-wide perspective.  Milstein et al. 
in the paper “Background on System Dynamics Simulation Modeling with a Summary of Major 
Public Health Studies” described the basic concepts of system dynamics, general problems that 
System Dynamics simulation addresses and potential roles for System Dynamics modeling in the 
public health area [42].  The authors also listed many important System Dynamics studies that 
have been previously conducted in the public health area.   
Homer et al. in the paper “System Dynamics Modeling for Public Health: Background 
and Opportunities” presented the power of the System Dynamics modeling approach in the 
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public health area and how a model helps public health agencies achieve their goals [43].  A 
System Dynamics simulation model incorporates diverse elements that have effects on the 
system environment and the interactions within the system, iteratively yielding possible 
outcomes.  The authors built a simple model to illustrate the essential structure and policy 
inputs of chronic disease prevention.  The simulation model projected different outcomes over 
50 years for two different types of preventions (upstream and downstream) and the status quo 
scenario.  By comparing the model output for three scenarios, public health policy makers could 
easily select the best one based on their goals and interest.  The authors also outlined possible 
applications of System Dynamics modeling to more complicated problems in the public health 
area and other population health areas. 
A System Dynamics model has been used to understand and evaluate a public health 
improvement program for chronic diseases by Homer et al. in the paper “Model for collaboration: 
how System Dynamics helped a community organize cost-effective care for chronic illness” [44].  
Chronic diseases, such as diabetes and heart disease, impose a heavy burden in Whatcom County, 
Washington, due to aging of the population and growing prevalence of obesity.  A large health 
care system improvement program called Pursuing Perfection (“P2”) would help to improve the 
care of chronic illness; but the adoption of the program introduces additional costs for the 
personnel, information system, screening and preventive education every year.  The authors 
used a System Dynamics model to project system-wide costs from diabetes for Status Quo and 
full program adoption during a 20-year time period.  The model also projected the program cost 
in the 20-year time period.  By comparing the saving from community costs and additional 
costs from the program adoption, people could easily see a great deal of positive impact from the 
P2 program adoption.  Another major contribution from this research is that the system costs 
including direct medical cost, employer loss and social loss were considered as burdens from 
diabetes (as Figure 3-1 shown). The separation would help to identify the benefit from the 
program adoption in different system sectors. 
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Figure 3-1. System Costs for Diabetes (taken from [44]) 
 
Tengs et al. developed a System Dynamics model to evaluate and compare different 
tobacco control policies [43]. The model divided the population into different age groups and 
gender groups.  The simulations show that interventions yield different results when they are 
applied to different population groups.  A given intervention could have more effective result 
on one population group than another one.  For instance, preventing smoking initiation would 
have more effective results in young age groups than on elder age groups; on the other hand, 
encouraging cessation would have better result on older age groups than in younger age groups.  
The simulation results of health gains from preventing smoking initiation, encouraging cessation 
and avoiding relapse on different ages and genders were compared in terms of Quality-Adjusted 
Life-Years (QALYs). The measurement of QALYs quantitatively represents the gains from 
different health policies, both in terms of length and quality of life. Policy makers or policy 
analysts can judge the impression of these policies easily and pick the best one from the 
alternatives.  It is often impossible to collect data for every parameter in the simulation model.  
A series of sensitivity tests were done in order to analyze the impact of assumptions in Tengs’ 
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research. In the case of limited or no available data, reasonable assumptions are necessary. 
Sensitivity tests are able to analyze the impact of assumptions and help reduce the chance that 
they are exercising undue influence over the results. 
Tengs et al. also applied System Dynamics model simulation to analyze the cost 
effectiveness of an anti-tobacco education program [41].  A System Dynamics model has been 
built to project costs and QALYs for status quo and intensive school based anti-tobacco 
education program over the next 50 years.  The model evaluated anti-tobacco programs having 
different levels of intensity and duration.  The results suggest that new costs introduced by the 
program cancel out saving from lower medical cost, but that total QALYs are increased by the 
program.  Effectiveness of the program varies depending on degree and longevity of the 
program.  Greater intensity and longer duration yields a lower cost for every additional QALY.  
In another word, the program is more efficient with greater intensity and longer duration.  
Another tobacco control policy study from Levy et al. used a simulation model to provide 
justification for tobacco control to policy makers [45]. The model is employed to assess the 
effectiveness of current tobacco control policies.  Long-term outcomes of current policies and 
future new policies can be projected from the simulation at a system level.  The model also 
captures multiplicative effects when multiple tobacco control policies are applied synergistically.  
Multiple policies were evaluated in this study since different policies have effects in different 
demographic groups or smoking groups. 
The System Dynamics modeling approach has been applied in public health strategic 
planning.  Lane et al. employed a System Dynamics model to identify key factors that cause 
overly long waiting time at emergency rooms [46].  Early research pointed out that hospital bed 
shortage delays emergency room admission, causes cancellations of non-emergency admission 
and leads to more future emergency cases.  The System Dynamics model simulated the 
scenarios that the hospital has more and less beds than current situation.  The results do not 
show any change on the waiting time.  On the other hand, demand for health services increase 
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the waiting time significantly.  A snapshot view on a complex system could provide misleading 
information and cause dysfunctional policies.  
Obesity is a well-known risk factor for type 2 diabetes.  A good understanding on 
obesity and its treatment could help us to develop feasible interventions to slow down the 
prevalence of type 2 diabetes.  The System Dynamics approach has been employed to analyze 
obesity as an epidemic in the public health area.  Homer et al. developed a System Dynamics 
model to simulate prevalence of overweight and obesity, and to gain an understanding of obesity 
dynamics in U.S. population [47].  The model is calibrated to produce the best fit simulation 
result when compared to historical data.  The calibration process found that growth in 
overweight and obesity prevalence decelerated during mid-to-late 90s and increasing prevalence 
in younger age groups would have a significant carryover effect on obesity in older age groups.  
Daily caloric imbalance relative to 1970 would need to be between 1% and 3% of the daily 
intake to explain the growth.   The authors also used the model to experiment with several 
interventions.  Experimental results conclude that a comprehensive intervention that targets all 
ages is more effective than an intervention only targeting school age children, but which has no 
linkage with the rest of community.         
Obesity has also been analyzed at the individual level using the System Dynamics 
modeling approach.  Adbel-Hamid demonstrated that the human body energy intake and 
consumption system using a System Dynamics model to simulate body weight change [48].  In 
terms of high level concepts, four inter-related subsystems: energy intake, energy expenditure, 
energy metabolism and body composition work together to create the dynamics of body weight.  
A System Dynamics model represented correlation and interactions among key factors in these 
four subsystems.   
The model was also used to simulate weight changes in separated body components for 
different treatment.  The two most common interventions (diet and exercise) were tested.  
Even though simulation results show both interventions could yield similar results in weight loss, 
exercise is more efficient in reduce fat mass in the body.  Diet does not only lose fat mass, but 
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also loses significant amount of fat free mass (about 30% of total weight loss).  In addition, the 
author tested different levels of exercise intensity.  The simulation results turned out low 
intensity exercise is more effective on weight loss, but moderate and high intensity exercise is 
more effective on reducing percentage of body fat.  Higher intensity exercise results yields an 
increase in fat free mass (mainly muscle) weight, which would reduce overall result on weight 
loss.  The simulation results surprisingly suggest that high intensity exercise has a smaller loss 
on body weight when compared to moderate intensity exercise.  One reason is that high 
intensity exercise results in a heavier fat free mass than the fat weight loss.   The second reason 
is that human body selects different energy sources (such as glucose) for a faster energy transfer 
rather than draw energy from body fat response to higher level energy consumption in high 
intensity exercise.   
Beside obesity, System Dynamics also has been widely applied to diabetes research.  The 
U.S. Centers for Disease Control and Prevention (CDC) started a modeling project in 2003 to 
construct a system dynamic model of diabetes [49].  The project team used the diabetes model to 
gain a better understanding of the diabetes burden in the U.S. and to evaluate possible interventions.  
The model simulates the diabetes onset process using the population at risk and the diabetes 
progression.  After the calibrating the model with historical data, the project team forecasted growth 
of diabetes and prediabetes prevalence through 2050 as the baseline for interventions evaluation. 
With several different scenario experiments, the CDC model successfully demonstrated an 
ability to evaluate health intervention policies.  Projected outcomes from upstream approach 
scenarios, downstream approach scenarios and balanced (combine both upstream and downstream) 
approach scenarios show that different intervention policies have different impacts. Downstream 
approaches are able to slow the growth of diabetes burden in a short time, but the benefit will be 
counteracted by the growth of diabetes prevalence.  After the growth of diabetes onset slowed for a 
short period, it resumed rapidly.  On the other hand, the result from the upstream intervention did 
not show any impact in the short run, but held back the prevalence of obesity, thus limiting diabetes 
onsets a great deal in the long run. 
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The CDC research focuses on the burden in the medical area.  In scenario evaluations, the 
burden estimated from current policies and the burden after possible interventions were represented 
using the population of people with diabetes.  The social, economic and human resource burden, 
however, were not included in this research.   My research has the similar objective and same 
approach; hence, I adapted some model structure and use it as a starting point of my research.  I also 
adapted some data for my research from data in the CDC model.  I will describe the detailed 
adaptation process in chapter 4.   
Jones et al. adopted the CDC research based on a similar System Dynamics model but with 
different scenario experiments [50]. The scenarios were characterized by the same categories 
(upstream, downstream and balanced approach) as scenarios in the CDC research; but they focus on 
social interventions rather than on the medical interventions using in the CDC model. For example, 
reducing obese prevalence was tested in Jones’ research rather than reducing caloric intake. Like the 
CDC research, Jones’ research used the size of the diabetic population to represent the burden. 
Rees et al. at Synergia Limited developed a System Dynamics model to assist development of 
strategic diabetes policy for Manukau, a large multi-cultural city in New Zealand [51].  In the first 
stage of the work, the project team created a simple stock-and-flow model to depict disease 
progression.  Figure 3-2 (taken from the project publication) illustrates concept of diabetes 
progression.  
 
 
Figure 3-2. Concept of Diabetes Progress (taken from [51]) 
 
A more refined model was developed based on the CDC model to examine possible 
interventions and estimate required resources to implement them.  The project team evaluated a 
range of interventions, and accounted for required resources from a whole-system perspective.  
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These interventions included an upstream approach, which works with the non-obese population, a 
downstream approach, which works directly with the diabetic population, and approach working with 
a potential high risk obese population.  Similar to the CDC model, the New Zealand model 
classifies people into several racial groups and age groups since different racial groups and age 
groups have different risk of developing diabetes.   
With a similar interest, I adapted a partial model structure from the New Zealand model since 
my research is also targeted on a multi-cultural urban health district.  The adaptation process will be 
described in chapter 4.     
3.2 Major Data Sources 
Data collection is a crucial step in model development before model parameterization.  
Modelers use simulation models to recreate real life problems in a controlled virtual environment 
by using mathematical equations.  All factors in the real world must be quantitatively converted 
into mathematical equations and numeric values in the model parameterization step.  The 
question is to identify the right quantity for each factor.  In order to answer this question, 
modelers need collect data for these factors.  For my research I mainly collect data from sources 
that can be grouped into three categories: local health authority reports, statistical surveys and 
the Canadian Census, and research papers.   
3.2.1 Local Health Authority Reports 
The Saskatoon Health Region Authority releases a report every year summarizing health 
region operations in the previous year [8, 33, 52, 53].  These annual reports supply information 
about the work force, facilities, operation cost, and service provided in the health region.  
Annual reports also describe demographic information and its dynamics about the health region.  
I was able to collect detailed demographic information especially regarding residents with 
Registered Indian status, who are at particularly high risk with respect to diabetes [69].  Annual 
reports describe the health status of residents in the region by using important health indicators; 
prevalence of diabetes is one of health indicators in the reports.  I was able to find the diabetes 
prevalence in the health region directly from the reports.  Besides the annual reports, the 
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Saskatoon Health Region Authority released a detailed health status report every five years [54].  
This report listed some key indicators, including population size, structure, birth rate, death rate 
and more, as attributes of overall health status of SHR population.  The values of many 
parameters in my model were drawn from in this report.  Both annual reports and health status 
reports can be obtained at the SHR website.               
"Diabetes 2000" is a strategic recommendation for diabetes published by Saskatchewan 
Health in year 2000 [55].  This document describes diabetes status – including prevalence and 
incidence rates – in Saskatchewan in 1996.  These rates are characterized by age, gender and 
race, and could be perfectly plugged into my model.  "Epidemiological Account of Diabetes in 
Saskatchewan: Diabetes Prevalence Rates in Health Districts, 1996" is another diabetes report 
released by Saskatchewan Health [56].  This report listed age and sex, and characterized 
prevalence of diabetes in all health districts.  The data can be used in the calibration step. 
The Health Quality Council recognizes the growing burden in Saskatchewan due to 
diabetes and possible improvement in disease management in the report “Quality of Diabetes 
Management in Saskatchewan” [34].  The supplementary tables and figures for this report 
provide a significant amount of data about diabetes in Saskatchewan in the 2003-04 fiscal year.  
These data including age-sex specific prevalence, age-sex specific incidence, incidence of end 
stage renal disease and mortality rates that can be adopted to my research.         
3.2.2 Statistical Surveys and the Canadian Census     
Statistical surveys are powerful instruments for collecting quantitative information in a 
population.  They obtain first-hand raw information directly from targeted population.  For my 
research I obtained data from several statistical surveys collected by Statistics Canada and other 
agencies. 
The National Population Health Survey (NPHS) is a broad health survey about Canadians’ 
physical and mental health conducted by Statistics Canada.  The NPHS collects cross-sectional 
and longitudinal data on economic, social, demographic, occupational and environmental health 
related data [57].  I have obtained the number of diabetes cases in Saskatchewan in the sample 
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set from the NPHS Cycle 3 Public Use Microdata File and use that to calculate diabetes 
prevalence in Saskatchewan.  Meanwhile, I obtained the body mass index information of 
Saskatchewan residents in the sample set, and estimated overweight and obesity prevalence in 
Saskatchewan. 
The Canadian Community Health Survey (CCHS) is another important cross-sectional 
health related survey from the Statistic Canada.  I collected a considerable amount of data from 
the CCHS for my model.  First, the CCHS asks health utility index (HUI) attributes in the 
questionnaires.  Hence, I was able to collect HUI data for normal weight, overweight/obese and 
diabetic population that measured in the unit of HUI, version 3 from CCHS Cycle 1.1 public use 
microdata file.  These HUI data initialize the HUI component in my model, which qualitatively 
measures improvement in health-related quality of length that result from interventions.  
Furthermore, I collected BMI data for population younger than 20 years from the CCHS.  The 
obesity measurement for children and youth is different from measurement for adults.  The 
CCHS Cycle 2.2 questionnaires cover measured weight and height data which can be used to 
measure obesity status for children and youth. 
Statistics Canada conducts a census every five years to capture a detailed demographic 
picture about the Canadian population.  I found data on the particular population structure of the 
SHR from 2001 Census data, and the finding has been calibrated with data from other sources to 
determine the initial population for my study.          
3.2.3 Related Research 
In previous section, I introduced some pioneering research of the System Dynamics 
approach in public health area.  Two of these studies were specifically for diabetes and 
intervention: the CDC model and the New Zealand model.  Although these two models targeted 
on different geographic area and populations but maintained many similar structure, I was able to 
use some common data for the initial values of parameters in my model. 
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3.3 Summary 
In this chapter, I reviewed some pioneering studies of applications of the System 
Dynamics methodology, which give an advanced starting point for my study.  These studies 
adopt the System Dynamics modeling approach to analysis and understand issues in chronic 
disease management.  Some of them have a broad scope, such as tobacco control; some of them 
focus on individuals, such as weight control; but all of these studies were creating a system-wide 
view for their targets and tried to estimate the impact over entire system rather than a small 
immediate sector from interventions. 
Beside the related research, I briefly described major data sources used in my research.  
Some statistical data from surveys, the Canadian Census and local health authority reports can be 
directly plugged into the model, but some requires tuning and adjustment.  I will describe the 
detailed data tuning process in the next chapter.   
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CHAPTER 4 
SIMULATION MODEL FOR DIABETES IN SASKATOON HEALTH 
REGION 
In this chapter, the development of my model is described.  First, I converted the New 
Zealand and the CDC diabetes models’ structures to Vensim, the software selected to build my 
model.  During the adaptation, I modified the original structure to represent the local population 
structure and health care system.  The model was also modified to accommodate our 
prospective goals.  Secondly, I extended the model with additional interrelated areas such as 
Health Related Quality of Life.  These additional sections would help users to observe and 
compare the impact of different policies on different components of the situation. 
This chapter also presents the detailed model structure.  The model contains two core 
sections and several accessory sections.  The two core sections are the normoglycemic 
population section and the hyperglycemic population section.  These two sections provide the 
basic population structure of the model and the formulae governing the dynamics within and 
between normoglycemic population and hyperglycemic population used in the simulation.  The 
accessory sections are the structure associated with the initial population, HRQoL, mortality, 
prediabetes diagnosis, diabetes diagnosis and early stage complication diagnosis.  Beside these 
accessory sections, the model has a calibration section, which will be described in the calibration 
chapter.  The model also has several customized output sections to help a user gain a better 
understanding of simulation results. 
4.1 Development of the System Dynamics Model 
4.1.1 Adaption of the New Zealand Model and the CDC Model 
In the last chapter, I reviewed several research publications about the diabetes model 
from the U.S. Centers for Disease Control and Prevention.  These contributions provide a solid 
foundation for my study.  With a similar research objective, I adapted the diabetes onset and 
progress structure from the CDC model illustrated in Figure 4-1. In the CDC model, the 
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hyperglycemic population is classified into three levels according to hyperglycemia progress: 
prediabetes, diabetes without complication, and diabetes with complication; and two stages 
according to hyperglycemia diagnosis status: diagnosed hyperglycemia and undiagnosed 
hyperglycemia.  During the adaptation, I applied a similar classification.  The hyperglycemic 
population in my (SHR) model is classified into four levels according to hyperglycemia progress: 
prediabetes, diabetes without complication, diabetes with early stage macrovascular 
complication and diabetes with late stage macrovascular complication.  With the exception of 
people with late stage macrovascular complication, the hyperglycemic population in the SHR 
model is classified into the same two categories as in the CDC model by hyperglycemia 
diagnosis: diagnosed hyperglycemia and undiagnosed hyperglycemia.  This classification 
clearly separates the hyperglycemic population into seven different stocks, so I can easily track 
changes in overall diabetes progression. 
The New Zealand model separates the normoglycemic population – called the “general 
population” – according to age and obesity status as shown in Figure 4-2.  This grouping 
method separates the normoglycemic population based on their latent risk of developing Type 2 
diabetes since Type 2 diabetes is highly relevant to aging and obesity.  By adapting this 
grouping method in my model, the model simulates Type 2 diabetes’ onset and progression in 
details.  Moreover, model users can have a detailed observation and better understanding of the 
potential risk of developing Type 2 diabetes.  
Both the CDC model and the New Zealand Model seek to simulate diabetes prevalence. 
By adapting similar structures from these pioneer studies, I seek to draw on insights from 
researchers involved in building those models, and to avoid mistakenly creating an unreasonable 
model. 
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Figure 4-1. Diabetes Onset and Progress Structure in the CDC Model 
 
 
Figure 4-2. General Population Structure in the New Zealand Model 
 
4.1.2 Structure Modification and Correction 
Although the New Zealand model helped me starting my modeling process, during the 
adaptation process, I found that some components in this model do not fit my research or the 
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specifics of the local situation.  Therefore, I selectively adapted and modified the model.   
The New Zealand model presents the process of aging and the process of becoming obese 
admirably. It logically shows the population flows from the normal weight to an obese state and 
then to diabetes.  However, the version of the model examined seems to be incomplete; there is 
no death outflow from the obese population, but the New Zealand model has an outflow “dying 
other causes” for every non-obese population stock.  Nevertheless, there is no outflow for obese 
population stocks except from the 65plus stock.  The absence of death flows leads an obvious 
issue: it does not reflect the situation of the real world, where deaths happen for every age.  If 
the obesity rate is high in a community, then obviously the overall health status will be getting 
worse since with more people become obese; the overall death rate will increase as many chronic 
diseases are highly associated with obesity.  However, the simulation results for the model 
available to us show a decreasing overall death rate because no obese people will die until they 
reach age 65. As a solution for our model, I added death outflows that are similar to those of 
non-obese general population stocks for each obese population stock. 
Although obese population has the highest level of risk of developing Type 2 diabetes, 
normal weight and overweight population also have levels of risk of developing Type 2 diabetes.  
The New Zealand model does not have a flow representing developing diabetes from normal 
weight population, and the only path to develop diabetes is becoming obese first.  Hence, I 
added developing diabetes from normal weight and overweight population flow into my model.     
Both the CDC model and the New Zealand model lack detailed age structures in the 
diabetes progression section.  The CDC model does not separate the population by age but 
instead use a coefficient to adjust the risk of developing diabetes for proportion in the population 
group.  The structure does not capture the co-variance between ethnicity and age structure of 
the population in the SHR: the Caucasian population tends to be older, but the Aboriginal 
population tends to be younger.  Most notable, the model does not track population age change 
over the simulation period, which could be several decades.   The New Zealand model 
separates non-diabetic population into 6 age groups, but there are no similar age groups for the 
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diabetic population.  Without age group structure for the hyperglycemic population, I found the 
model may produce misleading results when population flows from the normoglycemic 
population section into the hyperglycemic population section.  When acquiring diabetes, all 
individuals originating from different normoglycemic population age groups are aggregated 
together since there is no age structure in the hyperglycemic population section.  For the 
younger age groups, the expected life span in those age groups is longer than the expected life 
span for the aggregated diabetics. The model is thus capable of showing that acquiring diabetes 
will reduce the life span!  For the older age group, however, the lack of age structure in the 
diabetic section causes signification artifacts in the results.  For example, the expected life span 
for the 65plus age normoglycemic group is 10 years, but the expected life span for aggregated 
diabetics is more than 10 years in the model.  That means for the 65plus age group, acquiring 
diabetes will not reduce the life span but instead increases the life span.  In order to avoid this 
artifact, I extended the age structure into the hyperglycemic population section.  My model has 
the age group structure – 17 5-years age categories, starting from age 0 and ending at age 80 plus 
– for both normoglycemic population and hyperglycemic population.       
The CDC model and the New Zealand model were built to analyze research questions 
related to the diabetes burden in U.S. and New Zealand.  The structure I adopted from these 
models above does not capture some unique characteristics of diabetes prevalence in SHR.  
Therefore, I further modified the adapted structure in order to represent the local situation. 
First, I separated the normal weight, overweight and obese population.  Both overweight 
and obese populations suffer a higher risk of developing Type 2 diabetes and other chronic 
conditions than do the normal weight population.  Statistics Canada reports that the odds ratio 
of developing diabetes for the overweight and obese population are 1.73 and 3.79 (where the 
acceptable weight population is the control group) [58].  This grouping is able to highlight the 
different risks of developing diabetes between different populations.     
Second, I changed the ethnic classification of groups in my model based on Saskatoon 
local ethnic classification.  Both the CDC model and the New Zealand model classified the 
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population into different ethnic groups.  In the CDC model, the black and Hispanic 
subpopulation were separated from others since these two ethnic groups have a higher risk of 
developing Type 2 diabetes.  In the New Zealand model, Maori and Pacific Islanders were 
analyzed separately based on the similar considerations.  In Chapter 2, I noted that in the SHR 
diabetes has higher prevalence among Aboriginal subpopulation (especially among Aboriginal 
women) in the SHR.  Hence, I classified the population into two ethnic groups in my model: 
Aboriginal and other.  This classification allows us compare dynamics of both ethnic groups, 
and allows us to investigate the causes contributing to the higher prevalence among Aboriginal 
people.   
Beside the local ethnic group structure, I added a gender group structure into the model.  
The gender group structure assists the ethnic group structure to finely classify the population 
based on different risk of developing Type 2 diabetes and accurately characterize the local 
diabetes situation.  The gender group structure would also help us to extend the model to 
gestational diabetes in future.  These changes greatly increase accuracy of the model, but 
unfortunate also the complexity.    
4.2 Model Structure 
With these corrections and modifications, my model is able to systemically represent the 
high-level elements contributing to the burden from Type 2 diabetes in the SHR.  For a 
complete simulation I still need equations, parameters and initial values for the model.  In this 
section, I describe the model structures and equations. 
The model contains two core components: the normoglycemic population and the 
hyperglycemic population.  The normoglycemic population section represents people in the 
SHR whose blood glucose levels lie within a normal range.  This population group is divided 
into three major subgroups by weight categories: normal weight, overweight and obese.  The 
model simulates people’s weight change by a flow of the population among weight subgroups.  
The weight subgroups are represented as stock variables in the model sketch.  Within a 
subgroup, the population is classified into smaller scale subgroups by age, ethnicity and gender.  
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These final classifications are represented using subscripts in equations in order to keep the 
model sketch clean and organized.   
The hyperglycemic population section represents people who already developed 
prediabetes or Type 2 diabetes in the SHR.  The hyperglycemic population section is first 
divided into four hyperglycemia progress stages: prediabetes, diabetes without complication, 
diabetes with early stage macrovascular complication and diabetes with late stage macrovascular 
complication.  Every hyperglycemia progress stage includes two hyperglycemia diagnosis 
statuses: undiagnosed and diagnosed, except the diabetes with late stage macrovascular 
complication, which are considered to be all diagnosed according to our definition.  Hence, the 
hyperglycemic population is divided into seven major subgroups by hyperglycemia progress 
stages and hyperglycemia diagnosis status in the model.  The population in each major 
subgroup is further divided by age, ethnicity and gender as subscripts in equations.  
Beside the two core sections, the model has a Health Related Quality of Life (HRQoL) 
section.  The HRQoL section calculates aggregated HRQoL-related measures for population in 
different groups.  In other words, this section quantitatively converts aggregated quality of life 
associated with an individual’s health status from an abstract concept to a numerical value.  
Based on the HRQoL for different population categories (which are assumed to be identical 
across ethnic groups), this section of the model calculates the accumulated Quality Adjusted Life 
Years lived by the population as a whole.  By comparing the results simulated for a baseline 
status quo scenario and a different scenario simulating an intervention, users can gain insights 
into the potential impact of an intervention.  Although the comparison of HRQoL is not applied 
in my study, the HRQoL section can serve as a useful tool for future work.     
One purpose of the model is examining interventions.  Most interventions are reflected 
by rate changes in the model.  For instance, if we want to simulate the introduction of a physical 
activity program for high school students, the direct manner to present this intervention in the 
model is by decreasing the becoming overweight and the becoming obese flows for school age 
population groups.  I created an easy-to-use control interface for key rates in the model; hence, 
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users could easily introduce new intervention into the system. 
4.2.1 Normoglycemic Population Section  
The normoglycemic population is the population in the SHR except for the prediabetic 
and diabetic population.  The normoglycemic population is the population group who could 
potentially develop Type 2 diabetes.  Dependent on age, ethnicity, gender and level of obesity, 
people in the normoglycemic population section have different levels of risk of developing Type 
2 diabetes.  It is essential to recognize the different risk of developing diabetes between people; 
hence, I separate normoglycemic population into different subgroups.  First, I classify people 
into three groups by their body mass index: normal weight population, overweight population 
and obese population.  In accordance with the standard classification [59], people who have a 
BMI less than 25 are classified into the normal weight population group; people who have BMI 
greater than or equal to 25 but less than 30 are classified into the overweight population group; 
and people who have BMI greater than or equal to 30 are classified into the obese population 
group.  It is a well-known fact that Type 2 diabetes is highly associated with obesity.  People 
who are overweight or obese have much higher risk of developing Type 2 diabetes than normal 
weight people. The standard classification can highlight the higher risk among overweight and 
obese population in a simulation and capture impacts from interventions that cause changes in 
the weight distribution of the population.   
Beside body mass index, age is another important factor which makes a great 
contribution to the risk of developing Type 2 diabetes.  The National Diabetes Surveillance 
System (NDSS) data shows that Type 2 diabetes prevalence and incidence are much higher 
among the elderly population compared to the young population (see Figure 4-3).  In order to 
show this difference, I further divide the population in each weight group into 17 different age 
groups, using commonly used 5-year age categories: 0 to 4, 5 to 9, 10 to 14, 15 to 19, 20 to 24, 
25 to 29, 30 to 34, 35 to 39, 40 to 44, 45 to 49, 50 to 54, 55 to 59, 60 to 64, 65 to 79, 70 to 74, 75 
to 79 and 80 plus. 
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 Figure 4-3. Incidence Rate of Type 2 Diabetes in Saskatchewan, estimated from NDSS 
 
Figure 4-4 illustrates the conceptual structure of the normoglycemic population section in 
my model.  In the actual model sketch, all age groups are represented by subscripts in the 
equations rather than the individual stocks included in Figure 4-4.  I can easily add new 
parameters and modify equations that apply to all subgroups in the normoglycemic population 
section by using subscripts, but because subscripts hide many aspect of model structure, it is 
difficult to visually illustrate the aging chain in the model using subscripts.  Hence, I redrew age 
groups to stocks for an easy visual understanding of the aging chain structure.  The 
normoglycemic population stocks are grouped into three segments: normal weight population, 
overweight population and obese population.  Three aging chains for these three segments are 
circled by different color in Figure 4-4.  There are total 17 age group stocks for each aging 
chain.  Because 17 stocks and flows between stocks are too much to draw, I did not draw all 17 
stocks in Figure 4-4 but selected 5: the first age group, the last age group and three groups 
between the first age group and the last age group to show the chain structure. 
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Figure 4-4. Normoglycemic Population Aging Chain Structure 
 
The top portion of Figure 4-4 circled by the blue box is the aging chain structure for the 
normal weight population.  An aging flow connects every two adjacent age group stocks and 
forms chain structure.  These aging flows move people from younger population stocks to older 
population stocks as people age.   An aging flow is an outgoing flow, speaking from the view 
point of the younger age group stock but it is also an incoming flow from the view point of the 
older age group stock.  Hence, every age group stock except the 0 to 4 and the 80 plus age 
group has two aging flows; one from the previous age group and one to the next age group.  
Figure 4-5 shows a generic normal weight population stock and all flows that connect with the 
stock.  The incoming aging flow is named “normal weight aging from previous age group” and 
the outgoing aging flow is named “normal weight aging to next age group” in Figure 4-5.   
In order to simplify the calculation of the aging flow rates, I made the assumption that the 
population within each age group is evenly distributed across the ages included within that group.  
Hence, rates of the age flows (as measured in number of people per unit time) are only 
influenced by the width of the interval and population of the younger age group.  For example, 
on average 20% (1/5) of the population in the normal weight age group 5 to 9 age group ages to 
the normal weight age group 10 to 14 age group every year.        
The first age group – normal weight 0 to 4 – does not have an incoming aging flow since 
it has no age group younger than it.  However, it has a unique incoming flow from outside of 
the system: being born normal weight.  Every year the system generates a certain amount of 
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newborn infants based on total population in the system and the birth rate.  Theoretically, only a 
fraction of newborn infants flow to the normal weight population section and other infants flow 
to the overweight or obese population section according to their birth weight.  However, the 
birth weight has a U-shape relationship with risk of developing Type 2 diabetes at later age [60].  
I assumed all infants are born into the normal weight category in order to simplify the model by 
setting the fraction of normal weight infant in all newborn infants to 1.  The fraction of normal 
weight infant can be set to an accurate value later when data is available. 
 
 
Figure 4-5. Normal Weight Population Stock and Flows 
 
The normal weight 80 plus is the last stock in the normal weight population aging chain.  
Hence, unlike other stocks in the aging chain, it has no outgoing aging flow towards the next age 
group stock.  The population stays in the stock until they die or their health status changes. 
A part of the population in each normal weight population stock is dying from many 
causes, such as illness, accidents or other conditions other than diabetes.  This part of 
population flows out of the system through the normal weight dying all causes flow.  The flow 
rate is dependent on the mortality risk of the group.  Hence, the rates vary across the population 
stocks since different age groups have different mortality rates.  The mortality rate for each age 
and gender group in normal weight normoglycemic population is calculated by the number of 
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deaths in Saskatchewan and total population in Saskatchewan in 2001.  An identical mortality 
rate is applied to both ethnic groups.                
All normoglycemic subpopulations have a risk of developing hyperglycemia; young age 
groups have lower risks, elderly age groups have higher risks.  Reflecting this, a developing 
prediabetes flow is associated with all normal weight population stocks.  The developing 
prediabetes flow for a normal weight age group is controlled by prediabetes incidence base rate 
normal weight, prediabetes onset risk age multiplier, prediabetes onset age coefficient and the 
size of population in the age group.  The prediabetes incidence base rate normal weight and the 
prediabetes onset multiplier are obtained from the CDC model directly.  The prediabetes onset 
risk multiplier is the coefficient that highlights the different risk of developing diabetes from 
different age group.  However, this coefficient is too broad since it only differentiates the risks 
of developing diabetes in young population and in elderly population.  I introduced a new 
coefficient, the prediabetes onset age coefficient, to differentiate the different risks of developing 
diabetes among child, adolescent and adult subpopulation groups.  The prediabetes onset age 
coefficient is set to 0.1 before age 20 and 1 after age 20.  Results from multiplication of 
prediabetes incidence base rate normal weight, prediabetes onset age multiplier and prediabetes 
onset age coefficient highlight different risk of developing hyperglycemia with different age 
groups.   
The normal weight population is defined as people with BMI less than 25.  When people 
gain weight and the BMI exceeds 25, they are no longer classified as being of normal weight.  
They move to the next weight category, the overweight population, through the becoming 
overweight flows.  Rates of the becoming overweight flows are calculated based on the 
population in each normal weight stock and the incidence of becoming overweight for the stock.  
The incidence of becoming overweight is controlled by incidence of overweight base rate, 
weight change age coefficient, weight change gender coefficient and weight change ethnic 
coefficient.  An appraised value is assigned to the incidence of overweight base rate to initialize 
the model.  A more accurate value of incidence of becoming overweight is applied by 
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calibrating these three weight change coefficients.     
Equation 4.1 below shows the equation for the normal weight age population stocks 
except for those associated with the first and the last age group.  Equation 4.2 is for the 0 to 4 
age group and Equation 4.3 is for the 80 plus age group.  They are slightly different from 
Equation 4.1 since both age groups only have one aging flow.  All age groups in these equations 
contain subscripts for ethnic groups and gender groups in the model, but I did not list them here.  
 
𝑛𝑜𝑟𝑚𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛[𝑚𝑖𝑑𝑑𝑙𝑒 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝𝑠](𝑇)
=  � �𝑛𝑜𝑟𝑚𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑎𝑔𝑖𝑛𝑔 [𝑝𝑟𝑒𝑣𝑖𝑜𝑢𝑠 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝𝑠]𝑇
0
− 𝑛𝑜𝑟𝑚𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑎𝑔𝑖𝑛𝑔[𝑚𝑖𝑑𝑑𝑙𝑒 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝𝑠]
− 𝑛𝑜𝑟𝑚𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑑𝑦𝑖𝑛𝑔 𝑎𝑙𝑙 𝑐𝑎𝑢𝑠𝑒𝑠[𝑚𝑖𝑑𝑑𝑙𝑒 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝𝑠]
− 𝑏𝑒𝑐𝑜𝑚𝑖𝑛𝑔 𝑜𝑣𝑒𝑟𝑤𝑒𝑖𝑔ℎ𝑡[𝑚𝑖𝑑𝑑𝑙𝑒 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝𝑠]
− 𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑓𝑟𝑜𝑚 𝑛𝑜𝑟𝑚𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡[𝑚𝑖𝑑𝑑𝑙𝑒 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝𝑠]+  𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 𝑛𝑜𝑟𝑚𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡[𝑚𝑖𝑑𝑑𝑙𝑒 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝𝑠]�𝑑𝑡. 
(4.1) 
 
 
𝑛𝑜𝑟𝑚𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛[0 𝑡𝑜 4](𝑇)
=  � �𝑏𝑒𝑖𝑛𝑔 𝑏𝑜𝑟𝑛 𝑛𝑜𝑟𝑚𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 –𝑛𝑜𝑟𝑚𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑑𝑦𝑖𝑛𝑔 𝑎𝑙𝑙 𝑐𝑎𝑢𝑠𝑒𝑠[0 𝑡𝑜 4]𝑇
0
− 𝑏𝑒𝑐𝑜𝑚𝑖𝑛𝑔 𝑜𝑣𝑒𝑟𝑤𝑒𝑖𝑔ℎ𝑡[0 𝑡𝑜 4] − 𝑛𝑜𝑟𝑚𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑎𝑔𝑖𝑛𝑔[0 𝑡𝑜 4]
− 𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑓𝑟𝑜𝑚 𝑛𝑜𝑟𝑚𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡[0 𝑡𝑜 4]+ 𝑛𝑜𝑟𝑚𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦[0 𝑡𝑜 4]�𝑑𝑡. 
(4.2) 
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𝑛𝑜𝑟𝑚𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛[80 𝑝𝑙𝑢𝑠](𝑇)
=  � �𝑛𝑜𝑟𝑚𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑎𝑔𝑖𝑛𝑔 [75 𝑡𝑜 79]𝑇
0
−  𝑛𝑜𝑟𝑚𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑑𝑦𝑖𝑛𝑔 𝑎𝑙𝑙 𝑐𝑎𝑢𝑠𝑒𝑠[80 𝑝𝑙𝑢𝑠]
− 𝑏𝑒𝑐𝑜𝑚𝑖𝑛𝑔 𝑜𝑣𝑒𝑟𝑤𝑒𝑖𝑔ℎ𝑡[80 𝑝𝑙𝑢𝑠]
− 𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑓𝑟𝑜𝑚 𝑛𝑜𝑟𝑚𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡[80 𝑝𝑙𝑢𝑠]+ 𝑛𝑜𝑟𝑚𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦[80 𝑝𝑙𝑢𝑠]�𝑑𝑡. 
(4.3) 
 
The initial value of the normal weight population stocks are calculated based on the total 
normoglycemic population in the SHR and the overweight/obese rate for the Saskatchewan 
population. 
The middle portion of Figure 4-4 that is circled by a red box is the aging chain for the 
overweight population.  The overweight population aging chain has the same number of stocks 
as the normal weight population aging chain.  All age groups are associated with 5 year age 
category up to age 80.  The population moves to the corresponding age group stock in the 
overweight segment from the normal weight segment when their BMI changes to exceed 25.  
Figure 4-6 illustrates an overweight population stock and associated flows.  The structure of an 
overweight population stock is very similar to that of a normal weight population stock.  Every 
overweight population stock has two aging flows except the age group 0 to 4 and the age group 
80 plus.  Beside aging flows, an overweight population stock also has a dying all causes flow, a 
developing prediabetes flow and a prediabetes recovery flow. 
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Figure 4-6. Overweight Population Stock and Flows 
 
A becoming overweight flow connects a normal weight general population stock and an 
overweight general population stock in the same age group.  As I explained before, the rate of a 
becoming overweight flow is controlled by incidence of overweight.  In reality, a small portion 
of overweight people could lose weight and become normal weight again.  I made the 
assumption that incidence of overweight is a net value, which includes people become 
overweight and people back to normal weight, to simplify the model.  This assumption allows 
the model to examine the scenario where the incidence of becoming overweight changes to a 
smaller value, but does not allow the model to examine the scenario where people flow back to 
the normal weight general population stock from the overweight general population stock 
without necessary modification.     
The criterion for a person to be considered overweight is BMI higher than 25 but lower 
than 30.  When a person’s BMI exceeds 30, they move to the next level, to the obese population 
segment through a becoming obese flow that is colored in orange in Figure 4-6.  Structurally 
identical to becoming overweight flow, the rate of becoming obese flow is controlled by the 
incidence of obesity and population in the overweight population group.  The incidence of 
obesity is the product of incidence of obesity base rate, weight change age coefficient, weight 
change gender coefficient, and weight change ethnic coefficient.  Absent a reliable data source 
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on the weight change dynamics over time, these coefficients are adjusted by a calibration 
process.       
The Overweight dying all causes flow, overweight prediabetes recovery flow and 
developing prediabetes from overweight flow are structurally identical to the corresponding 
flows in the normal weight segment.  However, the flow rates show a significant difference 
since the two population groups have different level of risks of death and developing prediabetes.  
Mortality of the overweight population is calculated based on mortality of normal weight 
population and relative risk of death for different BMI levels.  The rate of developing 
prediabetes from overweight flow is calculated based on prediabetes incidence rate for normal 
weight population and prediabetes onset overweight multiplier.  While the CDC model did not 
disaggregate the population by weight status, it does make some attempts to capture the impact 
of overweight and the prediabetes onset overweight multiplier is set to 1.7 according to the CDC 
model.  The prediabetes recovery rate for overweight population initially is set to 10% per year 
according to the CDC model.  This value seems to be too high for the SHR; hence, it is changed 
to 3% instead.     
Equations 4.4 to 4.6 explain mathematically how these flows work together to create 
dynamics of an overweight population age groups.  Similar to the normal weight population 
groups, age group 0 to 4 has a unique incoming flow being born overweight and age group 80 
plus has no outgoing aging flow. 
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𝑜𝑣𝑒𝑟𝑤𝑒𝑖𝑔ℎ𝑡 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛[𝑚𝑖𝑑𝑑𝑙𝑒 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝𝑠] (𝑇)
=  � [𝑜𝑣𝑒𝑟𝑤𝑒𝑖𝑔ℎ𝑡 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑎𝑔𝑖𝑛𝑔 [𝑝𝑟𝑒𝑣𝑖𝑜𝑢𝑠 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝𝑠]𝑇
0
− 𝑜𝑣𝑒𝑟𝑤𝑒𝑖𝑔ℎ𝑡 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑎𝑔𝑖𝑛𝑔[𝑚𝑖𝑑𝑑𝑙𝑒 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝𝑠]
− 𝑜𝑣𝑒𝑟𝑤𝑒𝑖𝑔ℎ𝑡 𝑑𝑦𝑖𝑛𝑔 𝑎𝑙𝑙 𝑐𝑎𝑢𝑠𝑒𝑠[𝑚𝑖𝑑𝑑𝑙𝑒 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝𝑠]
− 𝑏𝑒𝑐𝑜𝑚𝑖𝑛𝑔 𝑜𝑏𝑒𝑠𝑒[𝑚𝑖𝑑𝑑𝑙𝑒 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝𝑠]+  𝑏𝑒𝑐𝑜𝑚𝑖𝑛𝑔 𝑜𝑣𝑒𝑟𝑤𝑒𝑖𝑔ℎ𝑡[𝑚𝑖𝑑𝑑𝑙𝑒 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝𝑠]
− 𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑓𝑟𝑜𝑚 𝑜𝑣𝑒𝑟𝑤𝑒𝑖𝑔ℎ𝑡[𝑚𝑖𝑑𝑑𝑙𝑒 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝𝑠]+  𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 𝑜𝑣𝑒𝑟𝑤𝑒𝑖𝑔ℎ𝑡[𝑚𝑖𝑑𝑑𝑙𝑒 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝𝑠]]𝑑𝑡. 
(4.4) 
 
 
𝑜𝑣𝑒𝑟𝑤𝑒𝑖𝑔ℎ𝑡 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛[0 𝑡𝑜 4] (𝑇)
=  � [𝑏𝑒𝑖𝑛𝑔 𝑏𝑜𝑟𝑛 𝑜𝑣𝑒𝑟𝑤𝑒𝑖𝑔ℎ𝑡 − 𝑜𝑣𝑒𝑟𝑤𝑒𝑖𝑔ℎ𝑡 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑎𝑔𝑖𝑛𝑔[0 𝑡𝑜 4]𝑇
0
− 𝑜𝑣𝑒𝑟𝑤𝑒𝑖𝑔ℎ𝑡 𝑑𝑦𝑖𝑛𝑔 𝑎𝑙𝑙 𝑐𝑎𝑢𝑠𝑒𝑠[0 𝑡𝑜 4] − 𝑏𝑒𝑐𝑜𝑚𝑖𝑛𝑔 𝑜𝑏𝑒𝑠𝑒[0 𝑡𝑜 4]+  𝑏𝑒𝑐𝑜𝑚𝑖𝑛𝑔 𝑜𝑣𝑒𝑟𝑤𝑒𝑖𝑔ℎ𝑡[0 𝑡𝑜 4]
− 𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑓𝑟𝑜𝑚 𝑜𝑣𝑒𝑟𝑤𝑒𝑖𝑔ℎ𝑡[0 𝑡𝑜 4]+  𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 𝑜𝑣𝑒𝑟𝑤𝑒𝑖𝑔ℎ𝑡[0 𝑡𝑜 4]]𝑑𝑡. 
(4.5) 
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𝑜𝑣𝑒𝑟𝑤𝑒𝑖𝑔ℎ𝑡 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛[80 𝑝𝑙𝑢𝑠] (𝑇)
=  � [𝑜𝑣𝑒𝑟𝑤𝑒𝑖𝑔ℎ𝑡 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑎𝑔𝑖𝑛𝑔 [75 𝑡𝑜 79]𝑇
0
− 𝑜𝑣𝑒𝑟𝑤𝑒𝑖𝑔ℎ𝑡 𝑑𝑦𝑖𝑛𝑔 𝑎𝑙𝑙 𝑐𝑎𝑢𝑠𝑒𝑠[80 𝑝𝑙𝑢𝑠] − 𝑏𝑒𝑐𝑜𝑚𝑖𝑛𝑔 𝑜𝑏𝑒𝑠𝑒[80 𝑝𝑙𝑢𝑠]+  𝑏𝑒𝑐𝑜𝑚𝑖𝑛𝑔 𝑜𝑣𝑒𝑟𝑤𝑒𝑖𝑔ℎ𝑡[80 𝑝𝑙𝑢𝑠]
− 𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑓𝑟𝑜𝑚 𝑜𝑣𝑒𝑟𝑤𝑒𝑖𝑔ℎ𝑡[80 𝑝𝑙𝑢𝑠]+  𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 𝑜𝑣𝑒𝑟𝑤𝑒𝑖𝑔ℎ𝑡[80 𝑝𝑙𝑢𝑠]]𝑑𝑡. 
(4.6) 
 
In a manner similar to what is used for the normal weight population, the initial value of 
the overweight population stocks is obtained from the total normoglycemic population in the 
SHR and overweight/obese rate for Saskatchewan population. 
The last segment in the normoglycemic population section is the obese population 
segment.  This segment is circled by a grey box in Figure 4-4.  People in this segment have 
BMI higher than 30.  Just as in the two previous segments, this segment has 17 age groups and 
each age group is further divided into subpopulations according to ethnicity and gender.   The 
model structure and equation structure are very similar to the structures in the overweight 
population segment.  The only difference in structure is that an obese population stock does not 
have a progress flow towards to the next heavier normoglycemic population segment since the 
obese population segment is the last segment in the normoglycemic population section.  Figure 
4-7 below shows the structure of an obese population stock and associated flows.  Equations 4.7 
to 4.9 mathematically characterize the formulation of the obese population stocks and flows. 
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𝑜𝑏𝑒𝑠𝑒 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛[𝑚𝑖𝑑𝑑𝑙𝑒 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝𝑠](𝑇)
=  � �𝑜𝑏𝑒𝑠𝑒 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑎𝑔𝑖𝑛𝑔 [𝑝𝑟𝑒𝑣𝑖𝑜𝑢𝑠 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝𝑠]𝑇
0
− 𝑜𝑏𝑒𝑠𝑒 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑎𝑔𝑖𝑛𝑔[𝑚𝑖𝑑𝑑𝑙𝑒 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝𝑠]
− 𝑜𝑏𝑒𝑠𝑒 𝑑𝑦𝑖𝑛𝑔 𝑎𝑙𝑙 𝑐𝑎𝑢𝑠𝑒𝑠[𝑚𝑖𝑑𝑑𝑙𝑒 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝𝑠]+  𝑏𝑒𝑐𝑜𝑚𝑖𝑛𝑔 𝑜𝑏𝑒𝑠𝑒[𝑚𝑖𝑑𝑑𝑙𝑒 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝𝑠]
− 𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑓𝑟𝑜𝑚 𝑜𝑏𝑒𝑠𝑒[𝑚𝑖𝑑𝑑𝑙𝑒 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝𝑠]+  𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 𝑜𝑏𝑒𝑠𝑒[𝑚𝑖𝑑𝑑𝑙𝑒 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝𝑠]�𝑑𝑡. 
(4.7) 
 
𝑜𝑏𝑒𝑠𝑒 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛[0 𝑡𝑜 4](𝑇)
=  � �𝑏𝑒𝑖𝑛𝑔 𝑏𝑜𝑟𝑛 𝑜𝑏𝑒𝑠𝑒 − 𝑜𝑏𝑒𝑠𝑒 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑎𝑔𝑖𝑛𝑔[0 𝑡𝑜 4]𝑇
0
− 𝑜𝑏𝑒𝑠𝑒 𝑑𝑦𝑖𝑛𝑔 𝑎𝑙𝑙 𝑐𝑎𝑢𝑠𝑒𝑠[0 𝑡𝑜 4] +  𝑏𝑒𝑐𝑜𝑚𝑖𝑛𝑔 𝑜𝑏𝑒𝑠𝑒[0 𝑡𝑜 4]
− 𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑓𝑟𝑜𝑚 𝑜𝑏𝑒𝑠𝑒[0 𝑡𝑜 4]+  𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 𝑜𝑏𝑒𝑠𝑒[0 𝑡𝑜 4]�𝑑𝑡. 
 
(4.8) 
𝑜𝑏𝑒𝑠𝑒 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛[80 𝑝𝑙𝑢𝑠](𝑇)
=  � �𝑜𝑏𝑒𝑠𝑒 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑎𝑔𝑖𝑛𝑔 [75 𝑡𝑜 79]𝑇
0
− 𝑜𝑏𝑒𝑠𝑒 𝑑𝑦𝑖𝑛𝑔 𝑎𝑙𝑙 𝑐𝑎𝑢𝑠𝑒𝑠[80 𝑝𝑙𝑢𝑠] +  𝑏𝑒𝑐𝑜𝑚𝑖𝑛𝑔 𝑜𝑏𝑒𝑠𝑒[80 𝑝𝑙𝑢𝑠]
− 𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑓𝑟𝑜𝑚 𝑜𝑏𝑒𝑠𝑒[80 𝑝𝑙𝑢𝑠]+  𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 𝑜𝑏𝑒𝑠𝑒[80 𝑝𝑙𝑢𝑠]�𝑑𝑡. 
(4.9) 
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Figure 4-7. Obese Population Stock and Flows 
 
The initial value of the obese normoglycemic population, like the initial value of the 
normal weight and overweight normoglycemic population, is calculated by the total 
normoglycemic population in the SHR and Saskatchewan overweight/obese rate.  The mortality 
of the obese populations is calculated based on the mortality of the normal weight population and 
relative rate of death.  The rate of the becoming obese flow is controlled by incidence of obesity 
base rate and three weight change coefficients.  Again, the values of the three weight change 
coefficients are adjusted by calibration due to lack of reliable data.  The rate of developing 
prediabetes from obese flow is based on prediabetes incidence base rate obese and the size of the 
obese population in the stock.  The prediabetes incidence base rate is calculated using the rate 
of prediabetes incidence base rate normal weight multiplied by prediabetes onset obese 
multiplier.  Prediabetes onset obese multiplier is set to a constant value of 2.6, which has been 
used in the CDC model.  The rate of the prediabetes recovery obese flow is set to 0 due to the 
assumption that “obese people must lose weight and become overweight before they can recover 
from prediabetes”. 
4.2.2 Hyperglycemic Population Section 
One of the major objectives of this study is to simulate the dynamics of the diabetic 
population in the SHR.  The “hyperglycemic population” section is intended to simulate the 
dynamics in the hyperglycemic population and between the hyperglycemic and the 
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normoglycemic population.  The section provides information regarding prevalence of Type 2 
diabetes by monitoring the population in the hyperglycemic population stocks, and information 
regarding incidence rate of Type 2 diabetes by monitoring the rates of flows.  The section also 
provides a testbed for downstream interventions.  By changing rates of various flows from the 
status quo or adding exogenous conditions to the section “hyperglycemic population”, the model 
can simulate different possible downstream interventions and project outcomes from the 
interventions.         
The population in the section “hyperglycemic population” is classified into different 
population stocks based on several criteria: diagnosis of the disease, progression of the disease 
and age, gender and ethnicity.  The classification distinguishes the unique characters of each 
population stock.  These population stocks are connected by flows and these flows capture the 
dynamics in the hyperglycemic population.  Figure 4-8 is the simplified model structure of the 
section “hyperglycemic population”. 
 
 
Figure 4-8. Development of Hyperglycemia 
 
The hyperglycemic population is divided into undiagnosed population stocks and 
diagnosed population stocks based on the diagnosis of hyperglycemia.  The three stocks in the 
solid box in Figure 4-8, the Undx Prediabetic Population stock, the Undx Diabetic without 
Complication Population stock and the Undx Diabetic with Early Stage Complication 
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Population stock, are the undiagnosed hyperglycemic population stocks.  The four stocks that 
are enclosed by the dashed box are the diagnosed hyperglycemic population stocks: the Dx 
Prediabetic Population stock, the Dx Diabetic without Complication Population stock, the Dx 
Diabetic with Early Stage Macrovascular Complication Population stock and the Dx Diabetic 
with Late Stage Macrovascular Complication Population stock.  Each undiagnosed population 
stock has a diagnosis flow that moves parts of the population to a corresponding diagnosed 
population stock once the hyperglycemia or related complications are diagnosed.  For example, 
the population moves from the Undx Diabetic without Complication Population stock to the Dx 
Diabetic without Complication Population stock once diabetes is diagnosed and the population 
moves from the Undx Diabetic with Early Stage Macrovascular Complication Population stock 
to the Dx Diabetic with Early Stage Macrovascular Complication Population stock after any 
diabetes related complication is diagnosed.  The only exception is that the Dx Diabetic with 
Late Stage Macrovascular Complication Population stock does not have a corresponding 
undiagnosed population stock due to the presence of obvious symptoms from late stage 
macrovascular complications.  As a consequence, I assumed that all patients with late stage 
macrovascular complications are diagnosed. 
The population in the section “hyperglycemic population” is also classified according to 
the progression of disease criterion into prediabetic population stocks, diabetic without 
complication population stocks, diabetes with early stage macrovascular complication population 
stocks and the diabetes with late stage macrovascular population stock.  Population stocks in 
these four diabetes progress stages clearly separate the hyperglycemic population according to 
the progression of hyperglycemia.   
Starting from the prediabetes stage, part of the population develops mild hyperglycemia.  
According to the WHO diabetes classification, a person whose blood glucose level is higher than 
in normoglycemia but which does not meet criteria of diabetes is prediabetic.  The Undx 
Prediabetic Population stock and the Dx Prediabetic population stock in Figure 4-8 belong to 
this stage.  The Undx Prediabetic Population stock has an incoming flow from each of the 
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normoglycemic population stocks. These incoming flows represent the population that develops 
prediabetes from the normal weight general population, the overweight general population and 
the obese general population.   
The prediabetic population has a risk of developing more serious hyperglycemia and 
becoming diabetic.  Hence, each prediabetic population stock has a progression flow, which 
connects to its corresponding diabetic without complication population stock.  The prediabetic 
population moves to the diabetes without complication stage and maintains the status of 
diagnosis through the progression flow.   Moreover, the Dx Prediabetic Population stock has 
another progression flow that connects to the Undx Diabetic Population stock.  Diabetes is a 
chronic disease and it has a gradual onset progress.  Patients developing diabetes from 
prediabetes may not be diagnosed with diabetes even if they were diagnosed with prediabetes 
previously.  The flow from the Dx Prediabetic Population stock to the Undx Diabetic 
Population stock represents this progress.  
The population in the Dx Prediabetic Population stock has a chance to recover from 
hyperglycemia and return to normoglycemic stage.  The Dx Prediabetic Population stock has 
three recovery flows that return population back to the Normal General Population, the 
Overweight General Population, and the Obese General Population stocks.         
The diabetes without complication stage is the next diabetes progress stage after the 
prediabetes stage.  In the diabetes without complication stage, hyperglycemic patients have 
blood glucose levels higher than the criteria of diabetes, but have not yet developed any diabetes 
related complications.  Some mild diabetic symptoms, such as blurry vision, increased thirst 
and itchy skin occur during this stage.  The Undx Diabetic without Complication Population 
stock and the Dx Diabetic without Complication Population stock in Figure 4-8 belong to this 
stage.  Each stock in this stage connects to a corresponding stock in the diabetes with early 
stage macrovascular complication stage by a diabetes progression flow. The hyperglycemic 
population in the diabetes without complication stage flows to the next stage, the diabetes with 
early stage macrovascular complication stage, once they develop any diabetes related 
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macrovascular complication. 
Unlike these prediabetic population stocks, the population stocks in the diabetes without 
complication stage and further diabetes progression stages do not have a recovery flow, which 
returns population back to the normoglycemia stage.  Diabetes is a life-long disease and 
currently there is no cure for it.  People who developed diabetes will stay in a diabetic 
population stock but will not return to a normoglycemic population stock.      
The next stage in diabetes progression is the diabetes with early stage macrovascular 
complication stage.  In this stage, diabetic patients start to develop macrovascular diseases 
caused by diabetes, such as coronary diseases and cerebrovascular disease.  The Undx Diabetic 
with Early Stage Macrovascular Complication Population stock and the Dx Diabetic with Early 
Stage Macrovascular Complication Population stock in Figure 4-8 belong to this stage.  
Starting from this stage, I assume that all diabetic patients are diagnosed with diabetes.  Based 
on this assumption, I define the population in the Undx Diabetic with Early Stage Macrovascular 
Complication Population stock as diagnosed with diabetes but not diagnosed with macrovascular 
complication.   
Similar to population stocks in the diabetes without complication stage, population stocks 
in the diabetes with early stage macrovascular complication stage have a progression flow to the 
next and the last diabetes progression stage – the diabetes with late stage macrovascular 
complication stage.  Progression flows from both the Undx Diabetic with Early Stage 
Macrovascular Complication Population stock and the Dx Diabetic with Early Stage 
Macrovascular Complication Population stock connect to the Dx Diabetic with Late Stage 
Macrovascular Complication Population stock, the only population stock in the last diabetes 
progression stage.   
The population in the final diabetes progression stage is the population who survived 
from the first attack of diabetes related macrovascular diseases, such as a heart attack or stroke.   
After the first attack of macrovascular diseases, any undiagnosed macrovascular complication 
are assumed manifest itself; hence, there is no undiagnosed population stock represented in the 
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final stage.  Diabetic patients stay in this stage until their death. 
Similar to other population stocks in the model, populations in the hyperglycemic 
population stocks are further divided according to age group, ethnic group and gender group 
using subscripts.  Aging flows connect all age group stocks from the youngest to the oldest 
stock, forming an aging chain.  Also, each population stock in the section “hyperglycemic 
population” has one or more death flows.  These death flows move the population out the 
system.  I will explain death flows in detail later. 
The Undx Prediabetic Population stock is the first stock in the section “hyperglycemic 
population”.  All hyperglycemic patients develop prediabetes without diagnosis first.  The 
dynamics of this population stock are controlled by several incoming flows and outgoing flows.  
Equation 4.10 shows the mathematical formulation,  
 
𝑈𝑛𝑑𝑥 𝑃𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛(𝑇)
= � [𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑓𝑟𝑜𝑚 𝑛𝑜𝑟𝑚𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡𝑇
0+ 𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑓𝑟𝑜𝑚 𝑜𝑣𝑒𝑟𝑤𝑒𝑖𝑔ℎ𝑡+ 𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑓𝑟𝑜𝑚 𝑜𝑏𝑒𝑠𝑒
− 𝑢𝑛𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑑𝑦𝑖𝑛𝑔 𝑎𝑙𝑙 𝑐𝑎𝑢𝑠𝑒𝑠
− 𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑓𝑟𝑜𝑚 𝑢𝑛𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠
− 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠 + 𝑢𝑛𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑎𝑔𝑖𝑛𝑔
− 𝑢𝑛𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑎𝑔𝑖𝑛𝑔]𝑑𝑡 , 
(4.10) 
where all positive parameters are incoming flows and all negative parameters are outgoing flows.  
All parameters in Equation 4.10 have age groups, gender groups and ethnic groups that are 
presented in subscripts.         
I was not able to find a data source that allowed me to directly find the initial value for 
the Undx Prediabetic Population stock.  I calculated and calibrated the initial value based on 
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the initial value of the Dx Prediabetic Population stock.  The initial value of the Dx Prediabetic 
Population stock is calculated based on the initial value of Dx Diabetic without Complication 
Population stock.  I assumed that the diagnosed prediabetic population has the same 
distribution as the diagnosed diabetic without complication population, but the diagnosed 
prediabetic population is 10 years younger than the diagnosed diabetic without complication 
population.  Therefore, the initial value of the Dx Prediabetic Population stock is the product of 
the diagnosed diabetic population shifted by 10 years and a diabetes to prediabetes coefficient, 
 
𝑖𝑛𝑖𝑡 𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛[𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝]= 𝑖𝑛𝑖𝑡 𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛[𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝 − 10]
∗ 𝑖𝑛𝑖𝑡 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑡𝑜 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡, 
(4.11) 
where the diabetes to prediabetes coefficient is set to 1 initially and calibrated later.       
After the initial value of the Dx Prediabetic Population stock is calculated, the initial 
value of the Undx Prediabetic Population stock is obtained from the product of the initial value 
of the Dx Prediabetic Population stock and several coefficients that reflect age, ethnicity and 
gender,   
 
𝑖𝑛𝑖𝑡 𝑢𝑛𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛= 𝑖𝑛𝑖𝑡 𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 ∗ 𝑖𝑛𝑖𝑡 𝑢𝑛𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑎𝑔𝑒 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡
∗ 𝑖𝑛𝑖𝑡 𝑢𝑛𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑖𝑒𝑡𝑖𝑐 𝑒𝑡ℎ𝑛𝑖𝑐 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡
∗ 𝑖𝑛𝑖𝑡 𝑢𝑛𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑔𝑒𝑛𝑑𝑒𝑟 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡, 
(4.12)    
where all coefficients are set to 1 initially and adjusted through calibration.  
An undiagnosed prediabetic patient could develop diabetes without diagnosis.  The 
flow developing undx diabetes from undx prediabetes in the model represents this progress.  
This progression flow moves people to the Undx Diabetic without Complication Population 
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stock when they develop diabetes.  The rate of flow (in persons per year) is the quotient 
obtained by dividing the population in the Undx Prediabetic Population stock by the 
constant avg years to develop diabetes from undx prediabetes.   
 
𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑓𝑟𝑜𝑚 𝑢𝑛𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐= 𝑈𝑛𝑑𝑥 𝑃𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
𝑎𝑣𝑔 𝑦𝑒𝑎𝑟𝑠 𝑡𝑜 𝑑𝑒𝑣𝑒𝑙𝑜𝑝 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑓𝑟𝑜𝑚 𝑢𝑛𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠. 
(4.13) 
 
Equation 4.13 is for the calculation of the developing undx diabetes from undx 
prediabetes flow rate.  The value of the avg years to develop diabetes from undx prediabetes 
parameter is set to 10 years initially, and is calibrated against historical data.  The calibration 
process will be described in the next chapter. 
The Undx Prediabetic Population stock also has a diagnosis flow, the prediabetes 
diagnosis , that moves population to the Dx Prediabetic Population stock when their prediabetes 
is diagnosed.  After undiagnosed prediabetic people receive a blood glucose test, their 
hyperglycemia may be diagnosed by doctors.  Once the hyperglycemia is diagnosed, they move 
from the Undx Prediabetic Population stock to the Dx Prediabetic Population stock through the 
diagnosis flow.   
I could not find reliable data sources for the prediabetes diagnosis rate for the SHR; 
hence, I use data and calculation from the CDC model.  The prediabetes diagnosis rate is 
calculated based on the fraction of prediabetes detected by two relevant tests FPGT and OGTT 
(see Chapter 2), the average time between screenings and the sensitivity of FPGT and OGTT for 
detecting prediabetes.  Equations from 4.14 to 4.19 below show the calculation steps for the 
prediabetes diagnosis rate and all constants are listed in Appendix B.   
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𝑎𝑣𝑔 𝑡𝑖𝑚𝑒 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔𝑠 𝑓𝑜𝑟 ℎ𝑖𝑔ℎ 𝑟𝑖𝑠𝑘 𝑎𝑠𝑦𝑚𝑝𝑡𝑜𝑚𝑎𝑡𝑖𝑐 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛= 𝑏𝑎𝑠𝑒 𝑡𝑖𝑚𝑒 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔𝑠 𝑓𝑜𝑟 ℎ𝑖𝑔ℎ 𝑟𝑖𝑠𝑘 𝑎𝑠𝑦𝑚𝑝𝑡𝑜𝑚𝑎𝑡𝑖𝑐 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗ 𝑡𝑖𝑚𝑒 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔𝑠 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑓𝑜𝑟 ℎ𝑖𝑔ℎ 𝑟𝑖𝑠𝑘 𝑎𝑠𝑦𝑚𝑝𝑡𝑜𝑚𝑎𝑡𝑖𝑐 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝𝑠
∗ 𝑡𝑖𝑚𝑒 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑓𝑜𝑟 ℎ𝑖𝑔ℎ 𝑟𝑖𝑠𝑘 𝑎𝑠𝑦𝑚𝑝𝑡𝑜𝑚𝑎𝑡𝑖𝑐 𝑒𝑡ℎ𝑛𝑖𝑐 𝑔𝑟𝑜𝑢𝑝𝑠
∗ 𝑡𝑖𝑚𝑒 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑓𝑜𝑟 ℎ𝑖𝑔ℎ 𝑟𝑖𝑠𝑘 𝑎𝑠𝑦𝑚𝑝𝑡𝑜𝑚𝑎𝑡𝑖𝑐 𝑔𝑒𝑛𝑑𝑒𝑟 𝑔𝑟𝑜𝑢𝑝𝑠. 
(4.14) 
 
𝑎𝑣𝑔 𝑠𝑒𝑛𝑠𝑖𝑡𝑣𝑖𝑡𝑦 𝑜𝑓 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔𝑠 𝑓𝑜𝑟 𝐼𝐺𝑇 𝑜𝑟 𝐼𝐹𝐺= 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 𝑜𝑓 𝑂𝐺𝑇𝑇 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔 𝑓𝑜𝑟 𝐼𝐺𝑇 𝑜𝑟 𝐼𝐹𝐺
∗ 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑎𝑠𝑦𝑚𝑝𝑡𝑜𝑚𝑎𝑡𝑖𝑐 ℎ𝑖𝑔ℎ 𝑟𝑖𝑠𝑘 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔 𝑢𝑠𝑖𝑛𝑔 𝑂𝐺𝑇𝑇+ 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 𝑜𝑓 𝐹𝑃𝐺𝑇 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔 𝑓𝑜𝑟 𝐼𝐹𝐺
∗ (1 − 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑎𝑠𝑦𝑚𝑝𝑡𝑜𝑚𝑎𝑡𝑖𝑐 ℎ𝑖𝑔ℎ 𝑟𝑖𝑠𝑘 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔 𝑢𝑠𝑖𝑛𝑔 𝑂𝐺𝑇𝑇). 
(4.15) 
 
𝑎𝑣𝑔 𝑡𝑖𝑚𝑒 𝑡𝑜 𝑛𝑒𝑥𝑡 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔 𝑓𝑜𝑟 𝑢𝑛𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑒𝑑 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛= 𝑎𝑣𝑔 𝑡𝑖𝑚𝑒 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑠𝑐𝑟𝑒𝑒𝑖𝑛𝑔𝑠 𝑓𝑜𝑟 ℎ𝑖𝑔ℎ 𝑟𝑖𝑠𝑘 𝑎𝑠𝑦𝑚𝑝𝑡𝑜𝑚𝑎𝑡𝑖𝑐 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗ �0.5 ∗ 𝑎𝑣𝑔 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 𝑜𝑓 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔𝑠 𝑓𝑜𝑟 𝐼𝐺𝑇 𝑜𝑟 𝐼𝐹𝐺 + 1
∗ (1 − 𝑎𝑣𝑔 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 𝑜𝑓 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔𝑠 𝑓𝑜𝑟 𝐼𝐺𝑇 𝑜𝑟 𝐼𝐹𝐺)�. 
 (4.16) 
 
𝑑𝑒𝑡𝑒𝑐𝑡𝑎𝑏𝑙𝑒 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛= 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑑𝑒𝑡𝑒𝑐𝑡𝑎𝑏𝑙𝑒 𝑏𝑦 𝑂𝐺𝑇𝑇
∗ 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑎𝑠𝑦𝑚𝑝𝑡𝑜𝑚𝑎𝑡𝑖𝑐 ℎ𝑖𝑔ℎ 𝑟𝑖𝑠𝑘 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔𝑠 𝑢𝑠𝑖𝑛𝑔 𝑂𝐺𝑇𝑇+ 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑑𝑒𝑡𝑒𝑐𝑡𝑎𝑏𝑙𝑒 𝑏𝑦 𝐹𝑃𝐺𝑇
∗ (1 − 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑎𝑠𝑦𝑚𝑝𝑡𝑜𝑚𝑎𝑡𝑖𝑐 ℎ𝑖𝑔ℎ 𝑟𝑖𝑠𝑘 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔𝑠 𝑢𝑠𝑖𝑛𝑔 𝑂𝐺𝑇𝑇). 
(4.17) 
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𝑑𝑒𝑡𝑒𝑐𝑡𝑎𝑏𝑙𝑒 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛= 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗ 𝑑𝑒𝑡𝑒𝑐𝑡𝑎𝑏𝑙𝑒 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛. 
(4.18) 
 
𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠= 𝑀𝐴𝑋 �0, 𝑑𝑒𝑡𝑒𝑐𝑡𝑎𝑏𝑙𝑒 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗ 𝑒𝑣𝑒𝑟 𝑠𝑐𝑟𝑒𝑒𝑛𝑒𝑑 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 ℎ𝑖𝑔ℎ 𝑟𝑖𝑠𝑘𝑠 − 𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗
𝑎𝑣𝑔 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 𝑜𝑓 𝑠𝑐𝑟𝑒𝑒𝑛𝑠 𝑓𝑜𝑟 𝐼𝐺𝑇 𝑜𝑟 𝐼𝐹𝐺
𝑎𝑣𝑔 𝑡𝑖𝑚𝑒 𝑡𝑜 𝑛𝑒𝑥𝑡 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔 𝑓𝑜𝑟 𝑢𝑛𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑒𝑑 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛�. 
(4.19) 
 
The death flow rate for the Undx Prediabetic Population stock is the product of the 
population in the stock and mortality rate of the undiagnosed prediabetic population.  
 
𝑢𝑛𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑑𝑦𝑖𝑛𝑔 𝑎𝑙𝑙 𝑐𝑎𝑢𝑠𝑒𝑠= 𝑢𝑛𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗ 𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑙𝑒𝑑 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑓𝑜𝑟 𝑢𝑛𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛. 
 (4.20) 
 
I do not have mortality rates for the undiagnosed prediabetic population.  I assumed the 
mortality rate of the undiagnosed prediabetic population would be close to the mortality rate of 
the obese general population since hyperglycemia has not yet done any serious damage.  Hence, 
I applied the mortality rate of the obese general population in the calculation.        
The aging flow of the Undx Prediabetic Population stock is the exactly same as aging 
flows for other population stocks.  The incoming aging flow is set to 0 for the Age Group 0 to 4 
group since it is the youngest age group in the model; and the outgoing aging flow is set to 0 for 
the Age group 80 plus group since it is the oldest age group in the system.  
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The Dx Prediabetic Population stock is the diagnosed population stock in the prediabetes 
stage.  After prediabetes is diagnosed, prediabetic patients move from the Undx Prediabetic 
Population stock to the Dx Prediabetic Population stock.  The population in this stock is 
controlled by several incoming flows and outgoing flows.  
 
𝐷𝑥 𝑃𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛(𝑇)
=  � [𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠 − 𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑑𝑦𝑖𝑛𝑔 𝑎𝑙𝑙 𝑐𝑎𝑢𝑠𝑒𝑠𝑇
0
− 𝑛𝑜𝑟𝑚𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦
− 𝑜𝑣𝑒𝑟𝑤𝑒𝑖𝑔ℎ𝑡 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 − 𝑜𝑏𝑒𝑠𝑒 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦
− 𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑓𝑟𝑜𝑚 𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐
− 𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑓𝑟𝑜𝑚 𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 − 𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑎𝑔𝑖𝑛𝑔+ 𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑎𝑔𝑖𝑛𝑔]𝑑𝑡. 
(4.21) 
 
Equation 4.21 shows the mathematical formulation.  Like other stocks, all parameters in 
the equation include implicit age, gender and ethnicity subscripts.        
The initial value for the Dx Prediabetic Population stock is calculated by shifting the 
initial value of the Dx Diabetic without Complication stock by 10 years.  A similar calculation 
for the initial value of the Undx Prediabetic Population stock was described above. 
The population in the Dx Prediabetic Population has the potential for recovering from 
prediabetes and returning back to a normoglycemia state.  Three recovery flows, the normal 
weight prediabetes recovery, the overweight prediabetes recovery and the obese prediabetes 
recovery represent the recovery progress.  The equation  
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𝑛𝑜𝑟𝑚𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦= 𝐷𝑥 𝑃𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗ 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 𝑟𝑎𝑡𝑒[𝑛𝑜𝑟𝑚𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡] 
(4.22) 
characterizes the mathematical representation of the recovery progress for the normal weight 
population, and equations for the overweight and the obese population are essentially the same.  
Prediabetes recovery rates are set to 0, 0.03 and 0 for the normal weight, the overweight and the 
obese population respectively.      
The developing dx diabetes from dx prediabetic flow is one of the two progression flows 
initialized from the Dx Prediabetic Population stock.  This flow represents the progression by 
which the diagnosed prediabetic population develops diabetes and where diabetes is diagnosed 
soon after onset (for example, due to close ongoing management of the prediabetes).  The rate 
of this flow is controlled by the population in the Dx Prediabetic Population stock and two 
parameters: the avg years to develop diabetes from dx prediabetes and the fraction developing 
diabetes without diagnosis; as equation 4.23 shows below.  The fraction developing diabetes 
without diagnosis is set to 0.1 initially, and its value is adjusted by calibration.  The avg years to 
develop diabetes from dx prediabetes is the product of the avg years to develop diabetes from 
undx prediabetes and the dx diabetes progress coefficient.  The dx diabetes progress coefficient 
is set to 1.5 initially since it usually takes longer to develop diabetes if the prediabetic patient is 
diagnosed and with good management; this coefficient is then calibrated against historical data.             
 
𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑓𝑟𝑜𝑚 𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐= 𝐷𝑥 𝑃𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
𝑎𝑣𝑔 𝑦𝑒𝑎𝑟𝑠 𝑡𝑜 𝑑𝑒𝑣𝑒𝑙𝑜𝑝 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑓𝑟𝑜𝑚 𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑠
∗ (1 − 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑤𝑖𝑡ℎ 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠). 
(4.23) 
 
The developing undx diabetes from dx prediabetic is another progression flow that is 
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initialized from the Dx Prediabetic Population stock.  Some prediabetic patients do not check 
with a doctor even after they are diagnosed.  Their hyperglycemia can become worse without 
notice and new conditions are undiagnosed.  This part of population moves to the undiagnosed 
diabetes stock when they progress to the next stage.  The developing undx diabetes from dx 
prediabetic flow moves these patients from the Dx Prediabetic Population stock to the Undx 
Diabetic without Complication Population stock.  Similar to the developing dx diabetes from dx 
prediabetic flow, the rate of the developing dx diabetes from dx prediabetic flow is determined 
by the population in the Dx Prediabetic Population stock, the avg years to develop diabetes from 
dx prediabetes and the fraction developing diabetes without diagnosis. 
 
𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑓𝑟𝑜𝑚 𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐= 𝐷𝑥 𝑃𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
𝑎𝑣𝑔 𝑦𝑒𝑎𝑟𝑠 𝑡𝑜 𝑑𝑒𝑣𝑒𝑙𝑜𝑝 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑓𝑟𝑜𝑚 𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑠
∗ (𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑤𝑖𝑡ℎ 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠). 
(4.24) 
 
The death flow for the Dx Prediabetic Population stock is the dx prediabetic dying all 
causes.  The rate of this death flow is the product of the population in the stock and mortality 
rate of the undiagnosed prediabetic population.  Equation 4.25 below shows the calculation.  I 
applied the mortality of the Obese General Population stock here since I do not have any data for 
the mortality of the prediabetic population in the SHR.        
 
𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑑𝑦𝑖𝑛𝑔 𝑎𝑙𝑙 𝑐𝑎𝑢𝑠𝑒𝑠=  𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗ 𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑙𝑒𝑑 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑓𝑜𝑟 𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛. 
(4.25) 
 
The Dx Prediabetic Population stock has the same aging chain structure as other 
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population stocks that are connected by aging flows. 
The Undx Diabetic without Complication Population stock is the undiagnosed population 
stock in the diabetes without complication progression stage.  Hyperglycemic patients in this 
stock have developed diabetes but have not developed any diabetes related complication, and the 
hyperglycemic condition remains undiagnosed.  Several incoming flows and outgoing flows 
together create the dynamics of the Undx Diabetic without Complication Population stock.  
Equation 4.26 shows the mathematical formation.  Each positive parameter represents an 
incoming flow and each negative parameter represents an outgoing flow in the integration.  
Corresponding to the population in the stock, each flow is also associated with age groups, 
gender groups and ethnic groups that are represented by subscripts.   
 
𝑈𝑛𝑑𝑥 𝐷𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝐶𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛(𝑇)
= � [𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑓𝑟𝑜𝑚 𝑢𝑛𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐𝑇
0+ 𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑓𝑟𝑜𝑚 𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 –𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠
− 𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑢𝑛𝑑𝑥 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑓𝑟𝑜𝑚 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐
− 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑑𝑦𝑖𝑛𝑔 𝑎𝑙𝑙 𝑐𝑎𝑢𝑠𝑒𝑠
− 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑖𝑡𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑎𝑔𝑖𝑛𝑔+ 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑎𝑔𝑖𝑛𝑔 ]𝑑𝑡. 
(4.26) 
 
The initial value of the Undx Diabetic without Complication Population stock is 
calibrated based on the initial value of the Dx Diabetic without Complication Population stock.  
I do not have any reliable source for the undiagnosed diabetic without any complication 
population.  Hence, I first calculated the total diagnosed diabetic population in the SHR from 
the total covered population in the SHR and the diabetes prevalence among the Saskatchewan 
population [61, 62].  Here I made the assumption that population in the SHR has the same 
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diabetes prevalence as Saskatchewan population.  After the total diagnosed diabetic population 
is obtained, I calculated the initial value of the Dx Diabetic without Complication Population 
stock from the total diagnosed diabetic population by using an estimated percentage of diabetic 
patients without any complication [63].  The initial value of the Undx Diabetic without 
Complication Population stock is set to the product of the initial value of the Dx Diabetic 
without Complication Population and three coefficients that reflect age, ethnicity and gender.  
By adjusting these three coefficients to match historical data, I find the best fit data for the initial 
value of the Undx Diabetic without Complication Population stock. 
 
𝑖𝑛𝑖𝑡 𝑈𝑛𝑑𝑥 𝐷𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝐶𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛= 𝑖𝑛𝑖𝑡 𝐷𝑥 𝐷𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝐶𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗ 𝑖𝑛𝑖𝑡 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑎𝑔𝑒 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡
∗ 𝑖𝑛𝑖𝑡 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑔𝑒𝑛𝑑𝑒𝑟 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡
∗ 𝑖𝑛𝑖𝑡 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑖𝑡𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑒𝑡ℎ𝑛𝑖𝑐 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡. 
(4.27) 
 
The Undx Diabetic without Complication Population stock has a diagnosis flow, the 
diabetes diagnosis, which moves diabetic patients to the Dx Diabetic without Complication 
Population stock after their diabetic condition is diagnosed.   Ideally, the rate of this flow 
should be set to a fraction of the incidence of diabetes in the SHR since the incidence of diabetes 
is the combined rate of the diabetes diagnosis, the developing dx diabetes from dx prediabetes 
and the developing undx early stage complication from undx diabetic flows.  Although I have 
data for the incidence in the SHR, I do not know what fraction of the different flows.  As a 
fallback, I adapted the diabetes diagnosis calculation from the CDC model as the initial value 
and calibrated the result with the historical data of incidence in the SHR.  Equations 4.28 to 
4.32 below are for the calculation of the flow rate of the diabetes diagnosis.  Some parameters 
were calculated previously for the prediabetes diagnosis rate.  All constant values are listed in 
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Appendix B. 
 
𝐷𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝐷𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠= 𝑀𝐴𝑋(0,𝑑𝑒𝑡𝑒𝑐𝑡𝑎𝑏𝑙𝑒 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗ 𝑒𝑣𝑒𝑟 𝑠𝑐𝑟𝑒𝑒𝑛𝑒𝑑 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 ℎ𝑖𝑔ℎ 𝑟𝑖𝑠𝑘
− 𝐷𝑥 𝐷𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝐶𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 )
∗  𝑎𝑣𝑔 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 𝑜𝑓 𝑠𝑐𝑟𝑒𝑒𝑛 𝑓𝑜𝑟 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑖𝑡𝑜𝑛
𝑎𝑣𝑔 𝑡𝑖𝑚𝑒 𝑡𝑜 𝑛𝑒𝑥𝑡 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔 𝑓𝑜𝑟 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛. 
(4.28) 
 
𝑑𝑒𝑡𝑒𝑐𝑡𝑎𝑏𝑙𝑒 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛= (𝐷𝑥 𝐷𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝐶𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑖𝑡𝑜𝑛 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛+ 𝑈𝑛𝑑𝑥 𝐷𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝐶𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛)
∗ 𝑑𝑒𝑡𝑒𝑐𝑡𝑎𝑏𝑙𝑒 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑖𝑡𝑜𝑛. 
(4.29) 
 
𝑑𝑒𝑡𝑒𝑐𝑡𝑎𝑏𝑙𝑒 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑖𝑡𝑜𝑛= 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑑𝑒𝑡𝑒𝑐𝑡𝑎𝑏𝑙𝑒 𝑏𝑦 𝑂𝐺𝑇𝑇
∗ 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑎𝑠𝑦𝑚𝑝𝑡𝑜𝑚𝑎𝑡𝑖𝑐 ℎ𝑖𝑔ℎ 𝑟𝑖𝑠𝑘 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔𝑠 𝑢𝑖𝑛𝑔 𝑂𝐺𝑇𝑇 +  𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑑𝑒𝑡𝑒𝑐𝑡𝑎𝑏𝑙𝑒 𝑏𝑦 𝐹𝑃𝐺𝑇
∗  (1 −  𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑎𝑠𝑦𝑚𝑝𝑡𝑜𝑚𝑎𝑡𝑖𝑐 ℎ𝑖𝑔ℎ 𝑟𝑖𝑠𝑘 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔𝑠 𝑢𝑖𝑛𝑔 𝑂𝐺𝑇𝑇). 
(4.30) 
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𝑎𝑣𝑔 𝑡𝑖𝑚𝑒 𝑡𝑜 𝑛𝑒𝑥𝑡 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔 𝑓𝑜𝑟 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛= 𝑎𝑣𝑔 𝑡𝑖𝑚𝑒 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔𝑠 𝑓𝑜𝑟 ℎ𝑖𝑔ℎ 𝑟𝑖𝑠𝑘 𝑎𝑠𝑦𝑚𝑝𝑡𝑜𝑚𝑎𝑡𝑖𝑐 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗ �0.5 ∗ 𝑎𝑣𝑔 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 𝑜𝑓 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔 𝑓𝑜𝑟 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑖𝑡𝑜𝑛+ 1
∗ (1 − 𝑎𝑣𝑔 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 𝑜𝑓 𝑠𝑐𝑟𝑟𝑛𝑖𝑛𝑔 𝑓𝑜𝑟 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑖𝑡𝑜𝑛)�. 
(4.31) 
 
𝑎𝑣𝑔 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 𝑜𝑓 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔 𝑓𝑜𝑟 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑖𝑡𝑜𝑛=  𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 𝑜𝑓 𝑂𝐺𝑇𝑇 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔 𝑓𝑜𝑟 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠
∗ 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑎𝑠𝑦𝑚𝑝𝑡𝑜𝑚𝑎𝑡𝑖𝑐 ℎ𝑖𝑔ℎ 𝑟𝑖𝑠𝑘 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔𝑠 𝑢𝑖𝑛𝑔 𝑂𝐺𝑇𝑇+ 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 𝑜𝑓 𝐹𝑃𝐺𝑇 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔 𝑓𝑜𝑟 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠
∗ (1 − 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑎𝑠𝑦𝑚𝑝𝑡𝑜𝑚𝑎𝑡𝑖𝑐 ℎ𝑖𝑔ℎ 𝑟𝑖𝑠𝑘 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔𝑠 𝑢𝑖𝑛𝑔 𝑂𝐺𝑇𝑇). 
(4.32) 
 
Besides the diagnosis flow, the Undx Diabetic without Complication Population stock 
has a progression flow, the developing undx early stage complication from undx diabetic.  This 
flow moves population to the next progression stage when the diabetic condition becomes worse 
and an individual develops diabetes related macrovascular complications.  I made the 
assumption that the diabetic population in the Undx Diabetic with Early Stage Complication 
Population stock is diagnosed with diabetes but is not diagnosed with diabetes related 
complication.  Thus, an individual moving to the next progression stage through this flow will 
be diagnosed with diabetes.  Hence, this flow can be seen as a diagnosis flow as well.  
Equation  
𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑢𝑛𝑑𝑥 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑓𝑟𝑜𝑚 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐= 𝑈𝑛𝑑𝑥 𝐷𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝐶𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
𝑎𝑣𝑔 𝑦𝑒𝑎𝑟𝑠 𝑡𝑜 𝑑𝑒𝑣𝑒𝑙𝑜𝑝 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑓𝑟𝑜𝑚 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 
(4.33) 
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shows that the rate of the developing undx early stage complication from undx diabetic flow is 
controlled by the population in the Undx Diabetic without Complication Population stock and 
the constant parameter avg years to develop early stage complication from undx diabetic.  The 
value of the constant parameter was set to 10 initially, and calibrated by matching a historical 
data set.  The calibration process will be explained in the next chapter. 
The population in the Undx Diabetic without Complication Population stock that is dying 
for any reason flows out the system through the undx diabetic without complication dying all 
causes flow.  The death flow is calculated using equation 
 
𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑑𝑦𝑖𝑛𝑔 𝑎𝑙𝑙 𝑐𝑎𝑢𝑠𝑒𝑠= 𝑈𝑛𝑑𝑥 𝐷𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝐶𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗ 𝑀𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑜𝑓 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑖𝑡𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛, 
(4.34) 
where the mortality of undx diabetic without complication population is calibrated using the 
average mortality of the diabetic population and a calibration coefficient.  
Like other population stocks in the system, the population in the Undx Diabetic without 
Complication Population stock is grouped into age groups using subscripts.  Age groups are 
linked by aging flows and form an aging chain.  Equations for aging flows for the Undx 
Diabetic without Complication Population stock are the similar to those for aging flows 
associated with other population stocks.      
During the diabetes without complication stage, undiagnosed diabetic patients can be 
diagnosed by medical practitioners.  These diabetic patients become diagnosed patients and 
move to the Dx Diabetic without Complication Population stock.  The population in the stock is 
influenced by three incoming flows and three outgoing flows, as indicated by the following 
equation 
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𝐷𝑥 𝐷𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝐶𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛(𝑇)
=  � [𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑓𝑟𝑜𝑚 𝑑𝑥 𝑝𝑟𝑒𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 +  𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠𝑇
0
−  𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑑𝑦𝑖𝑛𝑔 𝑎𝑙𝑙 𝑐𝑎𝑢𝑠𝑒𝑠
−  𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑑𝑥 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑓𝑟𝑜𝑚 𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐
−  𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑎𝑔𝑖𝑛𝑔+  𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑎𝑔𝑖𝑛𝑔]𝑑𝑡. 
(4.35) 
 
In the equation, the developing dx early stage complication from dx diabetic is the progression 
flow and the dx diabetic without complication dying all causes is the death flow that associated 
with the Dx Diabetic without Complication Population stock.      
The initial value of the Dx Diabetic without Complication Population stock is calculated 
based on the estimated total diabetic population in the SHR and ratio of diabetic population 
without complication in total diabetic population from Morgan et al.[63].  The initial value is 
listed in Appendix A.     
The progression flow, the developing dx early stage complication from dx diabetic, 
associated with the Dx Diabetic without Complication Population stock and moves population to 
the Dx Diabetic with Early Stage Macrovascular Complication Population stock when a diabetic 
patient develops diabetes related macrovascular complication.  The rate of this progression flow 
is calculated from 
 
𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑑𝑥 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑓𝑟𝑜𝑚 𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 = 𝐷𝑥 𝐷𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝐶𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
𝑎𝑣𝑔 𝑦𝑒𝑎𝑟𝑠 𝑡𝑜 𝑑𝑒𝑣𝑒𝑙𝑜𝑝 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑓𝑟𝑜𝑚 𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 , 
(4.36) 
where the avg years to develop early stage complication from dx diabetes parameter was set to 
15 years initially and adjusted through calibration.   
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The population in the Dx Diabetic without Complication Population stock who is dying 
from any cause flows out the stock through the diabetic without complication dying all causes 
flow.  The rate of the diabetic without complication dying all causes flow dependents on the 
mortality rate of the diagnosed diabetic without complication population in the SHR.  I do not 
have data that shows mortality just for diagnosed diabetic without complication population.  
Hence, I set the mortality of the diagnosed diabetic without complication population to the 
product of the mortality of the undiagnosed diabetic without complication population and a 
coefficient reflecting the diagnosed diabetic without complication population, then calibrate the 
coefficient to estimate a better value for both the mortality of the diagnosed diabetic without 
complication population and the mortality of the undiagnosed diabetic without complication 
population.   
 
𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑜𝑓 𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛= 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑜𝑓 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑖𝑡𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗ 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛. 
(4.37) 
 
The aging flows for the Dx Diabetic without Complication Population stock have the 
same structure as aging flows for other population stocks.  With the exception of the oldest age 
group, a part of population in an age group flows to the next age group every year.  
After years of diabetes, high levels of blood glucose damage patients’ organs, nervous 
systems and blood vessels systems over time.  Impaired organs, nervous systems and blood 
vessels cause diabetes related complications, such as coronary artery disease, heart attack, stroke, 
neuropathy, nephropathy and retinopathy.  These complications – and especially macrovascular 
complication – are the real killers of most diabetes patients, not the high level of blood glucose.  
Once diabetic patients develop any macrovascular complication, they move to the next diabetes 
progression stage, the diabetic with early stage complication phase.  If the new development of 
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macrovascular complication is not diagnosed, these part of patients flow to the Undx Diabetic 
with Early Stage Macrovascular Complication Population stock.   
The population in the Undx Diabetic with Early Stage Macrovascular Complication 
Population stock is calculated by using 
 
𝑈𝑛𝑑𝑥 𝐷𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝐸𝑎𝑟𝑙𝑦 𝑆𝑡𝑎𝑔𝑒 𝑀𝑎𝑐𝑟𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝐶𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛(𝑇)
=  � [𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑢𝑛𝑑𝑥 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑓𝑟𝑜𝑚 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐𝑇
0
− 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑑𝑦𝑖𝑛𝑔 𝑎𝑙𝑙 𝑐𝑎𝑢𝑠𝑒𝑠
− 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑑𝑦𝑖𝑛𝑔 𝑜𝑛𝑠𝑒𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑓𝑖𝑟𝑠𝑡 𝑚𝑎𝑗𝑜𝑟 𝑒𝑣𝑒𝑛𝑡 
− 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠
−  𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑠𝑢𝑟𝑣𝑖𝑣𝑒 𝑓𝑟𝑜𝑚 𝑡ℎ𝑒 𝑓𝑖𝑟𝑠𝑡 𝑚𝑎𝑗𝑜𝑟 𝑚𝑎𝑐𝑟𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑒𝑣𝑒𝑛𝑡+  𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑎𝑔𝑖𝑛𝑔
−  𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑎𝑔𝑖𝑛𝑔]𝑑𝑡, 
(4.38) 
where undx diabetic survive from the first major macrovascular complication event is the 
progression flow to the next disease progression stage.   
For the initial value of the Undx Diabetic with Early Stage Macrovascular Complication 
Population stock, I lack a direct data source that allows me to find the number of diabetic 
patients in the SHR that have undiagnosed early stage macrovascular complications.  Hence, I 
calculated the estimated initial value of the Undx Diabetic with Early Stage Macrovascular 
Complication Population stock from the total number of diabetic patient with early stage 
macrovascular complication in the SHR and three coefficients that reflect the difference between 
undiagnosed and diagnosed diabetic with early stage macrovascular complication population 
according to age, ethnicity and gender.  The calculation is defined as 
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𝑖𝑛𝑖𝑡 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑚𝑎𝑐𝑟𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛= 𝑖𝑛𝑖𝑡 𝑡𝑜𝑡𝑎𝑙 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑚𝑎𝑐𝑟𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗ 𝑖𝑛𝑖𝑡 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑎𝑔𝑒 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡
∗ 𝑖𝑛𝑖𝑡 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑒𝑡ℎ𝑛𝑖𝑐 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡
∗ 𝑖𝑛𝑖𝑡 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑔𝑒𝑛𝑑𝑒𝑟 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡, 
(4.39) 
where the init undx diabetic with early stage complication population ethnic coefficient is set to 
0.1 for both ethnic groups and init undx diabetic with early stage complication population 
gender coefficient are set to 0.1 for both gender groups initially.  To reduce the dimensionality 
of the parameter space searched during calibration, the init undx diabetic with early stage 
macrovascular complication age coefficient is made up of two separated coefficients; one for age 
from 0 to 49 and one for age 50 and up, rather than setting a value for each individual age group.  
The coefficient for the younger population, the init undx diabetic with early stage complication 
youth coefficient, is set to 0.5 initially.  The coefficient for older population, the init undx 
diabetic with early stage complication elderly coefficient, is set to 0.1 initially.  All coefficients 
are calibrated to better matching values during the calibration process.                 
If diabetic patients with undiagnosed macrovascular complications are diagnosed with 
macrovascular complications, this part of the undiagnosed population becomes the diagnosed 
population and flows to the Dx Diabetic with Early Stage Complication Population stock 
through the diabetes with early stage complication diagnosis flow.  The rate of the diabetes 
with early stage complication diagnosis flow is calculated from the population in the stock and 
three coefficients as 
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𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑖𝑡𝑜𝑛 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠= 𝑈𝑛𝑑𝑥 𝐷𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝐸𝑎𝑟𝑙𝑦 𝑆𝑡𝑎𝑔𝑒 𝑀𝑎𝑐𝑟𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝐶𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑚𝑎𝑐𝑟𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠 𝑎𝑔𝑒 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡
∗ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑚𝑎𝑐𝑟𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠 𝑒𝑡ℎ𝑛𝑖𝑐 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡
∗ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑚𝑎𝑐𝑟𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠 𝑔𝑒𝑛𝑑𝑒𝑟 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡, 
(4.40) 
where the early stage macrovascular complication diagnosis ethnic coefficient is set to 0.1 for 
both ethnic groups and the early stage macrovascular complication diagnosis gender coefficient 
is set to 0.1 for both gender groups.  Similar to the init diabetic with early stage complication 
age coefficient, the early stage macrovascular complication diagnosis age coefficient is made up 
of two parts, one for age from 0 to 49 and one for age 50 and up.  The one for younger age 
groups is set to 0 and the one for older age groups is set to 0.5 initially.  These early stage 
macrovascular complication diagnosis coefficients are calibrated to more consistent values by 
matching historical data in the calibration process. 
The population in the Undx Diabetic with Early Stage macrovascular Complication 
Population stock has a risk of attack from macrovascular complications, which are associated 
with high mortality.  If people survive the first attack of any major macrovascular complication, 
this part of population moves to the Dx Diabetic with Late Stage Macrovascular Complication 
Population stock from the Undx Diabetic with Early Stage Macrovascular Complication 
Population stock through the undx diabetic survive from the first major macrovascular 
complication event progression flow.  The flow rate of the undx diabetic survive from the first 
major macrovascular complication event is calculated as 
     
𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑠𝑢𝑟𝑣𝑖𝑣𝑒 𝑓𝑟𝑜𝑚 𝑡ℎ𝑒 𝑓𝑖𝑟𝑠𝑡 𝑚𝑎𝑗𝑜𝑟 𝑚𝑎𝑐𝑟𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑒𝑣𝑒𝑛𝑡= 𝑈𝑛𝑑𝑥 𝐷𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝐸𝑎𝑟𝑙𝑦 𝑆𝑡𝑎𝑔𝑒 𝑀𝑎𝑐𝑟𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝐶𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗ (1 −  𝑀𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑜𝑓 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑚𝑎𝑗𝑜𝑟 𝑚𝑎𝑐𝑟𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛). 
(4.41) 
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The Undx Diabetic with Early Stage Macrovascular Complication Population stock has 
two death flows.  The first death flow undx diabetic with early stage complication dying onset 
of the first major event is for people dying from the onset of the first major macrovascular event, 
like acute myocardial infarction (AMI, commonly known as a “heart attack”) and stroke.  I 
separate the population dying from the first major macrovascular complication event from the 
general death flow since the mortality for major macrovascular complication event is very high.  
The population flow out through this flow is calculated as  
 
𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑑𝑦𝑖𝑛𝑔 𝑜𝑛𝑠𝑒𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑓𝑖𝑟𝑠𝑡 𝑚𝑎𝑗𝑜𝑟 𝑒𝑣𝑒𝑛𝑡= 𝑈𝑛𝑑𝑥 𝐷𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝐸𝑎𝑟𝑙𝑦 𝑆𝑡𝑎𝑔𝑒 𝑀𝑎𝑐𝑟𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝐶𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗ 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑜𝑓 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑚𝑎𝑗𝑜𝑟 𝑚𝑎𝑐𝑟𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛.  
(4.42) 
 
The mortality of diabetic major macrovascular complication is obtained by combining 
the mortality of first-ever AMI onset and the mortality of first-ever stroke onset as 
 
𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑜𝑓 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑚𝑎𝑗𝑜𝑟 𝑚𝑎𝑐𝑟𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛= 𝑓𝑖𝑟𝑠𝑡 𝑒𝑣𝑒𝑟 𝐴𝑀𝐼 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦
∗ 𝑓𝑖𝑟𝑠𝑡 𝑒𝑣𝑒𝑟 𝐴𝑀𝐼 𝑜𝑛𝑠𝑒𝑡 𝑟𝑎𝑡𝑒 𝑓𝑜𝑟 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛+ 𝑓𝑖𝑟𝑠𝑡 𝑒𝑣𝑒𝑟 𝑠𝑡𝑟𝑜𝑘𝑒 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦
∗ 𝑓𝑖𝑟𝑠𝑡 𝑒𝑣𝑒𝑟 𝑠𝑡𝑟𝑜𝑘𝑒 𝑜𝑛𝑠𝑒𝑡 𝑟𝑎𝑡𝑒 𝑓𝑜𝑟 𝑑𝑎𝑖𝑏𝑒𝑡𝑖𝑐 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛. 
(4.43) 
 
The value of the first ever AMI mortality is obtained from “Outcomes of acute myocardial 
infarction in Canada” [70] and the value of the first ever AMI onset rate for diabetic population 
is obtained from “Alberta Diabetes Atlas” [64].  The value of the first ever stroke mortality is 
obtained from “Incidence, comorbidity, case fatality and readmission of hospitalized stroke 
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patients in Canada” [71] and the value of the first ever stroke onset rate for diabetic population 
is obtained from “Alberta Diabetes Atlas” [64]. 
The second death flow undx diabetic with early stage complication dying all causes is for 
people that are dying from all other causes except macrovascular complication major events.  
Similar to the situation with other general death flows, the rate of the undx diabetic with early 
stage complication dying all causes flow is determined by the mortality of the undiagnosed 
diabetic with early stage complication population as           
 
𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑑𝑦𝑖𝑛𝑔 𝑎𝑙𝑙 𝑐𝑎𝑢𝑠𝑒𝑠= 𝑈𝑛𝑑𝑥 𝐷𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝐸𝑎𝑟𝑙𝑦 𝑆𝑡𝑎𝑔𝑒 𝐶𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗ 𝑎𝑙𝑙 𝑜𝑡ℎ𝑒𝑟 𝑐𝑎𝑢𝑠𝑒𝑠 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑜𝑓 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛. 
(4.44) 
 
I do not have data for the all other causes except macrovascular major event mortality of 
the undiagnosed diabetic with early stage macrovascular complication population; hence, I 
calculated this mortality from the mortality of the undiagnosed diabetic without complication 
population by applying a coefficient that reflects the difference between two mortalities.  The 
mathematical notation is defined as  
   
𝑎𝑙𝑙 𝑜𝑡ℎ𝑒𝑟 𝑐𝑎𝑢𝑠𝑒𝑠 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑜𝑓 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛= 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑜𝑓 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗ 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛,   
(4.45) 
where the mortality coefficient undx diabetic with early stage complication is a constant greater 
than 1.  The value of the mortality coefficient is set to 1.2 initially, and it is adjusted in the 
calibration process.   
Like all population stocks in the model, the Undx Diabetic with Early Stage 
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Complication Population stock is disaggregated using subscripts according to age groups, ethnic 
groups and gender groups.  Moreover, aging flows between age groups move people to older 
age groups and form an aging chain structure.   
If diabetic patients with undiagnosed early stage macrovascular complications are 
diagnosed with macrovascular complication before the first major attack, they move to the Dx 
Diabetic with Early Stage Macrovascular Complication Population stock.  The population in 
this stock is calculated as 
 
𝐷𝑥 𝐷𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝐸𝑎𝑟𝑙𝑦 𝑆𝑡𝑎𝑔𝑒 𝑀𝑎𝑐𝑟𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝐶𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛(𝑇)
=  � [𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑑𝑥 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑓𝑟𝑜𝑚 𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐𝑇
0
− 𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑑𝑦𝑖𝑛𝑔 𝑎𝑙𝑙 𝑜𝑡ℎ𝑒𝑟 𝑐𝑎𝑢𝑠𝑒𝑠
− 𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑑𝑦𝑖𝑛𝑔 𝑜𝑛𝑠𝑒𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑓𝑖𝑟𝑠𝑡 𝑚𝑎𝑗𝑜𝑟 𝑒𝑣𝑒𝑛𝑡+ 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠
− 𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑠𝑢𝑟𝑣𝑖𝑣𝑒 𝑓𝑟𝑜𝑚 𝑡ℎ𝑒 𝑓𝑖𝑟𝑠𝑡 𝑚𝑎𝑗𝑜𝑟 𝑚𝑎𝑐𝑟𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑒𝑣𝑒𝑛𝑡
− 𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑎𝑔𝑖𝑛𝑔+ 𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑎𝑔𝑖𝑛𝑔]𝑑𝑡, 
(4.46) 
where positive parameters represent incoming flows and negative parameters represent outgoing 
flows.  
The initial population in the Dx Diabetic with Early Stage Macrovascular Complication 
Population stock is calculated backward from the total diabetic population in the SHR.  First, I 
obtained the total diabetic population with early stage macrovascular complications from the 
total diagnosed diabetic population by removing the diagnosed diabetic without complication 
population and diagnosed diabetics who have experienced their first major macrovascular 
complication event.  Second, I use three coefficients according to age, ethnicity and gender that 
reflect difference between the undiagnosed and the diagnosed diabetic with early stage 
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macrovascular complication.  These coefficients separate the undiagnosed and diagnosed 
diabetic population from the total diabetic with early stage macrovascular complication 
population. 
 
𝑖𝑛𝑖𝑡 𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑚𝑎𝑐𝑟𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛= 𝑖𝑛𝑖𝑡 𝑡𝑜𝑡𝑎𝑙 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑚𝑎𝑐𝑟𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗ (1 − 𝑖𝑛𝑖𝑡 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑎𝑔𝑒 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡)
∗ (1 − 𝑖𝑛𝑖𝑡 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑒𝑡ℎ𝑛𝑖𝑐 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡)
∗ (1
− 𝑖𝑛𝑖𝑡 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑔𝑒𝑛𝑑𝑒𝑟 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡). 
(4.47) 
 
The population in the Dx Diabetic with Early Stage Macrovascular Complication 
Population stock also has a high risk of macrovascular complication major event.  If diabetic 
patients survive from the first macrovascular complication major event, they move to the last 
progression stage: the diabetes with late stage macrovascular complication phase.  The number 
of diabetic patients surviving from a macrovascular complication major event is determined by 
the mortality of the macrovascular complication event.  The exact number of survivors is 
calculated as 
    
𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑠𝑢𝑟𝑣𝑖𝑣𝑒 𝑓𝑟𝑜𝑚 𝑡ℎ𝑒 𝑓𝑖𝑟𝑠𝑡 𝑚𝑎𝑗𝑜𝑟 𝑚𝑎𝑐𝑟𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑒𝑣𝑒𝑛𝑡= 𝐷𝑥 𝐷𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝐸𝑎𝑟𝑙𝑦 𝑆𝑡𝑎𝑔𝑒 𝑀𝑎𝑐𝑟𝑜𝑣𝑎𝑠𝑐𝑢𝑎𝑙𝑟 𝐶𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗ (1 −𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑜𝑓 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑚𝑎𝑗𝑜𝑟 𝑚𝑎𝑐𝑟𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝑐𝑜𝑚𝑝𝑙𝑖𝑎𝑡𝑖𝑜𝑛). 
(4.48) 
 
If diabetic patients unfortunately do not survive from the first major macrovascular 
complication event, this part of population flows out the system through the dx diabetic with 
81 
 
early stage macrovascular complication dying onset of the first major event death flow.  The 
mathematical notation for this death flow is defined as 
 
𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑑𝑦𝑖𝑛𝑔 𝑜𝑛𝑠𝑒𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑓𝑖𝑟𝑠𝑡 𝑚𝑎𝑗𝑜𝑟 𝑒𝑣𝑒𝑛𝑡= 𝐷𝑥 𝐷𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝐸𝑎𝑟𝑙𝑦 𝑆𝑡𝑎𝑔𝑒 𝑀𝑎𝑐𝑟𝑜𝑣𝑎𝑠𝑐𝑢𝑎𝑙𝑟 𝐶𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗ 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑜𝑓 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑚𝑎𝑗𝑜𝑟 𝑚𝑎𝑐𝑜𝑟𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛. 
(4.49) 
 
The Dx Diabetic with Early Stage Macrovascular Complication Population stock has 
another death flow, the dx diabetic with early stage complication dying all other causes, besides 
the dx diabetic with early stage complication dying onset of the first major event death flow.  
This flow represents the population in the Dx Diabetic with Early Stage Macrovascular 
Complication Population stock dying of all causes except macrovascular complication major 
event.  The rate of this death flow is calculated based on the population in the Dx Diabetic with 
Early Stage Macrovascular Complication Population stock and the mortality all other causes 
mortality of dx diabetic with early stage complication population.  The mathematical notation 
for the rate of the dx diabetic with early stage complication dying all other causes flow is 
defined as 
 
𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑑𝑦𝑖𝑛𝑔 𝑎𝑙𝑙 𝑜𝑡ℎ𝑒𝑟 𝑐𝑎𝑢𝑠𝑒𝑠=  𝐷𝑥 𝐷𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝐸𝑎𝑟𝑙𝑦 𝑆𝑡𝑎𝑔𝑒 𝑀𝑎𝑐𝑟𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝐶𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗ 𝑎𝑙𝑙 𝑜𝑡ℎ𝑒𝑟 𝑐𝑎𝑢𝑠𝑒𝑠 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑜𝑓 𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛. 
(4.50) 
 
The value of the all other causes mortality of dx diabetic with early stage complication 
population is calculated based on the value of the all other causes mortality of undx diabetic with 
early stage complication population since I do not have any data to calculate it directly.  Hence, 
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I define a coefficient to reflect the difference between the mortality of diagnosed and 
undiagnosed diabetic population and use this coefficient to calculated the value of the all other 
causes mortality of dx diabetic with early stage complication population. 
 
𝑎𝑙𝑙 𝑜𝑡ℎ𝑒𝑟 𝑐𝑎𝑢𝑠𝑒𝑠 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑜𝑓 𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛= 𝑎𝑙𝑙 𝑜𝑡ℎ𝑒𝑟 𝑐𝑎𝑢𝑠𝑒𝑠 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑜𝑓 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗ 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛. 
(4.51) 
 
I assumed that the diabetic population with diagnosed complications has a lower 
mortality than the diabetic population with undiagnosed complication and that the coefficient is 
therefore less than 1.  The value of coefficient is set to 0.9 initially and is adjusted in calibration 
in order to find a better value for the all other causes mortality of dx diabetic with early stage 
complication population.   
The population in the Dx Diabetic with Early Stage Macrovascular Complication 
Population stock is grouped according to age, ethnicity and gender like other population stocks.  
Age groups in the diagnosed diabetic with early stage macrovascular complication population are 
connected by aging flows and form an aging chain.  
The difference between the early stage macrovascular complication stage and the late 
stage macrovascular complication stage is that people in the late stage have survived from the 
first attack of major macrovascular complications.  I assumed that patients in the late stage are 
hospitalized after their first macrovascular major event and their conditions are diagnosed.  
Hence, the Dx Diabetic with Late Stage Macrovascular Complication Population stock is the 
only stock in the late macrovascular complication stage; no corresponding undiagnosed stock 
exists.  The population who has late stage of macrovascular complications is facing a very 
serious condition of diabetes related macrovascular complications.  The mathematical equation 
for calculating population in the Dx Diabetic with Late Stage Macrovascular Complication 
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Population stock is defined as         
 
𝐷𝑥 𝐷𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝐿𝑎𝑡𝑒 𝑆𝑡𝑎𝑔𝑒 𝑀𝑎𝑐𝑟𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝐶𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛(𝑇)
=  � [𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑠𝑢𝑟𝑣𝑖𝑣𝑒 𝑓𝑟𝑜𝑚 𝑡ℎ𝑒 𝑓𝑖𝑟𝑠𝑡 𝑚𝑎𝑗𝑜𝑟 𝑚𝑎𝑐𝑟𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑒𝑣𝑒𝑛𝑡𝑇
0+ 𝑢𝑛𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑠𝑢𝑟𝑣𝑖𝑣𝑒 𝑓𝑟𝑜𝑚 𝑡ℎ𝑒 𝑓𝑖𝑟𝑠𝑡 𝑚𝑎𝑗𝑜𝑟 𝑚𝑎𝑐𝑟𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑒𝑣𝑒𝑛𝑡
− 𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑙𝑎𝑡𝑒 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑑𝑦𝑖𝑛𝑔 𝑎𝑙𝑙 𝑐𝑎𝑢𝑠𝑒𝑠+ 𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑙𝑎𝑡𝑒 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑎𝑔𝑖𝑛𝑔
− 𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑙𝑎𝑡𝑒 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑖𝑡𝑜𝑛 𝑎𝑔𝑖𝑛𝑔]𝑑𝑡. 
(4.52) 
 
The initial population in the Dx Diabetic with Late Stage Macrovascular Complication 
Population stock is calculated based on the total diagnosed diabetic population in the SHR and 
ratio between the diabetic population that have experienced a macrovascular major event and the 
total diabetic population.  First, I obtained the weighted number of diabetic patients who had 
macrovascular major event in Saskatchewan from a CCHS [72] dataset; and then I obtained the 
weighted number of diabetic patients in Saskatchewan from the same dataset.  Secondly, I 
calculated the ratio of diabetic patients with a macrovascular major event and the total number of 
diabetic patients based on the number I found from the CCHS dataset.  In the final step, I 
applied the ratio to the number of diabetic patients in the SHR to obtain the number of diabetic 
patients that had a macrovascular major event in the SHR.  The initial number of diabetic 
patient having a macrovascular major event in the SHR is listed in Appendix A.     
The Dx Diabetic with Late Stage Macrovascular Complication Population stock is 
associated with neither a progression flow nor a diagnosis flow.  The diabetic patients in the Dx 
Diabetic with Late Stage Macrovascular Complication Population stock stay in the stock until 
they die since this is the last stock in the diabetes progression.  The death flow dx diabetic with 
late stage complication dying all causes is controlled by the mortality of diagnosed diabetic with 
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late stage complication population.  The mathematical formulation of this flow is as follows: 
 
𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑙𝑎𝑡𝑒 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑑𝑦𝑖𝑛𝑔 𝑎𝑙𝑙 𝑐𝑎𝑢𝑠𝑒𝑠= 𝐷𝑥 𝐷𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝐿𝑎𝑡𝑒 𝑆𝑡𝑎𝑔𝑒 𝑀𝑎𝑐𝑟𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝐶𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗ 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑜𝑓 𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑙𝑎𝑡𝑒 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛. 
(4.53) 
 
The mortality of the diagnosed diabetic with late stage complication population is 
calculated based on the all other causes mortality of dx diabetic with early stage complication 
and a coefficient that reflects the difference between two mortalities.  The mathematical 
notation for the calculation is defined as 
 
𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑜𝑓 𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑙𝑎𝑡𝑒 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛= 𝑎𝑙𝑙 𝑜𝑡ℎ𝑒𝑟 𝑐𝑎𝑢𝑠𝑒𝑠 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑜𝑓 𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑒𝑎𝑟𝑙𝑦 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗ 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑑𝑥 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 𝑤𝑖𝑡ℎ 𝑙𝑎𝑡𝑒 𝑠𝑡𝑎𝑔𝑒 𝑐𝑜𝑚𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛, 
(4.54) 
where the mortality coefficient dx diabetic with late stage complication is set to 1.2 since I know 
the population with late stage complication is facing higher risk than the population with early 
stage complication.  The coefficient is fine tuned in the calibration process later.   
The Dx Diabetic with Late Stage Macrovascular Complication Population stock has an 
aging chain structure just like other population stock in the model.  The mathematical equations 
of the aging flows for the Dx Diabetic with Late Stage Macrovascular Complication Population 
stock are also similar to those applied for other aging flow.   
4.3 Summary 
In this chapter, I first reviewed the adaptation process of my model.  Pioneering research 
in the diabetes modeling area created a solid foundation for starting my model.  By adapting 
model structures from these pioneer models, I built my model that reflects the local environment.   
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After I reviewed the adaptation process, I went through the model structure in detail.  
First, I explained the “normoglycemic population” section in the model.  This section simulates 
the dynamic in the population who do not have hyperglycemia and provides a population base 
for the hyperglycemic population since every hyperglycemic patient originated in this section 
before developing hyperglycemia.  Second, I explained the “hyperglycemic population” section, 
the core section in my model.  This section simulates the dynamic in the hyperglycemic 
population, which is the most important subject of my research.  By observing dynamics in this 
section, I am able to evaluate impact from any endogenous and exogenous changes. 
During the model parameterization, I could not find direct data for many parameters.  In 
some cases I could only find data for other regions; in some cases I found aggregated data that is 
not separated by age, gender or ethnicity.  In the worst situation, I could not find any data at all.  
In these situations, I disaggregated data by using factors and used calibration techniques find out 
the best values for these factors and unknown parameters.  In the next chapter, I will explain the 
structure and process of calibrating the model.  
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CHAPTER 5 
CALIBRATION 
In the previous chapter, I mentioned the word “calibration” many times especially in 
cases I lacked data during parameterization.  But what actually is calibration?  Calibration is 
the action of adjusting experimental results to take external factors into account or to allow 
comparison with other data [65]. In the modeling world, calibration is the process that adjusting 
model parameters and finding an agreement between observed results and simulated results [66]. 
In this chapter, I will explain the basic concept of calibration in the modeling process.  
We will seek to provide an understanding how calibration makes use of historical data, 
discrepancy, weights and payoff in calibration.  We will provide an explanation of what 
calibration offer in a modeling process.      
After the basic concept of calibration, I will describe the calibration structure in my 
model and go through the calibration process in detail.  First, I will describe the historical data 
that is used in my calibration and the discrepancy between historical data and model output.  
Secondly, I will explain the weighting structure employed in the calibration and the assignment 
of weights.  Last but not the least, I will explain parameters that need to be adjusted in the 
calibration and their boundary settings.     
In the last part of this chapter, I will explain key findings from the calibration process.  
As the most important result from the calibration, the model is able to match the trend of the 
historical data with a relatively small discrepancy after the calibration.  Moreover, calibration is 
a very good tool for verifying model structure and data used in the model.  During the 
calibration process, I improved the model structure and verified values of parameters in the 
model from unexpected discrepancies and abnormal outputs.  I will describe these 
improvements in the chapter as well.   
5.1 Basic about Calibration 
In modeling context, calibration is the process of using observed data to examine model 
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structure, verify parameters in the model, and estimate unknown parameters from relevant data.  
It is a great tool to help improve and fine tune models.  The calibration process helps a modeler 
scrutinize the model structure and identify possible logical problems.  In a perfect world, a 
System Dynamics model would precisely characterize a complex system in the external world.  
However, a System Dynamics model does not always reproduce the real world system perfectly.  
Among the reasons for model inaccuracy are logical problems in the model structure.  These 
problems can cause misleading results or even a problematic model.  Therefore, we need a way 
to verify and improve the model so it can have a better fit with the system it represents.  
Calibration provides a great method that allows us to fine tune the model structure by using 
observed historical data as a standard.  By observing trends of model outputs and comparing 
them with historical data, we can identify any abnormal behavior and different trends in model 
outputs.  With further investigation into causes of the abnormal behavior, we can identify 
logical problems in the model structure, data or equations. 
Through the calibration process, modelers can estimate or interpolate missing data points 
from related data sources.  During the parameterization process, data may not be available for 
some model parameters and initial values of stock variables.  For example, the current model 
lacks initial values of the undiagnosed prediabetic population in the SHR.  In these kinds of 
situations, calibration is the best tool for finding missing pieces of the puzzle.  By adjusting the 
values of these unknown parameters in reasonable ranges, the model will produce different 
outputs.  The calibration software compares model outputs with observed data and minimizes 
difference between these two data.  Values of parameters that yield the best results are the best 
estimate for these unknown parameters.         
Besides finding values for unknown parameters, calibration can help in verifying and 
cross checking existing data in the model.  During the calibration process, we use data we 
obtain from other sources as the historical data.  If model outputs have huge difference from the 
historical data, we can tell there are disagreements between the data we applied in the model and 
the historical data we used for the calibration. We can identify problems by tracing causes of 
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huge difference among model outputs and historical data.      
A model calibration process involves multiple iterations of minimizing difference 
between historical data and model outputs and readjusting model for better outputs.  As the first 
step, we use the modeling software to calculate gaps between observed historical data and model 
output and try to minimize these gaps.  In this step, we create a list of model parameters that 
allows the modeling software to adjust freely within certain ranges.  By changing values of 
these model parameters, the modeling software will find the best combination of parameter 
values, which yields a result with a minimum gap from the historical data.   
After the calibration software finds the best combination, we analyze the final gap 
between historical data and model outputs, and estimated values of unknown model parameters.  
We also analyze the values of model parameters that were found by the calibration process.  In 
the analysis step, if there is a large gap or unmatched trend between model outputs and the 
historical data, we try to identify any problem in the data and the model structure.  Once all 
identified problems are fixed, we repeat the first calibration steps until we have an agreement 
between model outputs and historical data. 
A critical part of a calibration process is measuring gaps between model outputs and 
historical data.  We construct a calibration structure in the model to calculate the difference 
between model outputs and historical data automatically.  Figure 5-1 illustrates the conceptual 
structure of the calibration process.   
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Figure 5-1. Conceptual Structure of Calibration Process 
 
First of all, we collect historical data for model variables located in the calibration sector 
(“View”) of the model.  Secondly, we provide the calibration sector interface to the model 
outputs for the same variables.  After all data and equations are provided, the calibration 
software calculates the discrepancy between model outputs and historical data from the same 
time point.  The discrepancy is calculated as 
 
𝑑𝑖𝑠𝑐𝑟𝑒𝑝𝑎𝑛𝑐𝑦 =  � ℎ −𝑚
�
ℎ + 𝑚2 ��
2, 
 (5.1) 
where h is the historical datum and m is the model output.  The discrepancy has desirable 
characters such as being dimensionless, analytic, concave, symmetric and non-negative [67].  In 
the second step, we weight discrepancies related to a particular different model variable at a 
particular point in time based on the sample size of the historic data at that point in time and its 
90 
 
importance.    Finally, we added all weighted squared discrepancies together and define the 
negative sum as the final pay off.   
 
𝑝𝑎𝑦𝑜𝑓𝑓 =  −∑𝑤𝑒𝑖𝑔ℎ𝑡𝑒𝑑 𝑑𝑖𝑠𝑐𝑟𝑒𝑝𝑎𝑛𝑐𝑦. 
(5.2) 
 
Based on unknown parameters in my model and the availability of historical data, I 
selected five model outputs to calibrate with historical data: the total population in the SHR, the 
normoglycemic population in the SHR, the total mortality rate in the SHR, the prevalence rate of 
diabetes in the SHR and the incidence rate of diabetes in the SHR.  In the next section, I will 
describe the calibration structure of my model.     
5.2 Calibration Structure 
Before I can calibrate the model, I will need to create a calibration structure that 
calculates gaps between model outputs and observed data.  There are two main components of 
the calibration structure.  The first component consists of the structure to calculate the 
discrepancy between historical data and model outputs.  The second component is a list of 
parameters in the model whose values can be adjusted by the calibration algorithm to alter the 
model output.  Two parts of structure rely on each other and cooperate together to calibrate the 
model.  
5.2.1 Discrepancy Calculation         
In the discrepancy calculation component of the model, I have five observed time series 
of historical data against which I calibrate my model.  For each time series, I created a structure 
that is similar to the conceptual structure I explained previously and depicted in figure 5-1.  
After the discrepancy is calculated for all five series, I combine all weighted discrepancies as the 
final payoff for the calibration.  To allow the reader to better appreciate the mechanisms 
involved in calibration, I select the calibration process for the total population in the SHR as the 
example to illustrate the calibration process. 
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Figure 5-2 illustrates the calibration structure for the total population in the SHR.  The 
population in the SHR is separated into age, ethnic and gender groups in my model.  Therefore, 
I collected the population data for the SHR that is separated by age, ethnic and gender groups 
from year 2001 to 2005, and imported that data into the calibration structure as a time series.  
The modeling software, Vensim, can look up a corresponding value from the time series when 
the time step reaches the same time stamp in the time series.  The obtained historical data is 
stored in a variable, the historical population by time.  The modeling software uses the value 
from this variable and the corresponding population from the model output to calculate the 
fractional discrepancy, which is the discrepancy between the two variables, measured relative to 
the mean values of these two variables.              
 
𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛𝑎𝑙 𝑑𝑖𝑠𝑐𝑟𝑒𝑝𝑎𝑛𝑐𝑦 =  ℎ𝑖𝑠𝑡𝑜𝑟𝑖𝑐𝑎𝑙 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛−𝑚𝑜𝑑𝑒𝑙 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛(ℎ𝑖𝑠𝑡𝑜𝑟𝑖𝑐𝑎𝑙 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛+𝑚𝑜𝑑𝑒𝑙 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛)
2
 . 
 (5.3) 
 
After fractional discrepancies are calculated, I further obtain squared fractional 
discrepancies.  Squaring the discrepancies helps ensure that no negative discrepancies will 
cancel out positive discrepancies, and reflect that fact that a deviation of model estimate by a 
certain magnitude c is considered equally undesirable regardless of whether the model is under- 
or over-estimating the historical value by that magnitude.  Squared fractional discrepancies can 
also ensure the total discrepancy is concave.  That means a large discrepancy has larger impact 
on the total discrepancy than several small discrepancies even if the sum of these small 
discrepancy equals to the large discrepancy.  Among other factors, this will tend to make the 
calibration prefer to spread discrepancies more “equitably” between several variables, rather than 
“robbing Peter to pay Paul” by eliminating discrepancies in one variable only at the cost of 
creating similar discrepancies in other variables. 
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Figure 5-2. Calibration Structure for the total population in the SHR 
 
During my first several attempts at calibration, I chose all weight to be equal.  I found 
that some young age groups have very large (squared) fractional discrepancies that dominate the 
total discrepancy value.  This is caused by small sample size in both historical data and model 
output for these age groups.  A mismatch of one person count between the historic and model 
values with respect to these sparsely populated age groups can yield a significant fractional 
discrepancy.  Also, these young age groups are less important to diabetes rates in the short-term 
than are middle age groups and elderly age groups, since the younger age groups have limited 
contribution to the hyperglycemic population during that time period.  Therefore, in order to 
avoid situations such as where the squared fractional discrepancies from young age groups 
dominate the total discrepancy, I weighted the squared fractional discrepancies across all 
93 
 
calibrated outputs using weight factors.  The weight factor is proportional to the reciprocal of 
the discrepancy function [67].  Giving a binomially distributed population, the weight factor is 
calculated using 
𝑤 =  1
2
(𝑛𝑝)2(1−𝑝)2 , 
(5.4) 
where n is the population in the age group and p is the fraction of the age group in the total 
population. 
A new issue rises to the surface after the weight factor is incorporated into the calibration 
structure.  Huge weighted squared fractional discrepancies are calculated for middle age groups 
due to large weight factors, where those large weight factors are caused by the large sample sizes 
in these age groups.  As the solution for this issue, we introduced a new parameter to limit these 
large weight factors.  Given the factor the model has a variance, we recalculate all weight 
factors using 
 
𝑤� =  11
𝑤
+ 𝑚 ,  
(5.5) 
where m is the variance of the model.  We make the assumption that the model has a variance of 
0.1.  When weight w is relatively small, the value of the new weight factor 𝑤�  is closed to w; 
but when the weight w is huge, the value of 𝑤�  is limited by model variance m.    
After limited weight factors are calculated according to (5.5), I normalized and applied 
normalized weight factors to calculate weighted squared fractional discrepancies rather than 
using non-normalized weight factors directly.      
 
𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑤 =  𝑛𝑜𝑛−𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑤
∑𝑛𝑜𝑛−𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑤 . 
(5.6) 
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After the weighted squared fractional discrepancy for each population group is calculated, 
I add all of the weighted discrepancies together as contributions of the final payoff. 
The second section in the calibration structure is for calculating discrepancies in the 
fraction of normal weight, overweight and obese population in the youth and adult 
normoglycemic population.  The calibration structure is similar to the calibration structure for 
the other time series.  There are only a few differences in parameters between these two 
sections, such as historical data, model output and weight factors.   
The historical data for this section are the weight status for the Saskatchewan population 
[62].  I made a simplifying assumption here that the normoglycemic population in the SHR 
would have the same weight distribution as the Saskatchewan population.  The historical data is 
grouped into two age groups: the youth age group (12 – 19) and the adults age group (20 – 64).  
Hence, I redefined the population in the model into the same age groups corresponding to the age 
groups in the historical data.  The time series starts from year 2001 and ends at year 2005, but it 
has no data available for the years 2002 and 2004. 
I re-apply equation 5.4 to calculate non-normalized weight factors for discrepancies in 
the fraction of normal weight, overweight and obese population in youth and adult 
normoglycemic population.  For the version of the equation 5.4 applying to this section of the 
model, n is the population count in each group and p is historical fraction of normal weight, 
overweight or obese in each group in the equation 5.4.  The calculation for normalized weight 
factors given in formula 5.6 is used for this section as well.          
The third section in my calibration structure deals with calculating discrepancies in 
diabetes prevalence.  The calibration structure in this part is similar to the structure in other 
sections but uses different historical time series, model outputs and weight factors. 
The historical data for diabetes prevalence rates in the SHR are calculated based on 
estimates for the total number of diabetic patients and the total population in the SHR.  Like 
historical data for the total population, the historical diabetes prevalence rates are calculated for 
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each combination of age, gender and ethnic groups separately.  This time series starts from year 
2001 and end at year 2005. 
Weight factors for diabetes prevalence rates are calculated by using equation 5.4, where n 
is the population count in the population group and p is the historical prevalence rate for the 
population group.  I normalized these weight factors before I apply them to calculate weighted 
squared fractional discrepancies for diabetes prevalence.   
The fourth section in the calibration structure is for calibrating with historical diabetes 
incidence rates.  The calibration structure is the same as structures in other calibration sections, 
with the only differences lying in historical data, model output and weight factor.  
The historical data for the diabetes incidence rate for each combination of age, ethnic and 
gender groups in the SHR are calculated based on the number of new diagnosed diabetic patients 
in the corresponding population group and the total population of that population group [61].  
This time series is from year 2001 to year 2005.  
The calculation of weight factors for diabetes incidence rates is different from the weight 
factor calculation for diabetes prevalence rates.  This reflects that factor that the diabetes 
incidence rate is Poisson distributed with mean time occurrences λ.  Weight factors for diabetes 
incidence rates are calculated using  
𝑤 =  1
2
 (𝜆𝑛)2 , 
(5.7) 
where λ is the historical incidence rate and n is the number of person in the population group.  
After non-normalized weight factors are calculated using equation 5.7, I normalize them to 
normalized weight factors using equation 5.6 and apply these normalized factors into the 
calculation of the weighted squared discrepancy in incidence rate.     
Although the time series for diabetes incidence rates is from year 2001 to year 2005, the 
last year of data is invalid since the administrative data algorithm used to identify the cases 
requires two years to confirm a new diabetes case.  Therefore, I conditionally set weight factors 
to 0 when the time reaches year 2004 and beyond. 
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The last section in the calibration structure is for the discrepancy in mortality.  In this 
section, I obtain the Saskatchewan mortality rates by gender groups from year 2001 to year 2005 
[73] and use them as historical mortality rates. 
The calculation of non-normalized weight factors for discrepancy in mortality uses the 
same equation as the calculation of weight factor for discrepancy in incidence rate, where λ is the 
historical mortality hazard for each gender group and n is the population count in each gender 
group. 
After all weighted squared fractional discrepancies are calculated, they are added together 
into the total weighted squared fractional discrepancy.  The next step of the model calibration 
will alter constant parameters and repeat the discrepancy calculation to find a minimum total 
weighted squared fractional discrepancy.   
5.2.2 List of Constant Parameters     
The previous chapter mentioned many cases in which a parameter would be calibrated 
when I was unable to locate data for the parameter or I remained uncertain about the value of the 
parameter.  In this section, I provide the list of constant parameters and initial values for stock 
variables for which I do not have sufficient data.  Also, I seek to define a reasonable value 
range for each parameter.  Vensim randomly selects a value within the given range for each 
parameter and calculates the total weighted squared fractional discrepancy resulting from a 
scenario in which the model is run using that set of parameter values.  After exploring many 
possible combinations of values, Vensim will find the best combination of values for these 
parameters – that is, the combination of values which generates the minimum total weighted 
squared fractional discrepancy.  Table 5-1 below contains all parameters that were calibrated in 
the calibration process, their value ranges, and estimated values that give the best match with 
historical data. 
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Table 5-1. Parameters in Calibration List 
Parameter 
Lower 
Boundary 
Upper 
Boundary 
Estimated 
Value 
Init undx diabetic without complication population ethnic 
coefficient[Aboriginal, Other] 0.5 2.5 
1.20489, 
1.98039 
Init undx diabetic without complication population gender 
coefficient[Male, Female] 0.5 2.5 
1.18721, 
1.10509 
Init undx diabetic with early stage complication population ethnic 
coefficient[Aboriginal, Other] 0.01 0.1 
0.0101465, 
0.0999878 
Init undx diabetic with early stage complication population gender 
coefficient[Male, Female] 0.01 0.1 0.1, 0.1 
Init undx diabetic without complication population youth 
coefficient 0.3 1 0.808948 
Init undx diabetic without complication population elderly 
coefficient 0.3 1 0.540365 
Init undx diabetic with early stage comp population youth 
coefficient 0.05 0.3 0.3 
Init undx diabetic with early stage comp population elderly 
coefficient 0.01 0.3 0.010004 
Init diabetes to prediabetes coefficient[Male, Female] 0.4 2 0.4, 0.4 
Init undx prediabetic population ethnic coefficient[Aboriginal, 
Other] 1 5 
3.06172, 
2.82211 
Init undx prediabetic population gender coefficient[Male, Female] 1 5 
2.03095, 
1.66264 
Avg years to develop early stage complications from undx diabetes 5 15 15 
Dx diabetes progress coefficient 1 2.5 2.5 
Avg years to develop diabetes from undx prediabetes 8 15 15 
Dx diabetic complication progress coefficient 1 2.5 1 
early stage complication diagnosis youth coefficient 0 0.5 0 
early stage complication diagnosis elderly coefficient 0 1 1 
early stage complication diagnosis gender coefficient[Male, 
Female] 0.5 1 1, 1 
mortality coefficient dx diabetic without complication 0.4 1 1 
mortality coefficient dx diabetic with early stage comp 0.3 2 0.3 
mortality coefficient dx diabetic with late stage comp 1 4 1 
mortality coefficient undx diabetic without complication 0.4 1 1 
mortality coefficient undx diabetic with early stage comp 0.6 2 1.28717 
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5.3 Findings 
Calibration is a valuable tool for estimating unknown parameters, verifying existing data 
and identifying problems in the model.  Through the calibration process, I was able to estimate 
best matching values for unknown parameters listed in Table 5-1.  The calibrated model gives 
the minimum -2503.8 weighted squared fractional discrepancy and exhibits a relatively close 
trend with historical data by using these best estimated values.  Figure 5-3a and 5-3b below 
show that outputs from the model have close trends and small gaps in comparison with historical 
data.   
 
 
Figure 5-3a. Comparison of Total 
Population 
 
Figure 5-3b. Comparison of Diabetes 
Prevalence Rate for RI 55-59 Age Group 
 
The model contains hundreds parameters and constants. We cannot always find a good 
match from calibration. Figure 5-4a and 5-4b show two examples of cases where the chosen 
parameter values assigned by calibration do not yield a good fit to historic data.  
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Figure 5-4a. Comparison of Diabetes 
Incidence Rate for RI 25-29 Age Group 
 
Figure 5-4b. Comparison of Diabetes 
Incidence Rate for non-RI 25-29 Age 
Group 
One possible reason for poor calibration matches is that the duration of the calibration is 
too short.  The diabetes incidence rates for the RI 25-29 age group in Figure 5-4a have large 
gaps and different trend at the beginning of the calibration.  Although curves converge, they 
still do not quite match at the end of the calibration. 
Another possible reason for poor calibration matches is less significance of the 
unmatched time series.  Figure 5-4b shows very low incidence rates for non-RI 25-29 age group.  
Although gaps between model outputs and historical data are not large, curves are diverging 
during calibration.  The failure of the calibration algorithm to calibrate it partly reflects the fact 
of the lower priority (via weight) associated with this outcome variable. 
The third possible reason for poor calibration matches is that the model structure limits 
the possible changes of variables in the calibration.  All variables in the model are related.  
Changes in one variable will have effects on other variables.  It may not be possible to match 
one piece of the model to historical data without significantly diminishing the quality of another 
match.     
Although the set of estimated values for unknown parameters generates the best match 
against historical data, some of these estimated values reach boundaries of given ranges.  When 
a parameter reaches the boundary of the associated calibration range, it indicates that the 
calibration process may have been able to find a better match by assigning a value that is beyond 
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the defined range.  Whether the calibration range is too tight or other issues in the model lead 
the estimated value to reach the boundary, such boundary values require investigation. 
Several parameters in the calibration list for calculating unknown initial values of stock 
variables reach either the lower boundary or the upper boundary of the specified calibration 
range.  The Init undx diabetic with early stage complication population ethnic coefficient, for 
example, reaches the lower boundary 0.01 for RI population, the upper boundary 0.1 for non-RI 
population.  This parameter is used for calculating the initial population of undiagnosed 
diabetics with early stage complication from the initial population of diagnosed diabetics with 
early stage complication.  The first thought is that the model tries to lower the initial population 
of undiagnosed diabetic with early stage complication for the RI group and raise the initial 
population of undiagnosed diabetic with early stage complication for the non-RI population.  
However, the lower boundary of the Init undx diabetic with early stage complication population 
ethnic coefficient is small enough to make the initial population of RI undiagnosed diabetic with 
early stage complication 100 times less than the initial population of RI diagnosed diabetic with 
early stage complication.  A lower value of the Init undx diabetic with early stage complication 
population ethnic coefficient for the RI population would appear to make the number of 
undiagnosed RI diabetic with early stage complication unrealistically small.  In addition, I 
manually adjusted the value of the Init undx diabetic with early stage complication population 
ethnic coefficient for the RI population to an unrealistically low value, but it did not reduce the 
total weighted squared discrepancy significantly.  I also tried to adjust the Init undx diabetic 
with early stage complication population ethnic coefficient to values greater than the upper 
boundary, but there was no significant improvement in the total weighted squared discrepancy.  
Similarly, I tried to recalibrate the model by giving wider ranges to these parameters, but I still 
did not see any significant improvement.  A possible explanation is that these parameters are for 
calculation of initial values of stock variables.  Initial values are only used for starting the 
simulation.  In some circumstances, changes in initial values of stock parameters would fade 
out through the simulation process and will not have large impact on the final result.   
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Beside parameters for calculating unknown initial values, some unknown constant 
parameters in the calibration list reach the boundary as well.  For instance, the mortality 
coefficient undx diabetic without complication is one of the unknown constant parameters that 
reach the upper boundary.  However, there is no space allowing me to loosen the boundary.  The 
mortality coefficient undx diabetic without complication is for calculating the mortality of 
undiagnosed diabetic without complication population based on the average mortality of diabetic 
population, which includes the diabetic with early stage complication population and the diabetic 
with late stage complication population.  By its definition, the diabetic without complication 
population has the lowest risk compared to the diabetic with early stage complication and the 
diabetic with late stage complication population.  Therefore, the mortality of undiagnosed 
diabetic without complication population should not be higher than the average mortality of 
diabetic population and the mortality coefficient undx diabetic without complication should not be 
higher than 1.  Similarly, the mortality coefficient dx diabetic with late stage comp is for 
calculating the mortality of dx diabetic with late stage complication from the all other causes 
mortality of dx diabetic with early stage macrovascular complication population.  It should not 
be less than 1 since diabetic with late stage complication population has much higher risk than 
diabetic with early stage complication population.   
It is clear that the model has some issues causing values of unknown parameters reach 
boundaries.  Unfortunately, I do not have enough time to do further investigation within the scope 
of the thesis.   
Calibration also is a useful tool for verifying and cross checking data in the model from 
related historical data.  The data used in the model should produce the results similar to historical 
data from a different data source, especially at the beginning of a simulation.  For example, the 
sum of each population groups in the model should match the covered population in the SHR in 
year 2001 at the beginning of a simulation.  If data from different sources has a disagreement, 
then either model data or historical data has problem.  At the beginning of my calibration process, 
there was a difference between the initial total population in the model and the total covered 
102 
 
population from the SHR’s reports.  After a quick investigation, I found there was an input error 
in the historical data, which could have caused a much bigger problem later.          
Besides verifying data in the model, calibration can be used to examine model structure as 
well.  I was able to identify some bugs in my model structure through the calibration process, such 
as missing an input population subgroup when accumulating individual population subgroups to 
an aggregate population group. 
5.4 Summary 
Calibration is a valuable tool for estimating values for unknown parameters, verifying data 
in the model and examining model structure.  Through the calibration process, we made the 
model more robust, reliable, and eliminated model formulation problems.   
In Chapter 5, I explained the procedure of calibration in the modeling world.  First of all, I 
briefly explained the basic calibration structure and procedure by going through a conceptual 
calibration structure.  The basic calibration procedure includes several iterations of calculating 
discrepancies between the model outputs and historical data based on possible model parameter 
values and adjusting such parameters so as to minimize such discrepancies, while remaining inside 
specified ranges for the adjusted parameters.  I also explained some basic components in a 
calibration structure; such as model data, historical data, discrepancy and payoff.      
After explaining some basic facts about model calibration, I provide a detailed explanation 
of my calibration structure.  There are total five time series in my calibration structure: the total 
population count in the SHR, the weight status for the Saskatchewan population, the total 
mortality of the Saskatchewan population, the diabetes prevalence rate in the SHR and the 
diabetes incidence rate in the SHR.  Calibration structures for these five time series are very 
similar.  Therefore, I selected the calibration structure for the total population in the SHR as an 
example to explain the discrepancy calculation.  I also explained the weight calculation for 
different time series.    
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Finally I discussed several important findings from the calibration process.  It is clear 
there are some issues in the model when calibrated parameters reach boundaries.  These issues 
will be added into my future work list.   
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CHAPTER 6 
RESULTS 
As my thesis title suggests, the ultimate goal of my study is to create a simulation model 
for the burden of Type 2 Diabetes in the Saskatoon Health Region.  After the calibration process, 
major structural defects in the model are corrected and missing parameters are plugged into the 
model with the best estimated values.  Robustness and integrity of the model are improved to an 
acceptable level.  The model is able to reproduce the historical burden of diabetes in the SHR 
with an adequate degree of fidelity.  The model now can be used to project the trend of diabetes 
burden in the near future; longer-term projection is possible, but results are contingent upon 
assumptions regarding exogenous factors (e.g. assumptions regarding changes in the incidence of 
overweight and obesity, migration, changes in diagnostic technologies and treatments for 
pre-diabetes, diabetes and complications).  It also can be used as an assistant tool to help 
decision makers understand the basic causes of diabetes burden and test potential intervention 
policies. 
The burden imposed by Type 2 diabetes includes many components such as the diabetes 
prevalence, the diabetes incidence rate, the diabetes-related costs for the health care system, the 
diabetes-related costs for individual patient, and the quality of life.   
In this chapter, I am going to focus on the diabetes prevalence and the diabetes incidence 
rate as the diabetes burden.  I will illustrate some simulation results as important indicators, 
such as diabetes prevalence and diabetes incidence.  I use the model to simulate the evolution of 
the diabetes burden in the Saskatoon Health Region in the next 100 years from year 2001.  The 
simulation results will show the dynamics of diabetes burden in the SHR and create a broad 
picture of the diabetes burden in the future. 
6.1 Simulation Results 
After the model is calibrated, I ran the model to simulate the diabetes burden from year 
2001 to year 2101 based on current conditions.  The simulation results are the projections of the 
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diabetes burden without any intervention, and assuming current levels of exogenous factors.  
These results can provide a good view on the trend of diabetes burden. 
Figure 6-1 illustrates the trajectory of the total population in the SHR.  The projection of 
the total population slowly increases during the first 20 years of the simulation period.  After 
the total population reaches its peak level around the year 2025, it starts to decrease slowly.    
 
Figure 6-1. Total Population 
 
The diabetic population in the SHR is the most important indicator of diabetes burden.  
Figure 6-2a shows the simulation result of the total diabetic population from year 2001 to year 
2101.  The total diabetic population increases in the first half simulation period.  It reaches the 
peak level between year 2046 and year 2056, and slowly decreases afterwards.  Figure 6-2b 
illustrates the diabetic populations in different ethnic and gender population groups.  Most of 
the diabetic population is non-Aboriginal due to the large population base.  The Aboriginal 
female diabetic population is slightly greater than the Aboriginal male diabetic population during 
the entire 100-year simulation period.  The non-Aboriginal female diabetic population is a little 
less than male at the beginning of the simulation, but it quickly rises to exceed the number of 
male non-Aboriginal diabetic population around the year 2015.  
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Figure 6-2a. Total Diabetic Population  
Figure 6-2b. Total Diabetic Population by 
Ethnic and Gender Groups 
The dynamics in the size of the total diabetic population is influenced by many factors in 
the model.  These factors cause the observed behavior in the size of the total diabetic population.  
The change in the obese population is one of the leading causes of this trend.  As is widely 
known, obesity is the most important risk factor of developing type 2 diabetes.  An increase in 
the obese population will lead to growth in the prediabetic population and further spur an 
increase in the diabetic population. The simulation results from my model show that the obese 
population increases immediately and reaches a peak level between year 2021 and year 2026.  
The increase in the obese population leads the increase in the prediabetic population.   
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Figure 6-3. Comparison of Total Obese normoglycemic, Prediabetic and Diabetic 
Population 
 
Figure 6-3 shows that the prediabetic population increases with a slightly slower speed 
and slight delay from, but with a little longer term than the obese population.  The prediabetic 
population reaches its peak level between the year 2026 and the year 2031.  The diabetic 
population also increases with the obese population but with a slower speed because of the long 
time delays involved and because not every obese person will develop diabetes.  The increase in 
the diabetic population also has a longer period than the increase in the obese population since it 
will take years to develop diabetes.  Figure 6-2 shows that the diabetic population reaches its 
peak level between the year 2046 and the year 2051.       
The size of the diabetic population indicates an important component of the absolute 
burden of diabetes, but it does not reflect the relative level of burden within some population 
groups.  The prevalence of diabetes is an appropriate indicator for highlighting the relative level 
of the diabetes burden in population groups.  Although the number of RI diabetic patients is much 
less than the number of non-RI diabetic patients, the prevalence of diabetes in the RI population is 
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not less than the prevalence of diabetes in the non-RI population.  Figure 6-4 shows that the 
prevalence of diabetes in RI female population is higher that the prevalence in the non-RI female 
population until the year 2071.  The prevalence in the RI male population is very close to the 
prevalence in the non-RI male population.  Figure 6-4 also shows that the prevalence in the 
female populations is higher than in the male population for both RI and non-RI groups for the 
most of time simulation timeframe.  However, Figure 6-4 does not itself show an important 
contributing factor affecting the results shown:  The age structure of the underlying population.  
We discuss this next.    
 
Figure 6-4. Diabetes Prevalence by Ethnic and Gender Groups 
 
The diabetes prevalence among the non-RI populations keeps a steady state after it reaches 
its peak value.  However, the diabetes prevalence among the RI population starts to decrease after 
reaches the peak value.  One major reason is the Aboriginal population count decreases after the 
year 2040.  Due to insufficient data for the birth rate of the Aboriginal population, I applied the 
birth rate of the general population to the Aboriginal population in the model. The decreasing in 
the Aboriginal population causes the decreasing in the Aboriginal diabetic population and further 
causes the decreasing in the diabetes prevalence among the Aboriginal population. 
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Another major reason is the age structure of the Aboriginal population.  The prevalence 
and the incidence rates of population groups in the model are not age standardized.  Since a large 
percentage of the Aboriginal population are young, the prevalence of diabetes is low for the 
Aboriginal population.  However, the low prevalence of diabetes does not mean they are healthier 
than others.  The youth are still in high risk of developing diabetes.           
 
 
Figure 6-5. Comparison between Age 25 and Age 65 Population Groups 
 
The simulation results also indicate that older age groups have higher diabetes prevalence 
than younger age groups.  It is well known the risk of Type 2 diabetes is highly associated with 
age.  The simulation results clearly show the relationship between age and diabetes.  Figure 6-5 
illustrates that the diabetes prevalence of the age group 65 to 69 is much higher than for age group 
25 to 29. 
In addition to the diabetic population and the diabetes prevalence discussed above, the 
number of incident cases per year is another important factor to indicate diabetes burden.  It 
reflects the acceleration of the diabetes burden.  A rise in incidence cases leads to a faster increase 
in the diabetic population and in other components of the diabetes burden as well.  Figure 6-6a 
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illustrates the trend of diabetes incidence over the next 100 years.  The total incidence case drops 
in the first 5-year period, which may be due to a drop in the total population and that the incorrect 
initial values which are not consistent with the estimated transition rates.  After the first 5-year 
period, the impact of the incorrect initial values fades out and the rate of diabetes incidence starts 
rising.  The number of incident cases per year reaches the peak value - 1106 person per year - in 
year 2031, and then start dropping slowly afterwards due to the decreasing in the population at the 
risk.   
As Figure 6-6b shows, the number of diabetes incident cases per year in the Aboriginal 
population basically exhibits the same trend as the total number of incident cases.  However, the 
number of incident cases in the Aboriginal population has a longer increase time period.  It 
reaches its peak value around year 2041 compared to year 2031 for the total number of incident 
cases.  After it reaches the peak value, the annual number of incident cases rapidly decrease.  
Similar to the prevalence of diabetes for the Aboriginal population, the decrease in the annual 
number of incident cases for the Aboriginal population is caused by the decrease in the potential 
population and the age structure.     
      
 
Figure 6-6a. Total Incident Cases 
 
Figure 6-6b. Total Incident Cases in RI 
Population 
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Figure 6-6c. Total Incident Cases by 
Gender Groups 
 
Figure 6-6d. Total Incident Cases in 
Elderly Age Group 
 
Figure 6-6c illustrates that the number of annual incident cases in the female population 
increases more rapidly than the number of annual incident cases in the male population.  The 
model suggests that the absolute number of new cases in the female population per year will 
exceed the number of annual new cases in the male population around year 2016.  The number of 
annual incident cases in the female population raises until year 2036, but the number of annual 
incident cases in the male population rises until 2026.  These results suggest that diabetes may 
increase faster in the female population than in the male population.  The number of annual 
incident cases in both male and female population start to decrease after they reach their peak 
values due to the decrease in the potential population.     
Similar to the diabetes prevalence, the annual diabetes incidence for the elderly population 
is much higher than the annual incidence for the youth population.  Figure 6-6d shows that the 
number of new annual cases of diabetes from the elderly population (age 50 and plus) forms about 
¾ of the total number of new annual cases of diabetes. 
The simulation results appear to be relatively reasonable projections of the diabetes burden 
in the SHR in the medium-term future.  The results suggest that the diabetes prevalence and the 
annual incident of new cases will rise during the first half simulation period.  The annual incident 
of new cases, however, will decrease during the second half simulation period due to the decrease 
of the potential population.  The decrease in the annual incident of new cases of diabetes will slow 
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down the acceleration of diabetes prevalence.  The decrease of potential diabetic population and 
the young age structure will finally lead a small decrease in the diabetes prevalence for the 
Aboriginal population.   
Through the analysis, we can point out the major causes of diabetes burden and plan 
targeted interventions to reduce diabetes burden.  For example, the simulation results show the 
diabetes prevalence and incidence are high among the female population.  One possible 
intervention could be having physical activity or healthy eating programs specifically targeted on 
obese or overweight females to reduce the rate of new cases of diabetes in the female population.  
However, the simulation results are scenario projections.  They have limitations due to the 
availability of data and simplification of the model structure. In the next section, I will explain the 
limitations of the model.      
6.2 Limitations   
The simulation model is a very useful tool to help us understand the diabetes burden in the 
SHR and to predict the trend of the burden.  However, it is not a magic crystal ball that allows us 
see the future.  The model has some important limitations.  Hence we must treat the simulation 
results carefully in order to avoid misleading analysis results and improper interventions.   
Figure 6-6a shows a decrease in the total number of new cases of diabetes in the first 5-year 
simulation period.  It is clear the rate of incident cases is not in an equilibrium state at the 
beginning of the simulation.  One possible reason is incorrect initial values such as the initial 
diabetic population, the initial mortality rate or the initial diagnosis rate.  The incorrect initial 
values are out of balance with the estimated transition rates; and the inconsistency leads to an 
oscillation during the beginning of the simulation.  After the effect of initial values faded out, the 
diabetes incidence raises.  
Some of the initial values for the model are carefully chosen from historical data and 
related research.  Some of the initial values are the best estimates from the calibration process.  It 
is possible the estimated initial values are at variance with the true underlying values, but they are 
reasonable estimates based on available data.  Moreover, uncertainties in model parameters may 
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not cause the same uncertainties in the model outputs or may only have limited impacts on the 
model outputs.  I examined impacts from uncertainties in several model parameters in chapter 7.  
Even if the uncertainties have large impacts on the model result, but they may not exert a large 
change on relative desirability between different interventions.       
The model results are not age standardized.  Hence, the age structures of population 
groups have impacts on the results that cross age groups, such as the prevalence and the incidence 
rates.  This is one of the reasons that cause the prevalence and the incidence rates to drop for the 
Aboriginal population during the second half of the simulation period.      
The model also does not consider the effect from migration of the population.  The 
population in the city of Saskatoon is growing.  A large part of the growth is the migration from 
other cities, provinces and countries.  I made a simplifying assumption in my model that the 
population is only affected by the birth rate and mortality rate, but experience no net migration.  
This simplification could lead less population in the simulation results than it should be if the 
population in the city of Saskatoon keep grows.  This may lead to a smaller size of diabetic 
population in the simulation results.  However, the trend of population migration is difficult to 
predict since it depends on many factors.  For many years, Saskatoon experienced a net 
outmigration of population. The prediction of population migration does not fall within the scope 
of this thesis.  I will leave the population migration section out of my study and the addition of a 
population migration section can be a possible topic for farther study.   
The model is not to be intended to forecast the exact diabetes situation in the future.  
There are many factors that our model does not consider.  We made simplifying assumptions 
about these factors.  The result from the model is one possible projection conditional on certain 
assumptions.          
6.3 Summary              
The goal of my study is to build a model simulating the dynamics of diabetes in the SHR 
and to use the simulation results to analyze the diabetes burden in the SHR.  In the previous 
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chapters, I explained the construction of my model.  In this chapter, I explained the findings from 
the simulation.   
The simulation results suggest that the diabetes burden will increase in the next 30 to 40 
years.  Both the diabetes prevalence and new diagnosis incidence cases will go up for all ethnic 
and gender groups.  The number of diabetes new diagnosed incidence for the general population 
in the SHR increases and will reach a peak value around the year 2031.  The increase of the 
number of new diabetes cases in the Aboriginal population has a longer time period and it will 
reach the peak value around the year 2041.  After the number of diabetes new diagnosed cases 
reaches the equilibrium, it will decrease slowly.  The decrease in the number of annual incident of 
new cases slows down the acceleration in the diabetes prevalence.   The prevalence of diabetes 
continuously increases until around the year 2051.  The increases are especially notable in the 
Aboriginal population and female population.  The Aboriginal female population has the highest 
diabetes prevalence among all ethnic and gender groups.  
The simulation results suggest that, absent aggressive intervention, the diabetes prevalence 
is likely to continuously increase and will not slow down in the near future.  We will need to think 
of feasible interventions to slow down the rate of increase or even reduce the diabetes burden.  In 
the next chapter, I will test the sensitivity of model parameters that are related to the simulation 
results and examine some possible interventions based on the observed parameters’ sensitivity.  
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CHAPTER 7 
SENSITIVITY ANALYSIS AND INTERVENTIONS 
The simulation results suggest that the diabetes burdens, especially the diabetes 
prevalence and the incidence rate in the SHR will keep increasing in the near future.  It 
is important to find solutions to slow the increase or even lower the diabetes prevalence 
and the incidence rate.  Before we can start our investigation, we need to know which 
model parameters have a large impact and which only have small impacts on the diabetes 
burdens.  If all other things are equal, we would anticipate that intervention policies 
based on changes on the parameters which have large impact on the simulation results 
would have a larger effects on the diabetes burdens.  In this chapter, we will investigate 
which parameters have large impacts on the model results through sensitivity analysis 
(SA).  The sensitivity analysis of model parameters will show the importance of the 
parameters to the model outputs.  I will examine the sensitivity of the several parameters 
in the model, such as the prediabetes diagnosis rate, the diabetes diagnosis rate, the 
overweight incidence rate, etc.  By altering the values of the chosen parameters to 80%, 
85%, 90%, 95%, 105%, 110%, 115% and 120% of the original values, we can observe 
the changes on the model outputs and determine the levels of impacts from these altered 
parameters. 
After the sensitivity analysis, I will examine several interventions based on our 
observations.  By comparing the results from different interventions side by side, 
decision makers more easily find the impacts from different interventions and adapt them 
to a feasible intervention policy for the SHR.  The results from sensitivity analysis are 
also useful to point out directions of future research.   
7.1 Sensitivity Analysis 
In the sensitivity analysis, I examined the sensitivity of selected variables in the 
model.  The simulation timeframe begins in year 2001 and extends for 100 years.  
These test variables undergoing sensitivity analysis are systemically selected because of 
their impacts on the flow rates in the model.  They have the potential of changing 
simulation results all the way through entire simulation period.   
The test variables are selected from 4 general categories: the hyperglycemia 
diagnosis rates, the progress rates, the mortality rates, and the birth rate.  The selected 
hyperglycemia diagnosis rates are the prediabetes diagnosis rate and the diabetes 
diagnosis rate.  The selected progress rates include the overweight incidence rate, the 
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obesity incidence rate, the developing prediabetes from obese incidence rate, average 
years to develop diabetes from undiagnosed prediabetes, average years to develop 
diabetes from diagnosed prediabetes, average years to develop early stage complication 
from undiagnosed diabetes, average years to develop early stage complication from 
diagnosed diabetes and the prediabetes recovery rate.  The selected morality rates 
include the mortality rate of the diagnosed prediabetic population, the mortality rate of 
the diagnosed diabetic without complication population, the mortality rate for the 
diagnosed diabetic with early stage complication population, and the mortality rate for 
the diagnosed diabetic with late stage complication population.  The selected birth rate 
is the SHR birth rate for the Aboriginal population.   
I also added several aggregative results variables, which summarize values cross 
the population, into the model to help the reader observe and compare the changes during 
the sensitivity analysis.  These result variables are the cumulative incidence of diabetes, 
the cumulative diagnosed incidence of diabetes, the cumulative number of diabetic, the 
cumulative number of diagnosed diabetic and the cumulative death of diabetic.  Besides 
cumulative result variables, I also employed two non-cumulative result variables, the 
total prevalence of diagnosed diabetes and the total diabetes incidence, to show the 
system responses from the changes of the test variables.  These result variables will be 
plotted into graphs to illustrate the changes. 
7.1.1 Single-variable Sensitivity Analysis 
I start my sensitivity analysis by only altering one test variable each time and 
observe the changes in the result variables.  This process helps us answer the question 
“which variable has a large impact on the simulation results”.  It also provides a solid 
foundation for the next step sensitivity analysis with multiple variables on the selection 
and combination of modifications to the test variables.   
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Figure 7-1. Sensitivity Results for Prediabetes Diagnosis Rate 
 
Figure 7-1 shows the sensitivity results for the prediabetes diagnosis rate.  
Figure 7-1a suggests that the cumulative incidence of diabetes is sensitive to the changes 
in the prediabetes diagnosis rate.  The changes in the prediabetes diagnosis rate affect 
the number of diagnosed prediabetic population and further affect both the undiagnosed 
and diagnosed diabetes population.  Figure 7-1b and 7-1d show the levels of impacts 
from the changes in the prediabetes diagnosis rate are reduced for the cumulative 
diagnosed incidence of diabetes and the cumulative number of diagnosed diabetic since a 
component of diagnosed prediabetic will develop diabetes without being diagnosed.  
The impacts are also delayed for the cumulative number of diabetic as the Figure 7-1c 
shows since it will take years to develop diabetes from prediabetes.  The impacts are 
further reduced and delayed for the cumulative death of diabetes.  However, the total 
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prevalence of diagnosed diabetes and the total incidence are relatively sensitive to the 
changes in the prediabetes diagnosis rate.  
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Figure 7-2. Sensitivity Results for Diabetes Diagnosis Rate 
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Figure 7-2 shows the sensitivity results for the diabetes diagnosis rate.  The 
diabetes diagnosis rate controls the population flow speed from the undiagnosed diabetic 
population to the diagnosed diabetic population.  This is associated with only one of 
several diabetes diagnosis paths that are included in the model to calculate the cumulative 
incidence of diabetes.  Figure 7-2a shows the cumulative incidence of diabetes 
responses but is not too sensitive to the changes in the diabetes diagnosis rate.  Figure 
7-2b shows the changes in the diabetes diagnosis rate have slightly heavier impacts on the 
cumulative diagnosed incidence of diabetes than on the cumulative incidence of diabetes.   
Diabetes diagnosis from the undiagnosed diabetic population is a diagnosis flow 
and it does not affect the timing diabetes onset.  Hence, the changes in the diabetes 
diagnosis rate visually have no impact on the cumulative number of diabetic as shown in 
Figure 7-2c.  However, the changes in the diabetes diagnosis rate affect the flow rate of 
the undiagnosed diabetic population becoming diagnosed and further change the 
cumulative number of diagnosed diabetic as shown in Figure 7-2d.   
The diagnosed diabetic population has very similar mortality as the undiagnosed 
diabetic population.  The changes in the diabetes diagnosis rate visually have no impacts 
on the cumulative death of diabetic as shown in Figure 7-2e.  Graph 7-2g shows that the 
total incidence is sensitive to the change in the diabetes diagnosis rate.  Any change in 
the diabetes diagnosis rate will be reflected in the total incidence immediately.  
Similarly, the impacts are reflected to the total prevalence of diagnosed diabetes 
immediately, but the levels of impacts are diluted by the total population as shown in 
Figure 7-2f and accumulate only over time.  
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Figure 7-3. Sensitivity Results for Overweight Incidence Rate 
 
Figure 7-3 shows the sensitivity results for the overweight incidence rate.  This 
sensitivity analysis alters the incidence rate of becoming overweight from the normal 
weight normoglycemic population.  The figures from 7-3a to 7-3e show that the changes 
in the overweight incidence rate impact the results variables in the long run.  The impact 
has been delayed since it will take relatively long time to develop diabetes from the 
overweight normoglycemic population.  Also, the changes in the overweight incidence 
rate have a relatively large impact on the total prevalence of diagnosed diabetes and on 
the total incidence in the long run since they impact on the diabetic population. 
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Figure 7-4. Sensitivity Results for Obesity Incidence Rate 
 
Similar to the overweight incidence rate, the changes in the obesity incidence rate 
have a long run impact on the cumulative diabetic result variables, the total prevalence of 
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diagnosed diabetes and the total incidence.  Figure 7-4 illustrates the long run impacts 
from the changes in the obesity incidence.  Compared to the impact from the changes in 
the overweight incidence rate, the impact from changes in the obesity incidence rate is 
smaller.  The changes in the overweight incidence rate do not only have an impact on 
the overweight population but also have a second stage impact on the obese population.  
The changes in the obesity incidence rate only have impact on the obese segment of the 
normoglycemic population.  Hence, the changes in the obesity incidence rate have lower 
levels of impact on the diabetic result variables. 
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Figure 7-5. Sensitivity Results for Developing Prediabetes from Obese Population 
Incidence Rate 
 
Figure 7-5 illustrates one-way sensitivity analysis results for developing 
prediabetes from the obese population incidence rate.  We can see that the result 
variables are very sensitive to the changes in the developing prediabetes from obese 
population incidence rate.  The sensitivity graphs exhibit the large variance in the 
results, especially in the non-cumulative variables.  The changes in the prediabetes 
incidence rate have a direct impact on the undiagnosed prediabetes population, which 
serves as the headwater of all diabetic population groups.  Any change in the 
undiagnosed prediabetes population will have impact on every downstream diabetic 
population stock.    
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Figure 7-6. Sensitivity Results for Average Years to Develop Diabetes from 
Undiagnosed Prediabetes 
 
Average years to develop diabetes from undiagnosed prediabetes is another 
parameter that has a direct impact on the diabetic population.  Figure 7-6 illustrates the 
sensitivity test results for average years to develop diabetes from undiagnosed 
prediabetes.  This variable controls the number of undiagnosed prediabetics developing 
diabetes every year.  Changes in the average years to develop diabetes from 
undiagnosed prediabetes have a direct effect on the size of the undiagnosed diabetic 
population and a secondary effect on the size of the diagnosed diabetic population.  
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Graph 7-6a to 7-6e show that the cumulative outcome variables are quite sensitive to the 
changes in the average years to develop diabetes from undiagnosed prediabetes. Graph 
7-6f and 7-6g show that total prevalence of diagnosed diabetes and total incidence 
respond to the changes immediately and in a pronounced fashion.  
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Figure 7-7. Sensitivity Results for Average Years to Develop Diabetes from 
Diagnosed Prediabetes 
 
Similar to average years to develop diabetes from undiagnosed prediabetes, 
average years to develop diabetes from diagnosed prediabetes is another parameter that 
has a direct impact on the downstream diabetic population.  Compared to average years 
to develop diabetes from undiagnosed prediabetes, the average years to develop diabetes 
from diagnosed prediabetes has a lower impact on the outcome variables.  As I 
mentioned in the calibration chapter, average years to develop diabetes from diagnosed 
prediabetes is calibrated from average years to develop diabetes from undiagnosed 
prediabetes by using a constant coefficient.  The changes in average years to develop 
diabetes from undiagnosed prediabetes will thus affect the base value of average years to 
develop diabetes from diagnosed prediabetes indirectly.  Conversely, the changes in 
average years to develop diabetes from diagnosed prediabetes do not have the same 
effect on average years to develop diabetes from undiagnosed prediabetes.  Hence, the 
outcome variables are less sensitive to the changes in the average years to develop 
diabetes from diagnosed prediabetes.   
Average years to develop diabetes from diagnosed prediabetes controls the 
incidence of diabetes from the diagnosed prediabetic population directly.  Hence, the 
changes in average years to develop diabetes from diagnosed prediabetes have a large 
impact on the diabetes incidence related result variables, such as the cumulative 
diagnosed incidence of diabetes and the total incidence. 
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Figure 7-8. Sensitivity Results for Average Years to Develop Early Stage 
Complication from Undiagnosed Diabetes 
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Figure 7-8 shows the sensitivity test results for the average years to develop early 
stage complication from undiagnosed diabetes.  The cumulative outcome variables 
related to the total diabetic population are less sensitive to the changes in the average 
years to develop early stage complication from undiagnosed diabetes when compared to 
the cumulative outcome variables related to the diagnosed diabetic population.  Average 
years to develop early stage complication from undiagnosed diabetes controls the flow 
rate from the undiagnosed diabetes without complication population to the undiagnosed 
diabetes with early stage complication population.  It will not have large impacts on the 
total diabetic population since it has nothing to do with diabetes onset.  However, the 
flow from the undiagnosed diabetes without complication population to the undiagnosed 
diabetes with early complication population is a diagnosis flow according to our 
definition.  As mentioned in the chapter 4, the assumption is that undiagnosed diabetic 
patients will have their diabetes diagnosed even if the complications are not diagnosed.  
Average years to develop early stage complication from undiagnosed diabetes has direct 
impacts on the diagnosed diabetic population.  Hence, the cumulative diagnosed 
incidence, the cumulative number of diagnosed diabetic, the total prevalence of 
diagnosed diabetes and the total incidence are more sensitive to the changes in average 
years to develop early stage complication from undiagnosed diabetes compared to other 
outcome variables.  
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Figure 7-9. Sensitivity Results for Average Years to Develop Early Stage 
Complication from Diagnosed Diabetes 
 
Figure 7-9 illustrates the sensitivity levels of the outcome variable response to the 
changes in average years to develop early stage complication from diagnosed diabetes.  
From the graphs we can see that the outcome variables are insensitive to the changes in 
the parameter during my test time period.  Average years to develop early stage 
complication from diagnosed diabetes controls the flow from the diagnosed diabetes 
without complication population to the diagnosed diabetes with early stage 
macrovascular complication population.  The changes in the average years to develop 
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early stage complication from diagnosed diabetes do not affect the number of diabetes or 
the incidence of diabetes directly since they are diagnosed as diabetic already.  The 
impact on the outcome variables is indirect (e.g. via impact on the total population) and 
the level of impact is low.   
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Figure 7-10. Sensitivity Results for Prediabetes Recovery Rate 
 
The prediabetes recovery rate controls the number of diagnosed prediabetic 
recovered from hyperglycemia and moving back to the normoglycemic population groups.  
Figure 7-10 shows that the sensitivity levels of the prediabetes recovery rate are mild for 
the outcome variables.  The changes in this parameter have no direct impact on the 
diabetic population, but they have some levels of impact on the diagnosed prediabetic 
population and further affect the diabetic population.  
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Figure 7-11. Sensitivity Results for Diagnosed Prediabetes Mortality Rate 
 
In addition to diabetes progression rates, I also tested the sensitivity of model 
response to several mortality rates.  Graphs in Figure 7-11 show the sensitivity analysis 
results with respect to the mortality rate of diagnosed prediabetes.  The changes in the 
mortality rate of diagnosed prediabetes have only a minor impact on the cumulative 
incidence of diabetes, the cumulative incidence of diagnosed diabetes and the total 
incidence as shown on Figure 7-11a, 7-11b and 7-11g.  The changes in the mortality rate 
of diagnosed prediabetes have a direct impact on the size of the diagnosed prediabetes 
population, which are the potential new cases of diabetes.  Hence, the changes in the test 
parameter have a secondary impact on the cumulative incidence of diabetes, the 
cumulative incidence of diagnosed diabetes and the total incidence.  The level of impact 
from changes in the mortality rate of diagnosed prediabetes is not obvious on other 
outcome variables. 
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Figure 7-12. Sensitivity Results for Mortality Rate of Diagnosed Diabetes without 
Complication 
 
v3-28 Dx Diabetes without Complication Mortality Coefficient Adjustment
Cumulative incidece of diabetes
200,000
150,000
100,000
50,000
0
2001 2026 2051 2076 2101
Time (Year)
v3-28 Dx Diabetes without Complication Mortality Coefficient Adjustment
Cumulative diagnosed incidence of diabetes
100,000
75,000
50,000
25,000
0
2001 2026 2051 2076 2101
Time (Year)
v3-28 Dx Diabetes without Complication Mortality Coefficient Adjustment
Cumulative number of diabetic
4 M
3 M
2 M
1 M
0
2001 2026 2051 2076 2101
Time (Year)
v3-28 Dx Diabetes without Complication Mortality Coefficient Adjustment
Cumulative diagnosed incidence of diabetes
100,000
75,000
50,000
25,000
0
2001 2026 2051 2076 2101
Time (Year)
v3-28 Dx Diabetes without Complication Mortality Coefficient Adjustment
Cumulative death of diabetic
200,000
150,000
100,000
50,000
0
2001 2026 2051 2076 2101
Time (Year)
v3-28 Dx Diabetes without Complication Mortality Coefficient Adjustment
total prevalence of diagnosed diabetes
0.2
0.15
0.1
0.05
0
2001 2026 2051 2076 2101
Time (Year)
v3-28 Dx Diabetes without Complication Mortality Coefficient Adjustment
Total incidence
0.006
0.005
0.004
0.003
0.002
2001 2026 2051 2076 2101
Time (Year)
134 
 
Figure 7-12 illustrates the sensitivity analysis results for mortality rate of 
diagnosed diabetes without complication.  This test variable has a direct impact on the 
cumulative death of diabetic.  Figure 7-12e shows that the cumulative death of diabetic 
is relatively sensitive to changes in the mortality rate of diagnosed diabetes without 
complication from the beginning of the simulation.  The test variable also has a direct 
impact on the size of the diagnosed diabetics without complication population.  Hence, 
the cumulative number of diabetic and the total prevalence of diagnosed diabetes are also 
relatively sensitive to changes in the mortality rate of diagnosed diabetes without 
complication.  However, the sensitivity levels are not high due to the low mortality rate 
and the relatively small population in the diagnosed diabetes without complication 
population group.  
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Figure 7-13. Sensitivity Results for Mortality Rate of Diagnosed Diabetes with Early 
Stage Complication 
 
Figure 7-13 shows the sensitivity test results for the mortality rate of diagnosed 
diabetes with early stage complication.  Like other mortality rates, the mortality rate of 
diagnosed diabetes with early stage complication has a direct impact on the 
corresponding population (here, diagnosed diabetics with early stage macrovascular 
complications).  However, the levels of impacts are not obvious in the graphs.  The 
diagnosed diabetes with early stage macrovascular complication population is a small 
fraction of the total diabetic population.  The changes in the diagnosed diabetes with 
early stage macrovascular complication population only cause small changes on the 
outcome variables.  Hence, the outcome variables are very insensitive to the changes in 
the mortality rate of diagnosed diabetes with early stage complication as shown in Figure 
7-13.     
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Figure 7-14. Sensitivity Results for Mortality Rate of Diagnosed Diabetes with Late 
Stage Complication 
 
Similar to the mortality rate of diagnosed diabetes with early stage complication, 
the changes in the mortality rate of diagnosed diabetes with late stage complication do 
not have an obvious impact on any result variable due to the small population base as 
shown in Figure 7-14. 
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Figure 7-15. Sensitivity Results for SHR Birth Rate of Aboriginal Population 
 
As previously described in chapter 6, I made the assumption that the Aboriginal 
population has the same birth rate with the non-Aboriginal population due to insufficient 
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data.  However, it is a well known fact that the Aboriginal population has a higher birth 
rate than the general population in the SHR.  Hence, I tested the sensitivity level of the 
result variables in response to changes in assumption regarding the birth rate of the 
Aboriginal population.  Figure 7-15 shows the changes in the result variables as a result 
of changes in the Aboriginal component of the population birth rate variable.  The 
changes in the SHR birth rate of Aboriginal population do not impose heavy impacts on 
the result variables, and the assumption of using the same birth rate for the Aboriginal 
population is therefore not expected to strongly distort simulation results.      
After conducting sensitivity analysis for a single variable, we have gained some 
basic understanding on the questions “what kind of impact could happen from the 
changes in model parameter” and “what levels of impact could each test parameter 
cause”.  In general, changes in the upstream variables could lead to heavier impacts on 
the diabetes burdens than changes in the downstream variables.  For instance, changes 
in the mortality rate of diagnosed diabetes without complication have larger impacts on 
the result variables than the changes in the mortality rate of diagnosed diabetes with early 
stage complication.  Also, the changes on the rates, which are applied to a large 
population group, could have heavier impacts on the diabetes burdens than the changes 
on the rates when applied to a small population group.  For instance, changes in the 
average years to develop diabetes from undiagnosed prediabetes impose a larger impact 
than do changes in the average years to develop early stage complication from diagnosed 
diabetes.   
Nevertheless, the impacts from the changes in single variables are limited.  Can 
we amplify the impact if we change multiple variables at the same time?  Is the level of 
impact stronger or weaker than the level of impact by just adding the effects?  What 
variables can we alter together?  What variable combination can achieve maximum 
effects?  In order to answer these questions, I performed multi-variable sensitivity 
analysis after single-variable sensitivity analysis. 
7.1.2 Multi-variable Sensitivity Analysis 
Theoretically, we could change all variables in the model together to achieve the 
maximum effects.  However, it is rarely feasible to do that in practice.  First of all, not 
all variables in the model are feasible or ethical to change (consider affecting the birth 
rate).  Secondly, it may be too costly to undertake a sufficient number of simultaneous 
interventions to affect all variables together.  With limited resources, decision makers 
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must select and target certain focus areas carefully to optimize the utility while 
maintaining the feasibility of interventions.   
I proposed several combinations of variables based on the results from the 
single-variable sensitivity analysis.  Each variable combination could plausibly be 
altered by one intervention policy.   Then I tested the sensitivity levels of result 
variables response to the changes in the variable combinations.  By observing and 
analyzing the responses, we can develop potential intervention policies to aid in lowering 
the diabetes prevalence and diabetes incidence rate. 
Variables in each combination are altered independently during the multi-variable 
sensitivity analysis.  Effect from each variable could reinforce each other or could 
cancel out each other.  For instance, we have the scenario that the overweight incidence 
rate is raised to the maximum level and the obesity incidence rate is lowered to the 
minimum level at the same time.  We also have the scenario that both the overweight 
incidence and the obesity incidence rate are raised to the maximum level.           
 
Table 7-1. Variable Combinations for Multi-variable Sensitivity Analysis 
Variable Combination Potential Intervention 
Overweight incidence rate & obesity 
incidence rate 
Better weight management for the 
normoglycemic population 
Prediabetes diagnosis rate & diabetes 
diagnosis rate 
Better hyperglycemia diagnosis  
Average years to develop diabetes from 
undiagnosed prediabetes & average years 
to develop diabetes from diagnosed 
prediabetes 
Better prediabetes management 
Develop prediabetes from obese population 
incidence rate & prediabetes incidence rate 
Better weight management (e.g. through 
improved physical activity and nutrition) 
for high risk population groups 
Average years to develop early stage 
complication from diagnosed diabetes & 
mortality of diagnosed diabetes without 
complication population 
Better diabetes management 
Mortality of diagnosed diabetes with early 
stage complication population & mortality 
of diagnosed diabetes with late stage 
complication population 
Better diabetes complication treatment 
Prediabetes diagnosis rate & prediabetes 
recovery rate + average years to develop 
diabetes from diagnosed prediabetes 
Comprehensive prediabetes management 
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Figure 7-16. Sensitivity Results for Overweight Incidence Rate and Obesity 
Incidence Rate 
 
v3-28 Obesity Incidence + Overweight Incidence Coefficient Adjustment
Cumulative incidece of diabetes
200,000
150,000
100,000
50,000
0
2001 2026 2051 2076 2101
Time (Year)
v3-28 Obesity Incidence + Overweight Incidence Coefficient Adjustment
Cumulative diagnosed incidence of diabetes
100,000
75,000
50,000
25,000
0
2001 2026 2051 2076 2101
Time (Year)
v3-28 Obesity Incidence + Overweight Incidence Coefficient Adjustment
Cumulative number of diabetic
4 M
3 M
2 M
1 M
0
2001 2026 2051 2076 2101
Time (Year)
v3-28 Obesity Incidence + Overweight Incidence Coefficient Adjustment
Cumulative number of diagnosed diabetic
4 M
3 M
2 M
1 M
0
2001 2026 2051 2076 2101
Time (Year)
v3-28 Obesity Incidence + Overweight Incidence Coefficient Adjustment
Cumulative death of diabetic
200,000
150,000
100,000
50,000
0
2001 2026 2051 2076 2101
Time (Year)
v3-28 Obesity Incidence + Overweight Incidence Coefficient Adjustment
total prevalence of diagnosed diabetes
0.2
0.15
0.1
0.05
0
2001 2026 2051 2076 2101
Time (Year)
v3-28 Obesity Incidence + Overweight Incidence Coefficient Adjustment
Total incidence
0.006
0.005
0.004
0.003
0.002
2001 2026 2051 2076 2101
Time (Year)
141 
 
The first variable combination I tested is the combination of the overweight 
incidence rate and the obesity incidence rate.  The changes in this variable combination 
can be achieved by weight management programs.  Figure 7-16 illustrates the sensitivity 
levels of outcome variables response to the changes in the overweight incidence rate and 
the obesity incidence rate combination.  The changes in this variable combination have 
moderate levels of impacts on the diabetes incidence and the number of diabetic as shown 
in figures from 7-16a to 7-16d.  The changes also have relatively low level impacts on 
the cumulative death of diabetic.  However, the changes have high level impacts on the 
non-cumulative result variables in long run, especially on the total incidence. 
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Figure 7-17. Sensitivity Results for Prediabetes Diagnosis Rate and Diabetes 
Diagnosis Rate 
 
Figure 7-17 shows the sensitivity analysis results for the prediabetes diagnosis 
rate and the diabetes diagnosis rate combination.  The changes in this combination 
directly targeted on the prediabetes incidence and diabetes incidence.  Graphs 7-17a and 
7-17b show that the changes have heavy impacts on the cumulative incidence of diabetes 
and the cumulative diagnosed incidence of diabetes.  The impacts on the diabetes 
incidence are also reflected from the changes in the total incidence as shown in Figure 
7-17g.  The total incidence shows a large variance at the beginning of the simulation.  
Changes in the diabetes diagnosis rate have a direct impact on the total incidence.  A 
high diabetes diagnosis rate could lead to a lot of undiagnosed diabetic patients becoming 
diagnosed initially.  The size of undiagnosed diabetic population become much smaller 
than before after the initial diagnosis and will result in a fewer number of patients are 
diagnosed.  The oscillation finally reaches an equilibrium state in the long run as the 
variance converges in Figure 7-17g. 
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Figure 7-18. Sensitivity Results for Average Years to Develop Diabetes from 
Undiagnosed Prediabetes and Average Years to Develop Diabetes from Diagnosed 
Prediabetes 
 
The combination of simultaneous changes to the average years to develop 
diabetes from undiagnosed prediabetes and the average years to develop diabetes from 
diagnosed prediabetes has a direct impact on the diabetes incidence and the diabetes 
prevalence.  The average years to develop diabetes from undiagnosed prediabetes 
controls the number of undiagnosed prediabetic becoming diabetic in the model.  It has 
the direct impact on the count of diabetic and diabetes cases occurring per year.  It also 
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has secondary effects on the average years to develop diabetes from diagnosed 
prediabetes since the base value of the average years to develop diabetes from diagnosed 
prediabetes is calibrated from the average years to develop diabetes from undiagnosed 
prediabetes.   
Additional to the changes in the average years to develop diabetes from 
undiagnosed prediabetes, we change the value of the average years to develop diabetes 
from diagnosed prediabetes independently even though the base value is dependent on 
the value of the average years to develop diabetes from undiagnosed prediabetes.  The 
average years to develop diabetes from diagnosed prediabetes controls the number of 
diagnosed prediabetic becomes diabetic in the model.  It has the direct impact on the 
count of diabetic and diabetes incidence as well.   
This combination has significant impacts on every result variable as shown in 
Figure 7-18.  The level of impact from the variable combination is higher than 
individual variable when varied in isolation (as seen in Figure 7-6 and 7-7), but very 
close to the sum of impacts from individual variables.   
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Figure 7-19. Sensitivity Results for Develop Prediabetes from Obese Incidence Rate 
and Prediabetes Diagnosis Rate 
   
Figure 7-19 illustrates sensitivity results for changes in the combination of the 
develop prediabetes from obese incidence rate and the prediabetes diagnosis rate.  This 
variable combination has a focus on the prediabetic population, which is the headwater of 
the diabetic population.  Changes in the develop prediabetes from obese incidence rate 
affect the undiagnosed prediabetic population and the changes in the prediabetes 
diagnosis rate directly impact the diagnosed prediabetic population.  Although the 
changes do not directly impact the diabetic population, they still have heavy secondary 
impacts on the outcome variables as shown in Figure 7-19.    
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Figure 7-20. Sensitivity Results for Average Years to Develop Early Stage 
Complication from Diagnosed Diabetes and Mortality Rate of Diagnosed Diabetes 
without Complication 
 
v3-28 Avg Years to Develop Early Comp from Dx Diab + Mortality Dx Diab withou Comp Co  
Cumulative incidece of diabetes
200,000
150,000
100,000
50,000
0
2001 2026 2051 2076 2101
Time (Year)
v3-28 Avg Years to Develop Early Comp from Dx Diab + Mortality Dx Diab withou Comp Co  
Cumulative diagnosed incidence of diabetes
100,000
75,000
50,000
25,000
0
2001 2026 2051 2076 2101
Time (Year)
v3-28 Avg Years to Develop Early Comp from Dx Diab + Mortality Dx Diab withou Comp Co  
Cumulative number of diabetic
4 M
3 M
2 M
1 M
0
2001 2026 2051 2076 2101
Time (Year)
v3-28 Avg Years to Develop Early Comp from Dx Diab + Mortality Dx Diab withou Comp Co  
Cumulative number of diagnosed diabetic
4 M
3 M
2 M
1 M
0
2001 2026 2051 2076 2101
Time (Year)
v3-28 Avg Years to Develop Early Comp from Dx Diab + Mortality Dx Diab withou Comp Co  
Cumulative death of diabetic
200,000
150,000
100,000
50,000
0
2001 2026 2051 2076 2101
Time (Year)
v3-28 Avg Years to Develop Early Comp from Dx Diab + Mortality Dx Diab withou Comp Co  
total prevalence of diagnosed diabetes
0.2
0.15
0.1
0.05
0
2001 2026 2051 2076 2101
Time (Year)
v3-28 Avg Years to Develop Early Comp from Dx Diab + Mortality Dx Diab withou Comp Co  
Total incidence
0.006
0.005
0.004
0.003
0.002
2001 2026 2051 2076 2101
Time (Year)
147 
 
The combination of changes to the average years to develop early stage 
complication from diagnosed diabetes and the mortality rate of diagnosed diabetes 
without complication has its focus on the diabetic population.  It does not exert a direct 
impact on the diabetes incidence; hence, the sensitivity levels for the outcome variables 
that relate to diabetes incidence are not high, as shown in Figure 7-20a, 7-20b and 7-20g.  
The changes in this variable combination have direct impacts on the diagnosed diabetic 
without complication population and the diagnosed diabetic with early stage 
macrovascular complication population, but the levels of impacts are not obvious due the 
small population base.  The changes also have a direct impact on the death of diabetics, 
but the impact level is limited as shown in Figure 7-20e.   
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Figure 7-21. Sensitivity Results for Mortality Rate of Diagnosed Diabetes with Early 
Stage Complication and Mortality Rate of Diagnosed Diabetes with Late Stage 
Complication 
 
The combination of changes to the mortality rate of diagnosed diabetes with early 
stage complication and the mortality rate of diagnosed diabetes with late stage 
complication directly targets the mortality rates of diabetic patients.  The changes in this 
variable combination have no direct impacts on diabetes incidence and diabetes 
prevalence.  Figure 7-21a and 7-21b show the cumulative diabetes incidence and the 
cumulative diagnosed diabetes incidence exhibit little response to simultaneous changes 
in the variable combination.   
Changes in mortality rates have direct impacts on the diabetic population and the 
death of diabetics, but the impacts are weakened on the cumulative number of diabetic, 
cumulative number of diagnosed diabetic and cumulative death of diabetes due to the 
small population base in the diagnosed diabetic with early stage macrovascular 
complication and the diagnosed diabetic with late stage macrovascular complication 
population groups.  These result variables only exhibit very small levels of variance as 
shown in Figure 7-21c, 7-21d and 7-21e.  
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Figure 7-22. Sensitivity Results for Prediabetes Diagnosis Rate, Prediabetes 
Recovery Rate and the Average Years to Develop Diabetes from Diagnosed 
Prediabetes 
 
Figure 7-22 illustrates sensitivity results for simultaneous changes to the 
combination of the prediabetes diagnosis rate, the prediabetes recovery rate and the 
average years to develop diabetes from diagnosed prediabetes.  This variable 
combination has its focus on the diagnosed prediabetic population.  The changes in the 
prediabetes diagnosis rate and the prediabetes recovery rate directly impact the 
diagnosed prediabetes population and further affect the incidence of diabetes and the 
prevalence of diabetes.  Average years to develop diabetes from diagnosed prediabetes 
controls the incidence of diabetes from the diagnosed prediabetic population.  The 
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changes in the average years to develop diabetes from diagnosed prediabetes have 
impacts on the incidence of diabetes and the prevalence of diabetes.  Therefore, the 
changes in these three test parameters significantly affect all cumulative and 
non-cumulative result variables.  The cumulative incidence of diabetes, cumulative 
incidence of diagnosed diabetes and total incidence are especially sensitive to the 
changes in the variable combination since all three test parameters have impacts on the 
incidence of diabetes. 
In the multi-variable sensitivity analysis, we tested several variable combinations, 
which have the potential to be modified by common intervention policies.  From the 
results, we can see that some variable combinations have greater impacts on the diabetes 
burden than others.  For instance, the combination of the average years to develop 
diabetes from diagnosed prediabetes and the average years to develop diabetes from 
undiagnosed prediabetes has heavy impacts on the diabetes population, but the 
combination of the mortality rate of diagnosed diabetes with early stage complication 
and the mortality rate of diagnosed diabetes with late stage complication has very light 
impacts on the diabetes population.  In the next section, I am going to discuss possible 
interventions based on the sensitivity analysis.  
7.2 Potential Interventions 
The results from the sensitivity analysis show that the simulated diabetes burden - 
such as the diabetes incidence and the diabetes prevalence - can be changed greatly if we 
alter certain parameters in the model.  This raises the potential of lowering the diabetes 
prevalence, diabetes incidence rate and other diabetes burden in the SHR if we can 
change some conditions in the current system.  Based on what we observed in the 
sensitivity analysis, several potential types interventions merit comment. 
7.2.1 Interventions for Normoglycemic Population 
As discussed in the previous section, the parameter combination of overweight 
incidence rate and obese incidence rate has a significant impact on the diabetic 
population.  Intervention policies based on lowering the overweight incidence rate and 
the obesity incidence rate - such as fitness classes, support for recreational facilities, and 
programs to make nutritious food more affordable and accessible when compared with 
less nutritious food, can help to lower the diabetes prevalence and diabetes incidence rate 
in the long run, as shown in the Figure 7-23.  The projections of diabetes prevalence and 
incidence rate given by lowering overweight incidence rate and obesity incidence rate by 
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fivefold, which are plotted by blue lines are lower than their the baseline projections.  
These intervention policies can lower the overweight incidence rate and the obesity 
incidence rate, and will slow down the rate at which the diabetic population and diabetes 
prevalence are rising, as well as the diabetes related burdens.   
This kind of interventions will not lower the diabetic population from its original 
path immediately since they are not intervening directly on the diabetic population 
directly.  The changes in the overweight and obese population will affect the diabetic 
population with levels of delays and manifest their impacts in the long run. 
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Figure 7-23. Changes in Diabetes Burdens from Lowering Overweight Incidence 
Rate and Obese Incidence Rate Fivefold 
 
7.2.2 Interventions Involving the Hyperglycemic Population 
In the sensitivity analysis, we tested several variable combinations that focus on 
the hyperglycemic population.  These variable combinations have impacts on the 
prediabetic population and all stages of the diabetic population.  The parameter 
combination of average years to develop diabetes from undiagnosed prediabetes and 
average years to develop diabetes from diagnosed prediabetes is one of these 
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combinations.  Intervention policies such as nutrition and diet education for prediabetic 
population, physical activity programs for high risk groups and frequent screening 
program for high risk population groups could be employed for the purpose of delaying 
progression time from prediabetes to diabetes.  The sensitivity analysis results in Figure 
7-18 suggest that the diabetes population is very sensitive to the changes in this parameter 
combination.  If we implement an intervention policy to delay diabetes onset in the 
prediabetic population, it could greatly lower diabetes incidence and the diabetes 
prevalence greatly.  Figure 7-24 illustrates the improvement in the diabetes prevalence 
and the number of new incident cases by doubling the average years to develop diabetes 
from undiagnosed prediabetes and the average years to develop diabetes from diagnosed 
prediabetes.  The diabetes prevalence and incident of new cases (illustrated by blue 
lines) are much lower than the baseline.     
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Figure 7-24. Changes in Diabetes Burdens from Doubling Average Years to Develop 
Diabetes from Diagnosed Prediabetes and Undiagnosed Prediabetes 
 
The sensitivity results for changing the parameter combination of developing 
prediabetes from obese population incidence rate and prediabetes diagnosed rate show 
that monitoring for high risk population groups can be an effective intervention policy.  
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Decreasing the developing prediabetes from obese population incidence rate could lower 
the prediabetes population and further reduce the diabetic population.  Increasing the 
prediabetes diagnosis rate could temporarily increase the diagnosed prediabetic 
population – reflecting the short-term increase individuals being diagnosed – but it will 
lower the diabetic population in the long run since the diagnosed prediabetic population 
has a lower risk of developing diabetes than the undiagnosed prediabetic population.  
The combination of decreasing the developing prediabetes from obese population 
incidence rate and increasing the prediabetes diagnosis rate can help to greatly lower the 
incidence of diabetes and the prevalence of diabetes.  Intervention policies such as blood 
glucose level monitoring programs and weight control programs (including different 
balances of physical activity and nutrition) for obese population could aid in lowering the 
developing prediabetes from obese population incidence rate and raising the prediabetes 
diagnosed rate.    
Figure 7-25 illustrates the changes in several important diabetes burden indicators 
that result from lowering the developing prediabetes from obese population incidence 
rate by a factor of five and raising the prediabetes diagnosed rate by a factor of five.  
The projection of the cumulative diagnosed incidence of diabetes, the cumulative number 
of diabetic and the total prevalence of diagnosed diabetes resulting from the intervention 
– which are plotted by the blue lines – are lower than their original baseline path (plotted 
by the red lines).  The total incidence projection associated with the intervention is 
slightly higher than the original path for a short time period at the beginning of the 
simulation, as shown in Figure 7-25d.  The increase in the total incidence results from 
the rising in prediabetes diagnosed rate.  After a brief period, the total incidence rapidly 
decreases, both in absolute terms, and when compared to the baseline.      
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(c)  (d) 
Figure 7-25. Changes in Diabetes Burdens from Lowering Developing Prediabetes 
from Obese Population Incidence Rate Fivefold and Rising Prediabetes Diagnosis 
Rate Fivefold 
     
7.2.3 Discussion 
Sensitivity analysis provides intuitive evidence that changes in model parameters 
can trigger changes in model results.  The diabetes burdens – such as the prevalence of 
diabetes and the incidence of diabetes – are sensitive to changes in some conditions.  By 
implementing intervention policies that alter these conditions, we can greatly lower the 
burden of diabetes.   
Moreover, the sensitivity analysis results suggest that the overall diabetes burden 
examined here are not sensitive to the changes in some other conditions.  For example, 
the changes in the mortality of diagnosed diabetes with early stage complication and the 
mortality of diagnosed diabetes with late stage complication do not have large impacts on 
the important indicators of diabetes burden discussed here.  However, that these 
conditions do not have large impacts on the overall diabetes burdens does not mean they 
are insignificant.  Specifically targeted intervention policies, which implement changes 
in these insensitive conditions, still greatly help lowering the diabetes burden in special 
areas.  For instance, if the health care system can provide a better treatment for diabetic 
with complications, it would lower the mortality of diagnosed diabetes with early stage 
complication and the mortality of diagnosed diabetes with late stage complication.  This 
intervention can save many diabetic patients’ lives even though it has no help on lowering 
the diabetes prevalence and the diabetes incidence. 
Intervention experiments show the possibility of reductions in the burden of 
diabetes.  Changes in certain conditions from the status quo could yield great 
improvements on the burden of diabetes.  However, our model does not capture inputs 
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requirement necessary for implementation of the interventions.  Some intervention 
policies can have significant improvements on the diabetes burdens, but they may require 
huge amount of capital, human resources and careful coordination to achieve.  Some 
intervention policies may only have certain levels of improvements, but they are 
relatively inexpensive to implement.  Moreover, my thesis does not compare the tradeoff 
within and between intervention policies, for example in the form of transfer effects.  
An intervention policy could save more lives in one population group but raise the risk of 
death for another population group, or saves life but lower quality of life at the same time.  
These features lie outside the scope of my research, but they can be added into the model 
in the future. 
7.3 Summary       
Sensitivity analysis shows the behavior of the simulated system when changing 
certain conditions in the system.  In this analysis process, I changed the value of single 
or multiple test parameters to 80%, 85%, 90%, 95%, 105%, 110%, 115% and 120% from 
their original values, and observed the changes in selected outcome variables.   
The test parameters are variables selected to initialize the change in this process.  
The selection of the test parameters covers three broad areas: hyperglycemia diagnosis 
rates, progress rates and mortality rates for different population groups.  The 
hyperglycemia diagnosis rates test parameters include the prediabetes diagnosis rate and 
the diabetes diagnosis rate.  The test parameters that belong to the hyperglycemia 
progress rates are the overweight incidence rate, the obesity incidence rate, the 
developing prediabetes from obese population incidence rate, the prediabetes recovery 
rate, the average years to develop diabetes from undiagnosed prediabetes, the average 
years to develop diabetes from diagnosed prediabetes, the average years to develop early 
stage complication from undiagnosed diabetes and the average years to develop early 
stage complication from diagnosed diabetes.  The mortality rates test variables are the 
mortality rate of diagnosed prediabetes, the mortality rate of diagnosed diabetes without 
complication, the mortality rate of diagnosed diabetes with early stage complication and 
the mortality rate of diagnosed diabetes with late stage complication. 
The outcome variables are defined in the system in order to observe and compare 
levels of changes from the sensitivity test. The outcome variables are important indicators 
for diabetes burdens as well.  There are seven outcome variables I defined in the system; 
they are the cumulative incidence of diabetes, the cumulative diagnosed incidence of 
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diabetes, the cumulative number of diabetic, the cumulative number of diagnosed 
diabetic, the cumulative death of diabetic, the total prevalence of diagnosed diabetes and 
the total incidence of diabetes.      
I performed single parameter sensitivity testing as the first step.  In this step, I 
altered one test parameter while holding other test parameters constant.  Any change in 
the system is influenced by the altered test parameter.  The sensitivity analysis shows 
that most outcome variables are not very sensitive to the changes in the hyperglycemia 
diagnosis rates.  The cumulative number of diabetic is relatively less sensitive to the 
changes in the hyperglycemia diagnosis rates since diagnosis does not change the status 
of having diabetes.  The cumulative death of diabetic is also less sensitive to changes in 
the hyperglycemia diagnosis rates.   
The outcome variables are quite sensitive to changes in the upstream 
hyperglycemia progress rates.  The changes in the overweight incidence rate, the obesity 
incidence rate, the developing prediabetes from obese population incidence rate, the 
average years to develop diabetes from undiagnosed prediabetes and the average years 
to develop diabetes from diagnosed prediabetes lead to relatively high impacts on the 
diabetes incidence and the number of diabetic population.  The impacts on the diabetic 
population lead to further changes in the diabetes prevalence and the number of deaths 
per year of diabetics.  The prediabetes recovery rate is an exception in the upstream 
hyperglycemia progress rates.  The outcome variables are relatively insensitive to the 
changes in the prediabetes recovery rate due to the small original value involved.     
Compared to the upstream progress rates, the downstream hyperglycemia 
progress rates have lower levels of impacts on the selected outcome variables.  The 
changes in the average years to develop early stage complication from undiagnosed 
diabetes lead to mild levels of changes in the underlying diabetes incidence since the 
development of complications is a path of diagnosis according our definition.  The 
levels of impacts are even lower on other result variables.  The chosen outcome 
variables are insensitive to the changes in the average years to develop early stage 
complication from diagnosed diabetes as well. 
The selected outcome variables are also very insensitive to the changes in 
mortality rates.  The changes in the mortality rate of diagnosed prediabetes, the 
mortality rate of diagnosed diabetic without complication, the mortality rate of diagnosed 
diabetic with early stage complication and the mortality rate of diagnosed diabetic with 
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late stage complication have very low levels of impacts due to the small original values 
and the small population bases, but also to the fact that the mortality rates do not have 
direct impact on the selected outcome variables. 
After the single variable sensitivity analysis, I performed multi-variable 
sensitivity analysis.  In this step, I grouped two or more test parameters based on their 
focus areas and altered values of test variables together within the group.  All parameter 
combinations and their focus areas are listed in Table 7-1.  Generally, the sensitivity 
levels for parameter combinations are higher than the sensitivity levels for each 
individual test parameter in the combination, but lower than the sum of the sensitivity 
levels for individual test parameter.     
Following sensitivity analysis, I proposed several intervention experiments that 
try to lower the diabetes burdens in the model based on observations from the sensitivity 
analysis.  If the outcome variables, which are the important indicators of diabetes 
burdens, are sensitive to the changes, then the likelihood of lowering diabetes burdens is 
higher when other conditions hold.  Hence, the intervention experiments I conducted are 
as follows: 1) lowering the overweight incidence rate and the obesity incidence rate, 2) 
increasing the average years to develop diabetes from diagnosed prediabetes and 
undiagnosed prediabetes (retard the onset of diabetes for diagnosed and undiagnosed 
prediabetics), and 3) lowering the development of prediabetes from the obese population 
incidence rate and elevating the prediabetes diagnosis rate.  The results suggest that the 
major diabetes burdens can be lowered by the intervention policies.                  
The calibration process and the model results show that the model simulates the 
diabetes burdens in the SHR with acceptable fidelity.  The model is able to reproduce 
the historical trace of diabetes burdens in the SHR and project the reasonable trend of the 
diabetes burdens based on available information.  The sensitivity analysis and the 
intervention experiments suggest significant opportunities for lowering the diabetes 
prevalence and the diabetes incidence rate in the SHR.  In conclusion, we believe that 
the model can be a very useful tool to help the decision makers examine and improve 
potential interventions.  In the next and the final chapter, we are going to review our 
study and conclusion.         
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CHAPTER 8 
CONCLUSION 
There is no doubt about burdens imposed by Type 2 diabetes in the SHR.  With increase 
in the prevalence of obese population, the prevalence of Type 2 diabetes also rapidly increased in 
the SHR.  In this thesis, we sought to build a System Dynamics simulation model that represents 
the Type 2 diabetes situation in the SHR.  The simulation model provides a good tool for gaining 
understanding on the reasons underlying high diabetes prevalence.  The model is also a useful 
tool to assist users to test potential interventions. 
In this chapter, I am going to review and summarize the process for constructing the 
simulation model, the calibration process after the model is created and the observations from the 
simulation results.  I will highlight some unique features of my study.  I also will briefly outline 
future research directions. 
8.1 Thesis Summary             
8.1.1 Model Construction 
For this thesis, I constructed a simulation model for the diabetes in the SHR using a 
System Dynamics approach.  The model uses population stocks and flows to simulate the 
dynamics in the Diabetes situation in the SHR.   
The model contains two core sections: the normoglycemic population section and the 
hyperglycemic population section.  I adapted the structure of the normoglycemic population from 
the New Zealand model [51], correcting for some important misformulations in that model and 
adding additional details.  As its name suggests, the normoglycemic population section 
represents the population that does not have hyperglycemia but has the risk of developing 
hyperglycemia.  The normoglycemic population section in my model is divided into three main 
subgroups: the normal weight population, the overweight population and the obese population.  
Different weight subgroups have different levels of risks of developing hyperglycemia.  
Individuals with heavier weights generally have a higher risk of developing hyperglycemia.   
The population in each main subgroup is further divided into small scale subgroups 
according age, ethnicity and gender in my model.  The population is disaggregated into 5-year 
age categories up to age 79; all of the population older than 80 (of a given ethnicity and gender 
group) forms another age group.  All age subgroups within a given weight group form an aging 
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chain together since every year some population flows to the next age group as they age.  The 
model in [51] does not disaggregate the diabetic population according to age, which in some 
cases causes misleading results.    
The population flows into the hyperglycemic population section once they develop any 
hyperglycemic condition.  The structure of the hyperglycemic population section was adapted 
from the CDC model [49], with addition of many details.  The hyperglycemic population section 
is divided into 4 hyperglycemia progression stages: the prediabetes stage, the diabetes without 
complication stage, the diabetes with early stage macrovascular complication stage and the 
diabetes with late stage macrovascular complication stage.  Population in each progression stage 
is further separated into two components:  the undiagnosed population and the diagnosed 
population, except for individuals with the diabetes with late stage macrovascular complication 
stage.  The hyperglycemic population, starts from the undiagnosed prediabetes group, moves to 
the next stage if the hyperglycemia condition becomes worse, or moves to the corresponding 
diagnosed group once the undiagnosed condition is diagnosed.  Like population groups in the 
normoglycemic population section, population groups in the hyperglycemic population section 
are further divided into small scale subgroups by age, ethnicity and gender. 
8.1.2 Model Calibration 
After the model is constructed, I parameterize the model using local diabetes data.  I was 
able to find data sources and parameterize most parameters in the model.  However, I was unable 
to locate reliable data for some model parameters.  Hence, I used calibration technique to 
estimate or interpolate the values of these unknown parameters from indirect or aggregate data 
sources.  The calibration software alters the unknown parameters within reasonable regions and 
the model outputs different results.  The software compares the model results with aggregate 
historical data.  The values of unknown parameters, which produce the best match result against 
historical data, are considered the best estimated values. 
I also verified the existing model data and examined the model structure through the 
calibration process.  By back tracing the disagreements between the existing model data and the 
historical data, I was able to identify issues in the existing model data, equations and structures, 
and fine tune the model. 
8.1.3 Model Results 
After the model is examined and fine tuned through the calibration process, I used the 
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model to project the diabetes prevalence and incidence over the mid-term future based on current 
conditions.  The simulation results show that the obese populations rapidly increases and reaches 
its peak value around the year 2026.  The prediabetic and diabetic populations also increase with 
the obese population.  The prediabetic population reaches its peak value around the year 2031 
and the diabetic population will reach the peak value around the year 2051.  After the obese, 
prediabetic and diabetic populations reach the peak values, they slowly decrease. 
The simulated prevalence of diabetes in the SHR steady climbs in the first half of 100-
years simulation period for both male and female of the non-RI population.  The acceleration of 
the prevalence slows down in the second half of the simulation period.  The simulation results 
exhibit the steady climb in prevalence for the RI population during the first half of the simulation 
period.  However, diabetes prevalence slowly decreases after the year 2061 for both male and 
female of the RI population.  This decrease I believe is due to decrease in the normoglycemic 
population and the young age structure in the RI population since the simulation results are not 
age standardized.   
The simulation results show that the number of incident new cases of diabetes quickly 
decreases in the first 5-year period. This decrease is caused by inconsistence between initial 
values and estimated transition rate.  After the impact of the initial values fade out, the number of 
incident cases of diabetes occurring per year increase rapidly.  The increase in the total number 
of diabetes incident cases rises continuously until the year 2031, then it starts to drop slowly.  
The number of diabetes incident cases in the RI population has a longer increase time period than 
the total number of incident cases cross all ethnic groups.  The number of annual diabetes 
incident cases of the RI population increases until the years 2041 and decreases afterwards.          
8.1.4 Sensitivity Analysis and Interventions 
I performed sensitivity analysis of selected model parameters to understand the possible 
levels of impacts from these chosen model parameters.  By altering the value of each such 
parameter to 80%, 85%, 90%, 95%, 105%, 110%, 115% and 120% from its baseline value, I 
observed the changes in several outcome variables.  The outcome variables are selected key 
indicators for the burden of diabetes in SHR, such as the cumulative diabetes prevalence, the 
cumulative diabetes incident cases and the cumulative deaths by diabetics.  By observing the 
changes in the outcome variables, we gained some good understandings on the levels of impacts 
of the diabetes prevalence and diabetes incidence from the differences of the model parameters. 
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From the observations, the outcome variables are not very sensitive to the prediabetes and 
diabetes diagnosis rates.  Nevertheless, the outcome variables are quite sensitive to the changes 
in the upstream progress rates, such as the overweight incidence rate, the obesity incidence rate, 
the developing prediabetes from obese population incidence rate, the average years to develop 
diabetes from undiagnosed prediabetes and the average years to develop diabetes from 
diagnosed prediabetes.  The downstream progress rates, such as the average years to develop 
early stage complication from undiagnosed diabetes and the average years to develop early 
stage complication from diagnosed diabetes, lead to lower level of impacts on the outcome 
variables than on the upstream progress rates.        
After having done a single-variable sensitivity analysis, I performed multi-variable 
sensitivity analysis.  I grouped two or more test model parameters, which likely can be altered by 
one intervention policy, and independently altered their values to 80%, 85%, 90%, 95%, 105%, 
110%, 115% and 120% from the baseline values.  From our observation, the sensitivity levels for 
parameter combinations are higher than the sensitivity levels for each individual parameter in the 
combination, but lower than the sum of the sensitivity levels for individual parameters. 
Based on our observations from the sensitivity analysis, I proposed several interventions.  
The projections of diabetes prevalence and incidence resulting from the interventions are lower 
than in the baseline projection.   
8.2 Contributions 
My simulation model is built on a foundation of pioneering research, but it also has many 
unique features that do not appear in other research efforts.  First, my model is characterized with 
the unique demographic structure in the Saskatoon Health Region.  The initial values of the 
population stocks are filled with demographic data specific to that context.  Secondly, the model 
is also distinguished by a finely disaggregated population structure.  The normoglycemic 
population in my model is disaggregated into subpopulation groups according to age, ethnicity, 
gender and weight status.  The CDC model does not contain the same disaggregated population 
structure.  The CDC model uses several risk factors (such as the risk multiplier for elderly and 
risk multiplier for obese) to represent different levels of risk of developing Type 2 diabetes in 
different subpopulation groups.  However, this structure can lead to artifacts in results for some 
subpopulation groups because the simple multiplication of risks implicitly assumes these risk 
factors are independent of each other.  The hyperglycemic population in my model is 
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disaggregated into subpopulation groups according to age, ethnicity and gender.  Although the 
New Zealand model contains some age and ethnicity structure in the normoglycemic population 
section, it does not disaggregate by age, ethnicity or gender in the hyperglycemic population 
section. As I described in chapter 4, my exploration with the model found that the lack of age 
structure in the hyperglycemic population section can cause significant artifacts in results.  The 
population structure in my model can capture the distinct difference in demographic structure 
between the Aboriginal population and the non-Aboriginal population.  This presence of 
disaggregated population structure can also highlight the fact that Type 2 diabetes is prevalent 
among elderly, Aboriginal female and non-Aboriginal male subpopulation groups. 
Thirdly, my model includes a detailed diabetes and – to the best of my knowledge – 
unique progression structure.  Starting from the prediabetes phase, progressing to diabetes 
without complication phase, to diabetes with early stage macrovascular complications phase, and 
ending at diabetes with late stage macrovascular complications phase, the diabetes progression 
structure distinguished different stages of diabetic population in different progression stages.  
After the consultation with an epidemiologist of the College of Medicine, University of 
Saskatchewan, I decided to use macrovascular complications as an important divide in diabetes 
progression since macrovascular complications are the main driving factors in diabetes-related 
deaths.    
Fourth, many parameters values in my model are derived through systematic search and 
analysis of secondary data sources.  In the cases where no local data was available, I estimated 
the parameters’ values from related-data of other regions.  In the cases in which there was no 
available data for the simulation period, I interpolated or “backed out” from the data for other 
time period.  In the cases in which no disaggregated data was available, I disaggregated the data 
by interpolation or applying related ratios.       
Finally, my model is intensively calibrated against other related data sources.  The 
calibration process identified major structural defects in the model and estimated values of 
unknown parameters using constraints imposed by model structure and historic data.  The 
calibration process was repeated several times after changes in model parameters or modification 
in model structure.  I added a weighting structure for the calibration process.  The weighting 
structure dynamically assigns different weight to different components based on their importance 
and with consideration of sampling errors and model errors.  Robustness and integrity of the 
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model are improved to an acceptable level after several iterations of the calibration process.     
8.3 Future Work 
Although the simulation model is based on reasonable assumptions and the simulation 
results suggests the potential interventions with the aim of lowering diabetes prevalence and 
incidence, there is still a large space for improvements.  There are also unsolved issues that merit 
further investigations.  
First, I defined a range for the value of each parameter in my calibration list during the 
calibration process.  The given range is either defined based on related research or on a 
reasonable guess.  In some cases, the calibration process assigned a boundary value as the “best 
fit” value of some calibrated parameters.  This suggests that the calibration process may find an 
even better match with historic data for values beyond the given range.  However, a value 
beyond the given range appears to make the estimated value of the parameter unreasonable.  I 
also tried to assign a value beyond the range to the parameter and observed the calibration payoff.  
The final payoff did not show a significant improvement.  It is possible the software tried to 
match other components in the model and has to accept larger discrepancies for some light 
weighted components.  Trying to find out why calibrated parameter values reach the given 
boundaries requires further investigation.  
Second, my research was focused on the diabetes prevalence and incidence rates.  There 
are many other important indicators for the burden imposed by diabetes beyond prevalence and 
incidence.  For example, diabetic patients’ wellness can be measured using quality of life and 
diabetes related expenditure can be measured using dollar value.  The measurement of quality of 
life is already built in the model but is not used.  Other add-on components can be added into the 
model as well.  Improvement on the other diabetes burden indictors constitutes one possible 
future research direction. 
Third, representation of other diabetes related complications can be considered as an 
important future work.  In my research, I used major macrovascular complications – such as 
AMI or stroke – to represent causes of dying from diabetes.  There are many other complications 
that are not reflected in my model, like nephropathy and neuropathy.  It will be important to 
incorporate these complications to improve the model in the future.  
Finally, population migrations deserve future investigations.  As one limitation of my 
model, we made a simplifying assumption that the net population migration for the SHR is zero.  
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However, this is not the case in reality.  The total population is covered in SHRA experienced 
relatively high levels of out migration and in migration during the last decade.  Without 
population migrations, the population counts – both for the normoglycemic population and the 
hyperglycemic population – in the model do not reflect the actual population size in the SHR.  
Hence, the model can be improved in accuracy if the population migration flows are added.     
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APPENDIX A: STOCK INITIAL VALUES 
Normal Weight General Population 
 
RI Non-RI 
Age 
Groups male female male female 
0 - 4 778.81 664.48 4864 4482 
5 - 9 572.51 567.95 4716 4442 
10 - 14 559.66 556.97 5078 5038 
15 - 19 320 398.36 3901 4392 
20 - 24 340.55 441.88 3845 5414 
25 - 29 176.31 301.98 2480 3754 
30 - 34 144.64 259.9 1697 3026 
35 - 39 94.54 165.43 2652 4227 
40 - 44 56.62 112.49 1898 4418 
45 - 49 15.06 40.54 1593 3522 
50 - 54 16.46 40.26 1060 2262 
55 - 59 11.85 13.46 716.59 1457 
60 - 64 7.669 5.72 639.51 1160 
65 - 69 5.61 4.659 544.31 1038 
70 - 74 3.505 2.531 511.48 748.04 
75 - 79 1.977 1.21 364.77 751.68 
80 plus 0.7944 1.126 590.83 1842 
 
  
176 
 
Overweight General Population 
 
RI Non-RI 
Age 
Groups male female male female 
0 - 4 128.02 151.12 562.94 703.42 
5 - 9 207.43 233.37 1041 1138 
10 - 14 185.23 162.15 1032 956.06 
15 - 19 260.1 211.16 1997 1612 
20 - 24 250.2 169.38 2612 1504 
25 - 29 303.98 178.72 2756 1774 
30 - 34 249.38 153.82 2954 1914 
35 - 39 181.53 112.63 2939 1676 
40 - 44 108.72 76.59 2952 1947 
45 - 49 34.91 26.27 3069 1601 
50 - 54 38.16 36.02 2554 1578 
55 - 59 18.62 1795 1443 1152 
60 - 64 12.05 7.627 746.09 1104 
65 - 69 8.816 6.212 882.16 915.03 
70 - 74 5.508 3.374 608.24 955.83 
75 - 79 3.108 1.613 496.49 966.23 
80 plus 1.248 1.501 484.48 889.28 
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Obese General Population 
 
RI Non-RI 
Age 
Groups male female male female 
0 - 4 160.03 143.93 346.42 331.02 
5 - 9 257.21 231.31 668.32 538.47 
10 - 14 240.41 162.15 678.95 465.11 
15 - 19 208.08 139.27 758.97 550.75 
20 - 24 104.25 125.2 798.15 601.65 
25 - 29 127.67 135.58 1653 1296 
30 - 34 104.74 116.69 1634 1235 
35 - 39 102.11 73.91 1577 1384 
40 - 44 61.15 50.26 2179 1123 
45 - 49 18.48 29.87 1239 1280 
50 - 54 20.2 29.66 1205 1420 
55 - 59 11.85 13.46 836.02 779.62 
60 - 64 7.669 5.72 746.09 497.23 
65 - 69 5.61 4.659 450.46 159.34 
70 - 74 3.505 2.531 262.65 374.02 
75 - 79 1.977 1.21 151.98 297.17 
80 plus 0.7944 1.126 106.34 444.64 
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Undx Prediabetic Population 
 
RI Non-RI 
Age 
Groups male female male female 
0 - 4 3.73 3.054 55.02 30.96 
5 - 9 14.92 15.27 89.41 56.3 
10 - 14 14.92 24.43 127.24 112.61 
15 - 19 33.57 45.81 151.31 143.58 
20 - 24 67.15 73.3 199.45 202.7 
25 - 29 74.61 97.74 330.14 273.09 
30 - 34 97 119.12 464.25 385.7 
35 - 39 104.46 131.34 694.66 472.98 
40 - 44 97 125.23 863.17 557.44 
45 - 49 89.54 100.79 887.24 529.29 
50 - 54 25.86 30.95 431.01 288.29 
55 - 59 15.91 21.17 422.01 789.79 
60 - 64 7.959 14.66 405.33 297.3 
65 - 69 3.979 6.516 304.46 279.28 
70 - 74 1.989 4.887 335.64 427.93 
75 - 79 1.989 4.887 335.64 427.93 
80 plus 1.989 4.887 335.64 427.93 
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Dx Prediabetic Population 
 
RI Non-RI 
Age 
Groups male female male female 
0 - 4 0.4 0.4 6.4 4.4 
5 - 9 1.6 2 10.4 8 
10 - 14 1.6 3.2 14.8 16 
15 - 19 3.6 6 17.6 20.4 
20 - 24 7.2 9.6 23.2 28.8 
25 - 29 8 12.8 38.4 38.8 
30 - 34 10.4 15.6 54 54.8 
35 - 39 11.2 17.2 80.8 67.2 
40 - 44 10.4 16.4 100.4 79.2 
45 - 49 9.6 13.2 103.2 75.2 
50 - 54 5.2 7.6 94 76.8 
55 - 59 3.2 5.2 96.4 77.2 
60 - 64 1.6 3.6 88.4 79.2 
65 - 69 0.8 1.6 66.4 74.4 
70 - 74 0.4 1.2 73.2 114 
75 - 79 0.4 1.2 73.2 114 
80 plus 0.4 1.2 73.2 114 
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Undx Diabetic without Complication Population 
 
RI Non-RI 
Age 
Groups male female male female 
0 - 4 0 0 3.803 3.54 
5 - 9 2.314 1.077 19.01 10.62 
10 - 14 1.157 1.077 30.43 19.47 
15 - 19 4.628 5.385 49.45 35.4 
20 - 24 4.628 8.616 70.37 70.81 
25 - 29 10.41 16.15 83.68 90.28 
30 - 34 20.82 25.82 110.31 127.46 
35 - 39 23.14 34.46 182.58 171.72 
40 - 44 30.08 42 256.76 242.54 
45 - 49 32.4 46.31 384.19 297.42 
50 - 54 20.09 29.49 318.88 234.15 
55 - 59 18.55 23.74 327.78 222.32 
60 - 64 10.04 13.67 298.59 227.05 
65 - 69 6.183 9.353 306.18 228.24 
70 - 74 3.091 6.475 280.77 234.15 
75 - 79 1.545 2.878 210.89 219.96 
80 plus 0.7729 2.158 232.49 337.03 
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Dx Diabetic without Complication Population 
 
RI Non-RI 
Age 
Groups male female male female 
0 - 4 0 0 2 2 
5 - 9 2 1 10 6 
10 - 14 1 1 16 11 
15 - 19 4 5 26 20 
20 - 24 4 8 37 40 
25 - 29 9 15 44 51 
30 - 34 18 24 58 72 
35 - 39 20 32 96 97 
40 - 44 26 39 135 137 
45 - 49 28 43 202 168 
50 - 54 26 41 251 198 
55 - 59 24 33 258 188 
60 - 64 13 19 235 192 
65 - 69 8 13 241 193 
70 - 74 4 9 221 198 
75 - 79 2 4 166 186 
80 plus 1 3 183 285 
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Undx Diabetic with Early Stage Complication Population 
 
RI Non-RI 
Age 
Groups male female male female 
0 - 4 0 0 0 0 
5 - 9 0 0 0 0 
10 - 14 0 0 0 0 
15 - 19 0 0 0 0 
20 - 24 0 0 0 0 
25 - 29 0 0 0 0 
30 - 34 0 0 0 0 
35 - 39 0 0 0 0 
40 - 44 0 0 0 0 
45 - 49 0 0 0 0 
50 - 54 0 0 0 0 
55 - 59 0 0 0 0 
60 - 64 0 0 0 0 
65 - 69 0 0 0 0 
70 - 74 0 0 0 0 
75 - 79 0 0 0 0 
80 plus 0 0 0 0 
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Dx Diabetic with Early Stage Complication Population 
 
RI Non-RI 
Age 
Groups male female male female 
0 - 4 0 0 0 0 
5 - 9 0 0 2.991 1.994 
10 - 14 0 0 4.985 3.988 
15 - 19 1 1 6.979 5.982 
20 - 24 1 2 8.973 9.97 
25 - 29 2 4 11.96 13.95 
30 - 34 5 7 16.94 20.93 
35 - 39 7 11 31.9 31.9 
40 - 44 10 15 49.85 50.84 
45 - 49 8 19 60.81 72.78 
50 - 54 11 21 104.98 99.98 
55 - 59 1 21 8 188.98 
60 - 64 7 7 127.98 67 
65 - 69 4 7 117.98 105.98 
70 - 74 3 7 151.98 149.98 
75 - 79 1 5 102.98 215.97 
80 plus 1 4 197.98 207.96 
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Dx Diabetic with Late Stage Complication Population 
 
RI Non-RI 
Age 
Groups male female male female 
0 - 4 0 0 0 0 
5 - 9 0 0 0 0 
10 - 14 0 0 0 0 
15 - 19 0 0 0 0 
20 - 24 0 0 0 0 
25 - 29 0 0 0 0 
30 - 34 0 0 0 0 
35 - 39 0 0 0 0 
40 - 44 0 0 0 0 
45 - 49 4 0 28 0 
50 - 54 2 0 21 0 
55 - 59 14 0 155 0 
60 - 64 3 8 57 83 
65 - 69 4 5 115 81 
70 - 74 2 4 110 85 
75 - 79 2 1 142 58 
80 plus 1 3 142 221 
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APPENDIX B: MODEL PARAMETER VALUES 
Avg years to develop diabetes from undx prediabetes=10 
Avg years to develop early stage complications from undx diabetes=10 
Avg. HRQoL for dx diabetic with early stage 
complication[AgeGroups,EthnicGroups,GenderGroups]=1 
Avg. HRQoL for dx diabetic with end stage 
complication[AgeGroups,EthnicGroups,GenderGroups]=1 
Avg. HRQoL for dx diabetic without complication[AgeGroups,EthnicGroups,GenderGroups]=1 
Avg. HRQoL for dx prediabetic[AgeGroups,EthnicGroups,GenderGroups]=1 
Avg. HRQoL for normal weight general population[AgeGroups,EthnicGroups,GenderGroups]=1 
Avg. HRQoL for obese general population[AgeGroups,EthnicGroups,GenderGroups]=1 
Avg. HRQoL for overweight general population[AgeGroups,EthnicGroups,GenderGroups]=1 
Avg. HRQoL for undx diabetic with early stage 
complication[AgeGroups,EthnicGroups,GenderGroups]=1 
Avg. HRQoL for undx diabetic without 
complication[AgeGroups,EthnicGroups,GenderGroups]=1 
Avg. HRQoL for undx prediabetic[AgeGroups,EthnicGroups,GenderGroups]=1 
Base time between screenings for high risk asympromatic population=2 
Birth rate switch=1 
Controlled birth rate[EthnicGroups,Female]=0 
Controlled birth rate[EthnicGroups,Male]=0  
Diabetic mortality from SHR report[AgeGroups,Aboriginal,Female]=0,-
0.0455556,0.0666667,0.00808081,0.0364331,0.0467909,0.011738,0.0139332,-
186 
 
0.000276298,0.0099266,0.0109431,0.0134912,0.0238086,0.0383159,0.0584447,0.0904008,0.17
81  
Diabetic mortality from SHR report[AgeGroups,Aboriginal,Male]=0,-0.0382022,0.0932735,-
0.0324324,0.0681818,0.051134,0.0135955,0.0166545,0.00648148,0.00535753,0.0159701,0.013
2609,0.0393896,0.0555597,0.0727832,0.102645,0.3572  
Diabetic mortality from SHR 
report[AgeGroups,Other,Female]=0,0.0332657,0.0364978,0.0260896,0.0228911,0.0348223,0.03
07011,0.0311824,0.0185299,0.0175289,0.0234839,0.0147463,0.0302566,0.0265915,0.0319387,
0.0396357,0.1781 
Diabetic mortality from SHR 
report[AgeGroups,Other,Male]=0,0.0240927,0.0265,0.00961232,0.0197951,0.0434004,0.04617
18,0.0358142,0.0355981,0.0271993,0.0229399,0.0181048,0.0324111,0.035572,0.0421769,0.063
0917,0.3572  
Diabetic mortality switcher=1 
Dx diabetes progress coefficient=1.5 
Dx diabetic complication progress coefficient=1.5 
Dx prediabetic mortality switch=1 
early stage complication diagnosis elderly coefficient=0.5 
early stage complication diagnosis ethnic coefficient[Aboriginal]=0.9  
early stage complication diagnosis ethnic coefficient[Other]=0.9 
early stage complication diagnosis gender coefficient[Female]=0.9 
early stage complication diagnosis gender coefficient[Male]=0.9  
early stage complication diagnosis youth coefficient=0 
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First-ever AMI 
mortality[AgeGroups,Female]=0,0,0,0,0.03,0.03,0.03,0.03,0.03,0.03,0.059,0.059,0.059,0.126,0.1
26,0.238,0.238 
First-ever AMI 
mortality[AgeGroups,Male]=0,0,0,0,0.014,0.014,0.014,0.014,0.014,0.014,0.038,0.038,0.038,0.0
94,0.094,0.22,0.22  
First-ever AMI onset rate for diabetic 
population[AgeGroups,Female]=0,0,0,0,0.0065,0.0065,0.0065,0.0343,0.0343,0.0343,0.0943,0.0
943,0.0943,0.1379,0.1379,0.1986,0.1986 
First-ever AMI onset rate for diabetic 
population[AgeGroups,Male]=0,0,0,0,0.0065,0.0065,0.0065,0.0343,0.0343,0.0343,0.0943,0.094
3,0.0943,0.1379,0.1379,0.1986,0.1986  
First-ever stroke 
mortality[AgeGroups,Female]=0,0,0,0,0,0,0,0.12,0.12,0.14,0.11,0.18,0.14,0.16,0.17,0.18,0.2 
First-ever stroke 
mortality[AgeGroups,Male]=0,0,0,0,0,0,0,0.11,0.13,0.12,0.09,0.11,0.1,0.12,0.16,0.19,0.17  
First-ever stroke onset rate for diabetic 
population[AgeGroups,Female]=0,0,0,0,0.045,0.045,0.045,0.073,0.073,0.073,0.173,0.173,0.173,
0.345,0.345,0.612,0.612 
First-ever stroke onset rate for diabetic 
population[AgeGroups,Male]=0,0,0,0,0.045,0.045,0.045,0.073,0.073,0.073,0.173,0.173,0.173,0.
345,0.345,0.612,0.612  
Fraction developing diabetes without diagnosis=0.1 
Fraction of asymptomatic high risk screenings uing OGTT=0.42 
Fraction of diabetes detectable by FPGT=0.94 
Fraction of diabetes detectable by OGTT=1 
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Fraction of early stage complication diabetes using OGTT=0.52 
Fraction of normal weigth infants[EthnicGroups,GenderGroups]=1 
Fraction of obese infants[EthnicGroups,GenderGroups]=0 
Fraction of overweight infants[EthnicGroups,GenderGroups]=0 
Fraction of prediabetes detectable by FPGT=0.84 
Fraction of prediabetes detectable by OGTT=1 
Glucose screening of high risks baseline=0.89 
Health access fraction baseline=0.85 
Incidence of obesity base rate[AgeGroup0to4,EthnicGroups,GenderGroups]=0  
Incidence of obesity base rate[AgeGroup10to14,EthnicGroups,GenderGroups]=0.1  
Incidence of obesity base rate[AgeGroup15to19,EthnicGroups,GenderGroups]=0.1  
Incidence of obesity base rate[AgeGroup20to24,EthnicGroups,GenderGroups]=0.1  
Incidence of obesity base rate[AgeGroup25to29,EthnicGroups,GenderGroups]=0.1  
Incidence of obesity base rate[AgeGroup30to34,EthnicGroups,GenderGroups]=0.05  
Incidence of obesity base rate[AgeGroup35to39,EthnicGroups,GenderGroups]=0.05  
Incidence of obesity base rate[AgeGroup40to44,EthnicGroups,GenderGroups]=0.005  
Incidence of obesity base rate[AgeGroup45to49,EthnicGroups,GenderGroups]=0.05  
Incidence of obesity base rate[AgeGroup50to54,EthnicGroups,GenderGroups]=0.05  
Incidence of obesity base rate[AgeGroup55to59,EthnicGroups,GenderGroups]=0.05  
Incidence of obesity base rate[AgeGroup5to9,EthnicGroups,GenderGroups]=0.05  
Incidence of obesity base rate[AgeGroup60to64,EthnicGroups,GenderGroups]=0.01  
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Incidence of obesity base rate[AgeGroup65to69,EthnicGroups,GenderGroups]=0.01  
Incidence of obesity base rate[AgeGroup70to74,EthnicGroups,GenderGroups]=0.01  
Incidence of obesity base rate[AgeGroup75to79,EthnicGroups,GenderGroups]=0.01  
Incidence of obesity base rate[AgeGroup80plus,EthnicGroups,GenderGroups]=0 
Incidence of overweight base rate[AgeGroup0to4,EthnicGroups,GenderGroups]=0  
Incidence of overweight base rate[AgeGroup10to14,EthnicGroups,GenderGroups]=0.1  
Incidence of overweight base rate[AgeGroup15to19,EthnicGroups,GenderGroups]=0.1  
Incidence of overweight base rate[AgeGroup20to24,EthnicGroups,GenderGroups]=0.1  
Incidence of overweight base rate[AgeGroup25to29,EthnicGroups,GenderGroups]=0.1  
Incidence of overweight base rate[AgeGroup30to34,EthnicGroups,GenderGroups]=0.05  
Incidence of overweight base rate[AgeGroup35to39,EthnicGroups,GenderGroups]=0.05  
Incidence of overweight base rate[AgeGroup40to44,EthnicGroups,GenderGroups]=0.05  
Incidence of overweight base rate[AgeGroup45to49,EthnicGroups,GenderGroups]=0.05  
Incidence of overweight base rate[AgeGroup50to54,EthnicGroups,GenderGroups]=0.05  
Incidence of overweight base rate[AgeGroup55to59,EthnicGroups,GenderGroups]=0.05  
Incidence of overweight base rate[AgeGroup5to9,EthnicGroups,GenderGroups]=0.05  
Incidence of overweight base rate[AgeGroup60to64,EthnicGroups,GenderGroups]=0.01  
Incidence of overweight base rate[AgeGroup65to69,EthnicGroups,GenderGroups]=0.01  
Incidence of overweight base rate[AgeGroup70to74,EthnicGroups,GenderGroups]=0.01  
Incidence of overweight base rate[AgeGroup75to79,EthnicGroups,GenderGroups]=0.01  
Incidence of overweight base rate[AgeGroup80plus,EthnicGroups,GenderGroups]=0 
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Init diabetes to prediabetes coefficient[Female]=0.6 
Init diabetes to prediabetes coefficient[Male]=1  
Init dx diabetic with late stage complication 
population[AgeGroups,Aboriginal,Female]=0,0,0,0,0,0,0,0,0,0,0,0,8,5,4,1,3  
Init dx diabetic with late stage complication 
population[AgeGroups,Aboriginal,Male]=0,0,0,0,0,0,0,0,0,4,2,14,3,4,2,2,1  
Init dx diabetic with late stage complication 
population[AgeGroups,Other,Female]=0,0,0,0,0,0,0,0,0,0,0,0,83,81,85,58,221 
Init dx diabetic with late stage complication 
population[AgeGroups,Other,Male]=0,0,0,0,0,0,0,0,0,28,21,155,57,115,110,142,142  
Init dx diabetic without complication 
population[AgeGroups,Aboriginal,Female]=0,1,1,5,8,15,24,32,39,43,41,33,19,13,9,4,3  
Init dx diabetic without complication 
population[AgeGroups,Aboriginal,Male]=0,2,1,4,4,9,18,20,26,28,26,24,13,8,4,2,1  
Init dx diabetic without complication 
population[AgeGroups,Other,Female]=2,6,11,20,40,51,72,97,137,168,198,188,192,193,198,186,
285 
Init dx diabetic without complication 
population[AgeGroups,Other,Male]=2,10,16,26,37,44,58,96,135,202,251,258,235,241,221,166,1
83  
Init normal weight 
population[AgeGroups,Aboriginal,Female]=775,780,641,547,401,293,235,188,132,97,55,33,25,
17,13,8,10  
Init normal weight 
population[AgeGroups,Aboriginal,Male]=842,806,707,562,373,274,212,177,110,71,39,26,20,14
,9,6,4  
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Init normal weight 
population[AgeGroups,Other,Female]=6078,6386,6637,6601,5944,4138,3532,5633,5674,4645,3
267,2049,1714,1915,1618,1712,3487 
Init normal weight 
population[AgeGroups,Other,Male]=5870,6934,7039,6855,4895,3651,2940,3568,3147,3085,197
6,1333,1431,1300,1308,1109,1631  
Init obese 
population[AgeGroups,Aboriginal,Female]=50,101,86,56,123,169,167,149,141,82,74,45,30,16,8
,4,2  
Init obese 
population[AgeGroups,Aboriginal,Male]=87,88,98,78,115,158,150,140,118,60,52,36,25,13,6,3,
1  
Init obese 
population[AgeGroups,Other,Female]=388,830,887,680,1088,1717,1844,2040,2270,2141,2358,
1697,1458,1216,985,743,987 
Init obese 
population[AgeGroups,Other,Male]=608,753,979,945,1502,2105,2090,2824,3366,2600,2656,18
24,1723,1233,823,546,404  
Init overweight 
population[AgeGroups,Aboriginal,Female]=139,171,184,176,306,300,311,238,201,146,107,70,3
0,25,18,11,10  
Init overweight 
population[AgeGroups,Aboriginal,Male]=142,165,199,196,284,280,281,224,169,106,75,56,25,2
1,12,8,4  
Init overweight 
population[AgeGroups,Other,Female]=1088,1405,1909,2127,2020,2027,2344,2439,2818,2649,2
309,2070,1871,1639,2075,1647,2086 
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Init overweight 
population[AgeGroups,Other,Male]=988,1416,1978,2386,3732,3737,3897,4509,4808,4627,3822
,2876,1771,1972,1814,1496,1648  
Init total diabetic with early stage complication 
population[AgeGroups,Aboriginal,Female]=0,0,0,1,2,4,7,11,15,19,21,21,7,7,7,5,4  
Init total diabetic with early stage complication 
population[AgeGroups,Aboriginal,Male]=0,0,0,1,1,2,5,7,10,8,11,1,7,4,3,1,1  
Init total diabetic with early stage complication 
population[AgeGroups,Other,Female]=0,2,4,6,10,14,21,32,51,73,100,119,67,106,150,216,308 
Init total diabetic with early stage complication 
population[AgeGroups,Other,Male]=0,3,5,7,9,12,17,32,50,61,105,8,128,118,152,103,198  
Init undx diabetic with early stage comp population elderly coefficient=0.1 
Init undx diabetic with early stage comp population youth coefficient=0.5 
Init undx diabetic with early stage complication population ethnic coefficient[EthnicGroups]=0.1 
Init undx diabetic with early stage complication population gender 
coefficient[GenderGroups]=0.1 
Init undx diabetic without complication population elderly coefficient=0.5 
Init undx diabetic without complication population ethnic coefficient[EthnicGroups]=1 
Init undx diabetic without complication population gender coefficient[GenderGroups]=1 
Init undx diabetic without complication population youth coefficient=0.8 
Init undx prediabetic population elderly age coefficient=0.8 
Init undx prediabetic population ethnic coefficient[EthnicGroups]=1 
Init undx prediabetic population gender coefficient[GenderGroups]=1 
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Init undx prediabetic population youth age coefficient=1.5 
Initinal covered population by age ethnic gender 
groups[AgeGroups,Aboriginal,Female]=963,1052,911,812,838,762,722,578,477,329,236,149,85
,58,41,23,22  
Initinal covered population by age ethnic gender 
groups[AgeGroups,Aboriginal,Male]=1071,1058,1004,835,779,712,650,544,400,240,165,119,70
,47,27,16,9  
Initinal covered population by age ethnic gender 
groups[AgeGroups,Other,Female]=5558,6202,6623,6782,7873,7293,6837,8129,8556,7547,6160
,4286,3708,3435,3287,2970,4869 
Initinal covered population by age ethnic gender 
groups[AgeGroups,Other,Male]=5841,6558,6983,6909,7595,7399,6989,8255,8435,7568,6041,4
273,3344,3028,2555,2044,2346  
Major macrovascular complication mortality switcher=1 
Major macrovascular complication risk factor for RI=1 
mortality coefficient dx diabetic with early stage comp=0.9 
mortality coefficient dx diabetic with late stage comp=1.2 
mortality coefficient dx diabetic without complication=0.9 
mortality coefficient undx diabetic with early stage comp=1.2 
mortality coefficient undx diabetic without complication=0.7 
Mortality of dx prediabetic 
population[AgeGroups,Aboriginal,Female]=0.971777,0.0967517,0.193503,0.387007,0.290255,0
.232237,0.466201,1.27796,1.2801,1.97838,3.21877,6.39928,7.72477,12.9136,16.7054,31.3575,9
0.2742  
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Mortality of dx prediabetic 
population[AgeGroups,Aboriginal,Male]=1.56489,0.0967517,0.0967517,0.870765,1.25777,1.42
541,2.14867,1.65607,1.99921,3.09877,5.65216,8.17938,13.8326,21.7865,32.4309,52.4955,125.2
64  
Mortality of dx prediabetic 
population[AgeGroups,Other,Female]=0.971777,0.0967517,0.193503,0.387007,0.290255,0.232
237,0.466201,1.27796,1.2801,1.97838,3.21877,6.39928,7.72477,12.9136,16.7054,31.3575,90.27
42 
Mortality of dx prediabetic 
population[AgeGroups,Other,Male]=1.56489,0.0967517,0.0967517,0.870765,1.25777,1.42541,2
.14867,1.65607,1.99921,3.09877,5.65216,8.17938,13.8326,21.7865,32.4309,52.4955,125.264  
Mortality of normal weight 
population[AgeGroups,Aboriginal,Female]=0.971777,0.0967517,0.193503,0.387007,0.290255,0
.193531,0.388501,1.06497,1.06675,1.64865,2.68231,5.33273,6.83608,11.428,16.2189,30.4442,8
7.6448  
Mortality of normal weight 
population[AgeGroups,Aboriginal,Male]=1.56489,0.0967517,0.0967517,0.870765,1.25777,1.18
784,1.79056,1.38005,1.66601,2.58231,4.71013,6.81615,12.2412,19.2801,31.4863,50.9665,121.6
15  
Mortality of normal weight 
population[AgeGroups,Other,Female]=0.971777,0.0967517,0.193503,0.387007,0.290255,0.193
531,0.388501,1.06497,1.06675,1.64865,2.68231,5.33273,6.83608,11.428,16.2189,30.4442,87.64
48 
Mortality of normal weight 
population[AgeGroups,Other,Male]=1.56489,0.0967517,0.0967517,0.870765,1.25777,1.18784,1
.79056,1.38005,1.66601,2.58231,4.71013,6.81615,12.2412,19.2801,31.4863,50.9665,121.615  
Mortality of obese 
population[AgeGroups,Aboriginal,Female]=0.971777,0.0967517,0.193503,0.387007,0.290255,0
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.232237,0.466201,1.27796,1.2801,1.97838,3.21877,6.39928,7.72477,12.9136,16.7054,31.3575,9
0.2742  
Mortality of obese 
population[AgeGroups,Aboriginal,Male]=1.56489,0.0967517,0.0967517,0.870765,1.25777,1.42
541,2.14867,1.65607,1.99921,3.09877,5.65216,8.17938,13.8326,21.7865,32.4309,52.4955,125.2
64  
Mortality of obese 
population[AgeGroups,Other,Female]=0.971777,0.0967517,0.193503,0.387007,0.290255,0.232
237,0.466201,1.27796,1.2801,1.97838,3.21877,6.39928,7.72477,12.9136,16.7054,31.3575,90.27
42 
Mortality of obese 
population[AgeGroups,Other,Male]=1.56489,0.0967517,0.0967517,0.870765,1.25777,1.42541,2
.14867,1.65607,1.99921,3.09877,5.65216,8.17938,13.8326,21.7865,32.4309,52.4955,125.264  
Mortality of overweight 
population[AgeGroups,Aboriginal,Female]=0.971777,0.0967517,0.193503,0.387007,0.290255,0
.160631,0.322456,0.883925,0.885404,1.36838,2.22632,4.42617,6.49427,10.8566,14.7592,27.70
42,79.7568  
Mortality of overweight 
population[AgeGroups,Aboriginal,Male]=1.56489,0.0967517,0.0967517,0.870765,1.25777,0.98
5908,1.48616,1.14545,1.38279,2.14332,3.90941,5.65741,11.6292,18.3161,28.6525,46.3795,110.
67  
Mortality of overweight 
population[AgeGroups,Other,Female]=0.971777,0.0967517,0.193503,0.387007,0.290255,0.160
631,0.322456,0.883925,0.885404,1.36838,2.22632,4.42617,6.49427,10.8566,14.7592,27.7042,7
9.7568 
Mortality of overweight 
population[AgeGroups,Other,Male]=1.56489,0.0967517,0.0967517,0.870765,1.25777,0.985908,
1.48616,1.14545,1.38279,2.14332,3.90941,5.65741,11.6292,18.3161,28.6525,46.3795,110.67  
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Mortality of undx prediabetic 
population[AgeGroups,Aboriginal,Female]=0.971777,0.0967517,0.193503,0.387007,0.290255,0
.232237,0.466201,1.27796,1.2801,1.97838,3.21877,6.39928,7.72477,12.9136,16.7054,31.3575,9
0.2742  
Mortality of undx prediabetic 
population[AgeGroups,Aboriginal,Male]=1.56489,0.0967517,0.0967517,0.870765,1.25777,1.42
541,2.14867,1.65607,1.99921,3.09877,5.65216,8.17938,13.8326,21.7865,32.4309,52.4955,125.2
64  
Mortality of undx prediabetic 
population[AgeGroups,Other,Female]=0.971777,0.0967517,0.193503,0.387007,0.290255,0.232
237,0.466201,1.27796,1.2801,1.97838,3.21877,6.39928,7.72477,12.9136,16.7054,31.3575,90.27
42 
Mortality of undx prediabetic 
population[AgeGroups,Other,Male]=1.56489,0.0967517,0.0967517,0.870765,1.25777,1.42541,2
.14867,1.65607,1.99921,3.09877,5.65216,8.17938,13.8326,21.7865,32.4309,52.4955,125.264  
Normal weight mortality switch=1 
Obese mortality switch=1 
Older age groups obesity 
prevalence[WeightOldAgeGroups,Aboriginal,Female]=0.17,0.22,0.22,0.21,0.21,0.28,0.28,0.3,0.
3,0.3,0.3,0.3,0.3  
Older age groups obesity 
prevalence[WeightOldAgeGroups,Aboriginal,Male]=0.15,0.21,0.21,0.27,0.27,0.27,0.27,0.28,0.2
8,0.28,0.28,0.28,0.28  
Older age groups obesity 
prevalence[WeightOldAgeGroups,Other,Female]=0.08,0.19,0.2,0.19,0.15,0.2,0.27,0.23,0.18,0.2
1,0.18,0.17,0.14 
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Older age groups obesity 
prevalence[WeightOldAgeGroups,Other,Male]=0.11,0.24,0.26,0.22,0.31,0.21,0.25,0.28,0.35,0.2
4,0.19,0.15,0.09  
Older age groups overweight 
prevalence[WeightOldAgeGroups,Aboriginal,Female]=0.23,0.29,0.29,0.32,0.32,0.34,0.34,0.4,0.
4,0.4,0.4,0.4,0.4  
Older age groups overweight 
prevalence[WeightOldAgeGroups,Aboriginal,Male]=0.36,0.5,0.5,0.48,0.48,0.51,0.51,0.44,0.44,
0.44,0.44,0.44,0.44  
Older age groups overweight 
prevalence[WeightOldAgeGroups,Other,Female]=0.2,0.26,0.31,0.23,0.26,0.25,0.3,0.34,0.4,0.37,
0.46,0.4,0.28 
Older age groups overweight 
prevalence[WeightOldAgeGroups,Other,Male]=0.36,0.4,0.47,0.41,0.42,0.52,0.53,0.48,0.35,0.47,
0.44,0.49,0.41  
Overweight mortality switch=1 
Prediabetes incidence base rate normal 
weight[AdultAgeGroups,EthnicGroups,GenderGroups]=0.01  
Prediabetes incidence base rate normal 
weight[AgeGroup10to14,EthnicGroups,GenderGroups]=0.01  
Prediabetes incidence base rate normal 
weight[AgeGroup15to19,EthnicGroups,GenderGroups]=0.01 
Prediabetes incidence base rate normal 
weight[ChildrenAgeGroups,EthnicGroups,GenderGroups]=0  
Prediabetes onset age coefficient[AdultAgeGroups]=1 
Prediabetes onset age coefficient[AgeGroup10to14]=0.1  
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Prediabetes onset age coefficient[AgeGroup15to19]=0.1  
Prediabetes onset age coefficient[ChildrenAgeGroups]=0.1  
Prediabetes onset obese multiplier=2.6 
Prediabetes onset overweight multiplier=1.7 
Prediabetes onset risk age multiplier[ElderlyAgeGroups]=1.15 
Prediabetes onset risk age multiplier[YoungAgeGroups]=1  
Prediabetes recovery rate[normalweight,AgeGroups,EthnicGroups,GenderGroups]=0  
Prediabetes recovery rate[obese,AgeGroups,EthnicGroups,GenderGroups]=0 
Prediabetes recovery rate[overweight,AgeGroups,EthnicGroups,GenderGroups]=0.03  
Sensitivity coefficient for avg years develop early stage complication from undx diabetes=1 
Sensitivity coefficient for avg years to develop diabetes from dx prediabetes=1 
Sensitivity coefficient for Avg years to develop diabetes from undx prediabetes=1 
Sensitivity coefficient for avg years to develop early stage complications from dx diabetes=1 
Sensitivity coefficient for diabetes diagnosis=1 
Sensitivity coefficient for diabetic with late stage complication mortality=1 
Sensitivity coefficient for dx diabetic with early stage complication mortality=1 
Sensitivity coefficient for dx diabetic without complication mortality=1 
Sensitivity coefficient for dx prediabetic mortality=1 
Sensitivity coefficient for incidence of obesity=1 
Sensitivity coefficient for incidence of overweight=1 
Sensitivity coefficient for prediabetes diagnosis=1 
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Sensitivity coefficient for prediabetes incidence rate obese=1 
Sensitivity coefficient for prediabetes recovery rate=1 
Sensitivity of FPGT screening for diabetes=0.65 
Sensitivity of OGTT screening for diabetes=0.97 
SHR birth rate[EthnicGroups,Female]=11.1/1000*0.49 
SHR birth rate[EthnicGroups,Male]=11.1/1000*0.51  
Tested fraction of early stage complication population due to symptoms=0.6 
Time between screening coefficient for high risk asmptomatic elderly=1 
Time between screening coefficient for high risk asmptomatic youth=2 
Time between screenings coefficient for high risks asymptomatic ethnic 
groups[EthnicGroups]=1, 1 
Time between screenings coefficient for high risks asymptomatic gender 
groups[GenderGroups]=1, 1 
Time between screenings coefficient for undx early stage complication age 
groups[AgeGroups]=1 
Time between screenings coefficient for undx early stage complication ethnic 
groups[EthnicGroups]=1, 1 
Time between screenings coefficient for undx early stage complication gender 
groups[GenderGroups]=1, 1 
Undx prediabetic mortality switch=1 
Weight change age coefficient[AgeGroup0to4]=1  
Weight change age coefficient[AgeGroup10to14]=0.1  
Weight change age coefficient[AgeGroup15to19]=0.1  
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Weight change age coefficient[AgeGroup20to24]=0.1  
Weight change age coefficient[AgeGroup25to29]=1  
Weight change age coefficient[AgeGroup30to34]=1  
Weight change age coefficient[AgeGroup35to39]=1  
Weight change age coefficient[AgeGroup40to44]=1  
Weight change age coefficient[AgeGroup45to49]=1  
Weight change age coefficient[AgeGroup50to54]=1  
Weight change age coefficient[AgeGroup55to59]=1  
Weight change age coefficient[AgeGroup5to9]=1  
Weight change age coefficient[AgeGroup60to64]=1  
Weight change age coefficient[AgeGroup65to69]=1  
Weight change age coefficient[AgeGroup70to74]=1  
Weight change age coefficient[AgeGroup75to79]=1  
Weight change age coefficient[AgeGroup80plus]=1 
Weight change ethnic coefficient[Aboriginal]=1  
Weight change ethnic coefficient[Other]=1 
Weight change gender coefficient[Female]=1.1 
Weight change gender coefficient[Male]=1  
weight limit=0.01 
Weighting switch=0 
Years in each age group[AgeGroups]=5 
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Young age groups obesity 
prevalence[WeightYoungAgeGroups,Aboriginal,Female]=0,0.2,0.23,0.23,0.08  
Young age groups obesity 
prevalence[WeightYoungAgeGroups,Aboriginal,Male]=0,0.2,0.26,0.35,0.09  
Young age groups obesity 
prevalence[WeightYoungAgeGroups,Other,Female]=0,0.08,0.09,0.09,0.05 
Young age groups obesity 
prevalence[WeightYoungAgeGroups,Other,Male]=0,0.08,0.11,0.14,0.05  
Young age groups overweight 
prevalence[WeightYoungAgeGroups,Aboriginal,Female]=0,0.21,0.23,0.23,0.24  
Young age groups overweight 
prevalence[WeightYoungAgeGroups,Aboriginal,Male]=0,0.16,0.21,0.26,0.29  
Young age groups overweight 
prevalence[WeightYoungAgeGroups,Other,Female]=0,0.17,0.19,0.18,0.23 
Young age groups overweight 
prevalence[WeightYoungAgeGroups,Other,Male]=0,0.13,0.17,0.21,0.29 
